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Steroid hormone use and venous thrombosis
In 1960, shortly after the introduction of combined oral contra-
ceptive Enovid ® (150 µg mestranol, an estrogen, and 985 mg
norethynodrel, a progestagen), the first case of venous thrombo-
sis associated with contraceptive use was reported1. Since then
many observational studies have been conducted to assess the
association between combined oral contraceptives and venous
thrombosis. Overall, combined oral contraceptive use is associ-
ated with a two-fold to six-fold increased risk of venous thrombo-
sis2–5. Nowadays many women worldwide use oral contraceptives
making the impact of oral contraceptive use on venous thrombo-
sis risk large, despite the low incidence of venous thrombosis of
about 3 per 10,000 woman-years among women of reproductive
age6.
The causality between hormone use and venous thrombosis
can be discussed using Hill’s criteria of causality7. A review by
Vandenbroucke et al8 showed that the association between com-
bined oral contraceptive use and venous thrombosis was consis-
tent and of the same strength over several observational studies.
The plausibility of the association is strengthened by the effect
of oral contraceptives on the levels of several coagulation factors
and the resulting shift in the balance of coagulation towards a
prothrombotic state. However, the mechanism behind this effect
remains unclear.
An outline of the current state of literature is given on the
risk of venous thrombosis associated with hormone use and the
biological mechanism that may explain the prothrombotic effect.
First, the association between hormone use and the risk of ve-
nous thrombosis will be evaluated. The following applications
of estrogens or progestagens will be addressed; contraception,
relieve of menopausal symptoms, restriction of tall stature and
sex change. Secondly, a hypothesis will be derived on whether es-
trogen, progestagen or combination of estrogen and progestagen
may lead to venous thrombosis. Thirdly, the effect of hormone
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use on coagulation factors, activated protein C resistance and
sex hormone binding globulin levels will be evaluated. Lastly,
the outline of this thesis with the research questions will be
proposed.
Hormonal contraception
Hormonal contraception is a birth-control method to prevent
ovulation and thus pregnancy. Hormonal contraception consists
of steroid hormone use in two main types of formulations; com-
bined formulations which contain both estrogen and progestagen
and progestagen-only formulations. Progestagen suppresses the
surge in luteinizing hormone (LH) and thereby prevents ovula-
tion. Estrogen reduces the secretion of follicle-stimulating hor-
mone (FSH) and thereby inhibits folliculogenesis. The estrogen
compound has a major role in drug compliance; by increasing
the stability of the endometrium, breakthrough bleeding and
spotting are reduced. Hormonal contraception is prescribed to
regulate the uterine, menstrual cycle or for other hormonally
dependent disorders as acne9 and hirsutism10.
The most commonly used estrogen in combined hormonal
contraceptives is ethinylestradiol, whereas different types of pro-
gestagens are used in combined or progestagen-only contracep-
tives. Contraceptive progestagens can be categorised according
to the time of their introduction (first, second and third gen-
eration, respectively introduced in the sixties, seventies, and
eighties of the last century) or according to their tetracyclic
structure11, i.e. estranes (derivatives of testosterone), pregnanes
(derived from the progesterone molecule) and gonanes. The fol-
lowing progestagens correspond to first generation progestagens:
norethisterone (NET), ethynodiol diacetate, lynestrenol (LYN),
and norethynodrel. Levonorgestrel (LNG) and norgestrel (NG)
correspond to second generation progestagens and third genera-
tion progestagens are desogestrel (DSG) and its active metabolite
etonogestrel, gestodene (GSD), and norgestimate (NGM) and
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its active metabolite norgestromin (NGMN). Examples of other
progestagens used in hormonal contraceptives are cyproterone ac-
etate (CPA), chlormadinone acetate, nomegestrol, drospirenone
(DRSP) and medroxyprogesterone acetate (MPA). These last
progestagens are classified as pregnanes based on their structure.
Estranes are comprised of the first generations progestagens,
while the second and third generation progestagens belong to
the gonanes.
Steroid hormones can be administered via different routes or
applications, such as orally (pill), intrauterinely (intrauterine de-
vice (IUD)), transdermally (patch), subcutaneously (injectable
or implant), or transvaginally (ring). The most commonly used
route for combined formulations is orally and occasionally trans-
dermally or transvaginally. Progestagen-only formulations are
administered orally (mini pill) as well as subcutaneously or in-
trauterinely.
Combined hormonal contraceptives Several large studies12–15 in
the 1990s have confirmed the two-fold to four-fold increase in
risk of venous thrombosis associated with oral contraceptive use,
which was already shown in four studies2–5 from the late 1960s.
The risk of venous thrombosis is the highest in the first three
months of combined oral contraceptive use, i.e., about twelve-
fold increased compared with non-users16–18. With extended use
the risk decreases to an approximately five-fold increased risk.
Because the estrogen compound in combined oral contraceptives
was thought to cause the increased risk of venous thrombosis,
the dose of estrogen has been lowered from 150-100 µg after the
introduction of the oral contraceptive to 50 µg in the 1960s to
30-35 µg and 20 µg in the 1970s19,20. The lower dose of ethinyl-
estradiol in combined oral contraceptives was associated with a
reduction in venous thrombosis risk12,21–24. The currently pre-
scribed combined oral contraceptives containing 30 µg of ethinyl-
estradiol are associated with a higher risk of venous thrombosis
than contraceptives containing 20 µg17,18.
7
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Besides adjustments in the dose of ethinylestradiol, the pro-
gestagen compound was changed to reduce side effects of oral
contraceptive use. After the introduction of the third genera-
tion progestagens as part of the combined oral contraceptives in
the eighties, the risk of venous thrombosis among users of those
compounds was investigated. It was shown that third generation
oral contraceptive users have a higher risk of venous throm-
bosis compared with second generation users8,16–18. However,
these results were disputed by reasoning that bias or confounding
could explain the difference in risk between these progestagens.
These issues were addressed in an opinion article25 and a meta-
analysis16 in which it was shown that the presence of bias or
confounding could not explain the observed results. Other pro-
gestagens have been developed after the introduction of the third
generation progestagens, e.g., drospirenone (introduced in 2001)
and dienogest (introduced in 1995). The use of drospirenone in a
combined oral contraceptive has been shown to increase the risk
of venous thrombosis17,18 compared with non-use and compared
with second generation contraceptive use26,27. No information
concerning the risk of venous thrombosis is available for the
contraceptive containing dienogest because this contraceptive is
mainly prescribed in Germany28.
To diminish the risk of venous thrombosis, it was attempted
to prevent the first-pass effect of steroids. Because of oral intake
of steroid hormones, the metabolism in the liver was thought to
be important in the pathogenesis of venous thrombosis. After
a drug is ingested, it is absorbed by the digestive system and
enters the liver through the hepatic portal system29. The liver
metabolizes many drugs before they enter the remaining circu-
lation. The first-pass through the liver may greatly affect the
bioavailability of an ingested drug29, hence the name first-pass
metabolism. This led to the hypothesis that transdermal and
transvaginal administration of estrogens and progestagens may
reduce venous thrombosis risk. The application of hormones via
the skin or vagina bypass the first-pass effect in the liver be-
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cause the hormones are first distributed to other organs and
later, diluted, to the liver30.
The information concerning the risk of venous thrombosis
with vaginal ring or transdermal patch use is lacking due to their
fairly recent introduction onto the market in 2001 and 2002, re-
spectively and due to a limited number of users of these types
of contraceptives. However, two case reports concerning mesen-
teric vein thrombosis31 and cerebral venous sinus thrombosis32
were reported in two vaginal ring users suggesting a potential
association between vaginal ring use and thrombosis. Further-
more, a deep vein thrombosis was reported as a serious adverse
event in vaginal ring users in each of two trials (of which one
randomized controlled trial (RCT)) evaluating the efficacy and
tolerability of the vaginal ring compared with a second gener-
ation combined oral contraceptive33,34. The FDA showed in a
large cohort study that vaginal ring use increased the risk of
venous thrombosis compared with combined oral contraceptive
users35. This result was confirmed by another large cohort study
conducted in Denmark36.
The risk of venous thrombosis in transdermal patch users has
been assessed in two observational studies using health insurance
databases. Both studies were supported by the manufacturers.
The first study reported no difference in venous thrombosis risk
between transdermal patch users and users of a third generation
combined oral contraceptive37. The second study, published one
year later, reported an increased risk of venous thrombosis in
patch users compared with third generation oral contraceptive
users38. These results were confirmed in updated analyses of
both studies39,40. After these results the US Food and Drug
Administration (FDA) issued the following warning on 22 Jan-
uary 2008: “FDA believes that Ortho Evra is a safe and effective
method of contraception when used according to the labeling,
which recommends that women with concerns or risk factors for
serious blood clots talk with their health care provider about
using Ortho Evra versus other contraceptive option”41. In 2011,
9
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the FDA performed their own study and showed that the use of
the transdermal patch increased the risk of venous thrombosis
compared with combined oral contraceptive users35. This result
was confirmed in a large cohort study from Denmark36.
In summary, the use of combined hormonal contraceptives is
associated with an increased risk of venous thrombosis whether
the hormones are administered in a pill, in a vaginal ring or in
a transdermal patch.
Progestagen-only contraceptives Injectable progestagen-only con-
traceptives were developed in the late 1950s and early 1960s as
a result of a growing understanding of steroid hormones and the
research into oral contraceptives. In the late 1960s, the first oral
progestagen-only contraceptive was developed when concerns
were raised about the side-effects of combined oral contracep-
tives. Progestagen-only implants were developed in 1960s and
1970s and the hormone-releasing IUD was developed in the early
1970s.
Four case-control studies have assessed the risk of venous
thrombosis associated with progestagen-only pills (POP) for con-
traceptive use: three studies23,42,43 reported a potential increase
in risk compared with either non-users or users of combined oral
contraceptives containing levonorgestrel, whereas one study44
reported a decrease in risk compared with non-users. The risk
of venous thrombosis was not separately assessed per type of
progestagen. A cohort study reported no increased risk of ve-
nous thrombosis in users of levonorgestrel or norethisterone or
in users of desogestrel, although a relatively small number of
women were using these contraceptives17.
Information about the risk of venous thrombosis in implant
users is lacking, probably due to the low number of women using
this type of contraceptive. A large cohort study showed that the
use of an implant was associated with an increased risk of venous
thrombosis compared with non-use36. Three studies42,45,46 have
investigated the use of injectables containing MPA and all three
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reported an increased risk of venous thrombosis relative to non-
users. Regarding IUD use, two observational studies showed that
the use of an IUD containing levonorgestrel was not associated
with venous thrombosis17,45.
In a nested case-control study, the risk of venous thrombosis
was not increased in users of progestagen-only contraceptives
(i.e., POP, injectable, and implant combined) compared with
non-users47. Venous thrombosis risk per type of administration
was not evaluated.
Currently, no definitive conclusion on the risk of venous
thrombosis associated with progestagen-only contraceptives can
be drawn due to variation in the progestagen used, the dose
and mode of administration, and because a small number of wo-
men use progestagen-only contraceptives. However, there is an
indication that users of IUD containing levonorgestrel or users
of oral levonorgestrel have the same risk of venous thrombosis
as non-users, whereas users of injectable methoxyprogesterone
acetate have an increased risk.
Hormone replacement therapy
Hormone replacement therapy (HRT) is mainly administered to
relief hot flushes caused by diminishing estrogen levels as a re-
sult of failing ovaries (e.g., premature ovarian failure or surgically
caused menopause) or physiological menopause48. Estrogen-only
HRT is prescribed to women without a uterus. In women with a
uterus, the estrogen compound is combined with a progestagen
as progestagen is needed to shed the developed endometrium
(when progestagen is sequentially administered) or to prevent
endometrial hyperplasia caused by estrogen (when progestagen
is continuously administered). Estrogens or the combination of
estrogen and progestagen are administered orally or transder-
mally via a patch. An estrogen implant can be used as well,
although it is not commonly applied. Besides the relief of symp-
toms of menopause, HRT was thought to prevent osteoporosis
11
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and cardiovascular diseases. It was hypothesized that the risk of
osteoporosis and cardiovascular diseases were due to the drop in
estrogen levels caused by menopause and that the risks could be
prevented by replenishing estrogen with HRT.
Combined and estrogen-only administration In 1895, it was sug-
gested that ovarian secretions could be used to treat ovarian
failure and in 1896 the first therapeutic interventions were re-
ported49. Over the course of the next thirty years, the ovarian
hormones were identified, i.e., estrone, estriol, estradiol and pro-
gesterone. In the 1930s estrogen was used as a therapy in women
with premature menopause (onset of menopause before the age
of 40)50. Use of estrogen-only HRT became widespread in the
1960s and 1970s. However, in the 1970s it was shown that wo-
men with an intact uterus using estrogen-only therapy were at
an increased risk for endometrial cancer51. Thereafter, combined
HRT was given to women with a uterus and estrogen-only to wo-
men without a uterus52. Since then many observational studies
were conducted to establish whether HRT was protective against
cardiovascular diseases. A meta-analysis of observational studies
published in 1991 showed that the use of HRT was protective
against cardiovascular diseases53. However, the hormones used
and dose and the mode of administration was different across
the studies making a comparison across studies difficult. Fur-
thermore, women taking HRT may be different from women not
taking HRT which can influence the results obtained in observa-
tional studies. These issues are reduced in trials where women
are randomized to receive HRT or a placebo.
The HERS study54 (Heart and Estrogen/progestin Replace-
ment Study) was one of the first trials showing that HRT use did
not reduce the rate of secondary coronary heart disease. In this
RCT, women with established coronary disease were random-
ized to receive either combined HRT or a placebo. In a Cochrane
review from 200555, the prevention of cardiovascular disease in
postmenopausal women using HRT was assessed. A total of ten
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RCTs were included of which two trials included healthy women
and eight trials included women with heart disease. No protective
effect of HRT was seen for any of the arterial outcomes assessed.
One of the secondary outcomes evaluated was venous thrombo-
sis. Combined oral HRT (i.e., conjugated equine estrogens (CEE)
with MPA) was associated with a twofold increased risk of venous
thrombosis. One trial used 17β-estradiol with norethisterone and
also found an increase in risk56. Estrogen-only oral HRT (i.e.,
17β-estradiol) was not associated with venous thrombosis; how-
ever, only two RCTs (i.e., SPRIT 200257 and WEST58 trial)
contained data on estrogen-only HRT. The Women’s Health Ini-
tiative (WHI) group conducted the WHI Conjugated Equine
Estrogen (CEE) trial published in 200659,60 (not included in
the aforementioned Cochrane review) and evaluated the use of
estrogen-only oral HRT on major disease incidence rates. The
results from this WHI CEE trial60 were that the use of estrogen-
only oral HRT increased the risk of venous thrombosis although
less pronounced than with the use of combined oral HRT (eval-
uated in the WHI E+P trial61). The results from the WHI
CEE trial are in contrast to the results from the SPRIT 2002
and WEST trials which can be explained by the small number of
events in the last two trials (a total of 9 and 7 events, respectively)
compared with 179 events in the WHI CEE trial. Furthermore,
both the SPRIT 2002 and WEST trial used 17β-estradiol as
estrogen and included women with a first myocardial infarction
(SPRIT 2002 trial) or women with an ischemic stroke or tran-
sient ischemic attack (WEST trial), whereas the WHI CEE trial
used CEE as estrogen and included healthy women without a
uterus. Besides data from RCTs, observational studies have also
shown that HRT use was associated with venous thrombosis. A
matched case-control study62 showed that all types of HRT were
associated with a 3.5-fold increased risk for venous thrombosis
compared with non-users. A nested case-control study63 con-
firmed these results showing that HRT use increased the risk of
venous thrombosis 2.1-fold compared with non-users. Data col-
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lected from observational studies and RCTs regarding HRT use
and the risk of venous thrombosis were summarized in a meta-
analysis. Both data from observational studies and RCTs showed
a twofold increased risk for venous thrombosis when using oral
HRT64.
In addition to 17β-estradiol and CEE, esterified estrogens can
also be used in HRT. Like CEE, esterified estrogens are a com-
bination of naturally occurring estrogens and their conjugates,
but in different relative amounts. In a case-control study65, the
risk of venous thrombosis with the use of esterified estrogens
and CEE with or without MPA in HRT has been evaluated.
Compared with non-users, the use of esterified estrogens with
or without MPA did not increase the risk of venous thrombosis.
Among hormone users, the use of CEE with or without MPA
increased the risk of venous thrombosis in comparison to users
of esterified estrogen without MPA.
No RCTs were conducted with HRT administered through a
patch. In total four studies, i.e., three case-control studies includ-
ing the ESTHER study62,63,66,67 and one cohort study (the E3N
cohort study)68 evaluating the risk of venous thrombosis with
HRT use provided data on the thrombotic risk of transdermal
administered steroid hormones. Two case-control studies62,63 re-
ported that after adjustment for multiple risk factors the risk of
venous thrombosis was increased with the use of transdermally
administered HRT. However, no information was provided on the
type of estrogen and whether in addition to estrogen, also a pro-
gestagen was supplied. The ESTHER study and the E3N cohort
study, both conducted by the same research group, reported no
increased risk for venous thrombosis in transdermal HRT users.
In these studies, mostly 17β-estradiol was used. It is unclear
whether this was estrogen only or combined with a progestagen.
However, in an earlier publication of the ESTHER study67 the
addition of a progestagen to transdermal 17β-estradiol did not
influence the risk of venous thrombosis.
In summary, the use of combined oral HRT is associated with
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an increased risk of venous thrombosis. For estrogen-only oral
HRT there is a strong indication that this is associated with an
increased thrombotic risk as well. With regard to transdermal
administered HRT, no firm conclusions can be drawn because
only a small number of women used this type of administration.
Other sex hormone applications
Growth inhibition Tall stature is defined as the height of an in-
dividual two standard deviations above the corresponding mean
height for a given age, sex and population group69. The strongest
increase in height occurs when estradiol levels are low, although
a direct relationship between estradiol and growth hormone lev-
els is not yet established69. Sex steroids, estrogens for females
and androgens for males, are used to limit the expected height in
tall children. High doses of gonadal steroids, especially estrogens,
accelerate bone maturation. In tall girls, 100-200 µg of ethinyl-
estradiol is continuously orally administered and in the last 7-10
days of each month together with a progestagen to shed the de-
veloped endometrium. Since higher doses of the same hormones
as in combined hormonal contraceptives are used, the question
is whether the treatment for tall girls is also associated with an
increase in risk of venous thrombosis.
Venous thrombosis during hormone treatment for tall stature
has been reported only sporadically70,71, and all such cases have
occurred in a clinical situation involving an elevated risk for ve-
nous thrombosis, e.g., immobilisation or surgery. Venous throm-
bosis is much less common in children (i.e. 1 in 100,000 person
per year) than in adults (i.e. 1 in 1,000 persons per year), and
any venous thrombosis event in this young age group is usually
due to a combination of multiple inherited and acquired risk
factors72.
Sex change Transsexuals denote individuals who desire to live
permanently as a member of the opposite sex and who want to
15
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undergo sex reassignment. To this end, transsexuals receive hor-
mone therapy for life. Female-to-male transsexuals receive andro-
gens to induce male body features, whereas male-to-female trans-
sexuals receive either gonadotrophin-releasing hormone (GnRH)
agonists or progestational compounds (e.g., CPA) to suppress
the original male sex characteristics and subsequently ethinyl-
estradiol (100 µg per day) to induce female body features. The
dose of progestagen is about fifty-fold higher and the estrogen
dose is about three times higher than in combined hormonal
contraceptives. One of the adverse events of this hormone ther-
apy is venous thrombosis. The occurrence of venous thrombosis
in male-to-female transsexuals receiving oral progestagen and
estrogen was 45-fold increased compared to the general popu-
lation73. Because of the high incidence of venous thrombosis
during this study, the administration route was changed from
oral to transdermal in male-to-female transsexuals over the age
of 40. The corresponding occurrence of venous thrombosis was
still twenty-fold increased compared with the general popula-
tion74. Of the 36 unprovoked cases, 21 transsexuals experienced
a venous thrombosis in their first year of hormone therapy resem-
bling the same risk pattern as in combined oral contraceptive
users.
In conclusion, the use of orally administered hormones to in-
duce female body characteristics in male-to-female transsexuals
is associated with an increased risk of venous thrombosis.
Towards a mechanism of combined oral con-
traceptive induced venous thrombosis
Hypothesis
After reviewing the literature regarding steroid hormone use and
venous thrombosis, we summarize several associations. The use
of combined oral contraceptives is associated with an increased
16
risk of venous thrombosis. Compared with combined oral con-
traceptives containing a second generation progestagen (i.e., lev-
onorgestrel), third generation contraceptives and contraceptives
containing other non-classified progestagens induce a higher risk
of venous thrombosis. Furthermore, the dose of ethinylestradiol
in combined oral contraceptives is positively and monotonously
gradedly associated with the risk of venous thrombosis. Regard-
ing contraceptives containing solely progestagen, only associa-
tions concerning progestagens levonorgestrel and MPA can be
summarized. Levonorgestrel administered orally or intrauterinely
without ethinylestradiol is not associated with venous throm-
bosis, whereas the progestagen MPA administered via injection
increases the risk. Finally, the use of combined and estrogen-only
HRT administered orally increases the risk of venous thrombo-
sis as well. In general, the use of orally administered synthetic
sex steroid hormones (combined therapy either for contraceptive
use or for HRT) is associated with an increased risk of venous
thrombosis (Table 1.1).
Regarding the association between oral contraceptives and
venous thrombosis, the progestagen levonorgestrel seems to have
a unique role. Combined with ethinylestradiol, levonorgestrel
users are at an increased risk of venous thrombosis, but not as
much as users of a third generation progestagen or other non-
classified progestagens, whereas the sole use of levonorgestrel
(i.e., IUD or oral) does not increase the risk of venous thrombosis.
Furthermore, levels of ethinylestradiol over 24 hours are lower in
levonorgestrel users than in desogestrel users while receiving the
same dose of ethinylestradiol (30 µg)75. Overall, levonorgestrel
appears to be able to modify the effect caused by ethinylestradiol,
whereas third generation progestagens seem to lack this ability.
Based on the literature it is difficult to determine whether
estrogen, progestagen or combination of both is pivotal in the
pathogenesis of venous thrombosis. However, based on the asso-
ciation between ethinylestradiol dose in combined oral contra-
ceptives and venous thrombosis, it is likely that ethinylestradiol
17
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Table 1.1: The risk of venous thrombosis for different applications of sex
steroid hormones in users versus non-users
Application Oral Patch Ring Injectable IUD Implant
Progestagen 3rd 3rd MPA LNG 3rd
Contraceptive use
EE + P + + ? NA NA NA
P -/+* NA NA + -/+ ?
HRT use
E + P + ? NA NA NA ?
E + ? NA NA NA ?
Growth restriction
EE + P ? NA NA NA NA NA
Sex change (♂  ♀)
EE + P + ? NA NA NA NA
EE, ethinylestradiol; E, estrogen; P, progestagen; NA, not applicable; +,
increased risk of venous thrombosis; -/+ no association with venous throm-
bosis; -, decreased risk of venous thrombosis; ?, no data available
* No increased risk in levonorgestrel users compared with non-users
plays a role in the pathogenesis of venous thrombosis. The ques-
tion is how ethinylestradiol leads to an increased risk of venous
thrombosis. Because ethinylestradiol is a synthetic hormone and
can be orally administered, the first-pass metabolism in the liver
may play an important role. The first-pass metabolism in the
liver is known to influence the bioavailability of many synthetic
drugs. Several coagulation factors are produced in the liver mak-
ing it likely that ethinylestradiol can influence the production of
coagulation factors. However, the use of a transdermal patch or
a vaginal ring that bypass this first-pass metabolism, is also as-
sociated with an increased risk of venous thrombosis suggesting
that the first-pass metabolism of ethinylestradiol may not be the
sole player in the pathogenesis of venous thrombosis. A study
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reported that the area under the curve (AUC) of ethinylestradiol
levels over 24 hours in vaginal ring and transdermal patch users
are larger than with oral administration76. Therefore, total levels
of ethinylestradiol may play a role as well.
In the Netherlands, the combined oral contraceptive is the
most popular birth control method making the risk of venous
thrombosis a realistic concern. Currently, it is still unclear how
combined oral contraceptives, in particular ethinylestradiol, can
cause venous thrombosis. The focus of this thesis is on the role
of ethinylestradiol in the pathogenesis of venous thrombosis in
premenopausal women.
Effects on coagulation andmarkers of coagulation or venous
thrombosis
In 2005, the European Medicines Agency (EMA) provided an
updated guideline on clinical investigation of newly developed
steroid contraceptives in women to establish the contraceptive
efficacy and to describe the risks and adverse events of the new
contraceptive77. Regarding the safety of the contraceptive con-
cerning venous thrombosis, the EMA suggested measuring the
following haemostatic variables: prothrombin fragment 1+2 lev-
els, D-dimer levels, factor VII, factor VIII, factor II, antithrombin,
protein S and protein C. Besides these individual coagulation
factors, measuring activated protein C (APC) resistance (ETP-
based, APTT-based) was recommended by the EMA as well.
APC resistance is the relative inability of protein C to cleave
activated factor V or activated factor VIII leading to a prothrom-
botic state. Both APC resistance assays use different triggers,
measure different endpoints and are influenced by different de-
terminants; therefore, both assays provide insights into different
mechanisms of APC resistance78. Further, EMA recommended
to measure sex hormone binding globulin (SHBG) levels as an
indicator of the hormonal activity of the contraceptives. These
19
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individual coagulation factors, APC resistance and SHBG levels
suggested by the EMA will be evaluated regarding the use of eth-
inylestradiol in contraception, restriction of tall stature and sex
change. HRT use will not be assessed because ethinylestradiol is
not used in HRT.
Individual coagulation factors The use of combined hormonal
contraceptives influenced many coagulation factors (Table 1.2).
Use of combined oral contraceptives increased factors involved
in coagulation and fibrinolysis as well as some factors in an-
ticoagulation, whereas other anticoagulation factors were de-
creased79–81. In third generation combined oral contraceptive
users, the increase was more pronounced than in second genera-
tion users79–81. For instance, the increase in factor VII and the
decrease in protein S concentrations were more pronounced in
third generation oral contraceptive users.
The use of a vaginal ring containing a third generation pro-
gestagen showed the same effects on coagulation factors as com-
bined oral contraceptives with third generation progestagens82,83.
Compared with second generation combined oral contraceptive
users, vaginal ring users showed a more pronounced increase in
factor VII and a more pronounced decrease in functional protein
S levels83. However, another study82 reported that functional
protein S levels were not influenced by the vaginal ring, although
in this study women were able to choose their contraceptive, i.e.,
either a vaginal ring or a second generation combined oral con-
traceptive. As a consequence, the patient characteristics can
influence these results because they may be different between
users of a vaginal ring or a combined oral contraceptive.
The following coagulation factors were measured in transder-
mal patch (containing a third generation progestagen) users84:
prothrombin fragment 1+2, antithrombin, and protein S concen-
trations. The effect on these coagulation factors were the same
as in third generation combined oral contraceptive users with a
more pronounced decrease in protein S concentrations. However,
20
Table 1.2: Effect on markers of venous
thrombosis in sex steroid hormones versus
non-users




F1+2 + + +
Factor II + ? ?
Factor VII + ? +
Factor VIII + ? +
Anticoagulation
Antithrombin - - -/+
Protein C + ? +
Protein S - - -/+
Fibrinolysis
D-dimer + + +
APC (ETP-based)
APC resistance + + +
Hormonal activity
SHBG + + +
APC, activated protein C; SHBG, sex
hormone binding globulin; +, increased
levels/activity; -/+ no change in lev-
els/activity; -, decreased levels/activity;
?, no data available
no other studies evaluated the effect of transdermal patch use
on coagulation factors.
Treatment for growth inhibition in tall girls (i.e., ethinyles-
tradiol with a progestagen added in the last days of the cycle)
lowered protein S concentrations85 and functional antithrombin
levels85–87, and increased functional protein C levels85 and pro-
thrombin 1+2 concentrations85. Another study88 showed that
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factor II concentrations were increased in tall girls, whereas no
effect was observed for factor VII, factor VIII and antithrom-
bin concentrations. However, in this study only eight girls were
included and compared to controls while the other studies com-
pared the effect before treatment with the effect during treatment
in a larger number of girls. Overall, treatment for growth inhi-
bition had the same effects on coagulation factors as the use of
combined oral contraceptives. Although the magnitude of the
effects was difficult to assess because no comparison was made
with a combined oral contraceptive.
Only functional protein C and protein S levels and factor
II concentrations were measured in male-to-female transsexuals
receiving ethinylestradiol and CPA. Male-to-female transsexuals
had lower protein S concentrations and slightly higher functional
levels of protein C than their baseline measurements89. No asso-
ciation between changes in coagulation and changes in hormone
levels of 17β-estradiol, testosterone, LH and FSH was observed
suggesting that the effect on coagulation is a sole effect of ethinyl-
estradiol. No other studies evaluated the effect of this hormone
therapy or any other coagulation factors.
The effects on coagulation factors in combined oral contra-
ceptive users have been extensively researched showing that the
use influenced levels of many coagulation factors. Few studies
researched the effects of hormone use for contraception adminis-
tered via a ring or patch, restriction of tall stature or sex change
on coagulation factors, but from the studies that were conducted,
it is likely that these applications can influence levels of coagu-
lation factors.
Activated protein C (APC) resistance As mentioned before, acti-
vated protein C resistance can be measured in two ways; APTT-
based or ETP-based. When the two methods were compared
with regard to the effect of combined oral contraceptive use, the
effect on the ETP-based APC resistance was more pronounced
than on the APTT-based test90. Furthermore, third generation
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combined oral contraceptives users showed a more pronounced
increase in APC resistance (ETP-based) than second generation
users providing a measure for the difference in venous thrombosis
risk between these generations. For these reasons the ETP-based
APC resistance test will only be taken into account.
The APC resistance predicts venous thrombosis risk in men
and women, as well as in oral contraceptive users and non-users91.
Several other studies confirmed that APC resistance was in-
creased in combined oral contraceptive users81,83,84 and that
the effect was more pronounced in users of a third generation
progestagen than with a second generation progestagen81. Both
in users of a vaginal ring and a transdermal patch, the APC
resistance was increased as well83,84. Compared with second gen-
eration combined oral contraceptive users, the increase in APC
resistance was more pronounced in vaginal ring users83. The
APC resistance increased appreciably with the use of a patch
compared with a third generation combined oral contraceptive84.
No data was available on girls receiving sex hormones for tall
stature and the effect on APC resistance. In the male-to-female
transsexuals receiving ethinylestradiol with CPA, the APC re-
sistance was increased compared to baseline89. Overall, the use
of ethinylestradiol with a progestagen led to the activation of
coagulation in women using contraceptives administered via a
pill, a vaginal ring or a transdermal patch, or in male-to-female
transsexuals.
Sex hormone binding globulin (SHBG) Sex hormone binding
globulin (SHBG) is a plasma glycoprotein, primarily produced
in hepatocytes, that binds androgens and thereby regulates their
bioavailability. SHBG levels vary due to multiple regulating fac-
tors such as age, body weight, sex steroids, or insulin. Estrogens
like ethinylestradiol are able to increase the production of SHBG,
whereas progestagens induce a decrease of SHBG levels depend-
ing on the type and dose92,93. Therefore, the effect of combined
oral contraceptives on SHBG levels can be seen as the sum of
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the stimulating effect of ethinylestradiol and the inhibiting ef-
fect of the progestagen resulting in the total estrogenicity of a
contraceptive93. This estrogenicity of a contraceptive can influ-
ence the venous thrombosis risk93. A positive correlation was
observed between SHBG levels and APC resistance supporting
the hypothesis that SHBG levels can be seen as a marker for
venous thrombosis93,94. However, SHBG levels have not yet been
researched in association with venous thrombosis risk.
In general, combined oral contraceptive use was associated
with an increase in SHBG levels and this increase was more pro-
nounced in third generation progestagen users than in second
generation users95,96. The use of a vaginal ring83 or a transder-
mal patch84 was also associated with an increase in SHBG levels.
Compared with a second generation combined oral contraceptive,
the SHBG levels were higher in both vaginal ring and transder-
mal patch users97. The SHBG increase was more pronounced in
transdermal patch users compared to vaginal ring users97. No
information was available on SHBG levels and hormone use for
tall stature or sex change.
Data presented here confirmed that combined oral contracep-
tive users, vaginal ring users and transdermal patch users have
an increased risk of venous thrombosis.
Experimental data on ethinylestradiol
Several epidemiological studies established that the use of com-
bined oral contraceptives increased the risk of venous thrombosis.
The use of contraceptives influenced the levels of coagulation
factors and increased APC resistance and SHBG levels. Data
from experimental research may provide further evidence on the
mechanism how ethinylestradiol can influence the risk of venous
thrombosis.
Ethinylestradiol on a cellular level Ethinylestradiol is able to
bind to the estrogen receptor. This complex of ethinylestradiol
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and estrogen receptor was able to function as a transcription
factor, to enter the nucleus and to bind to estrogen response
elements (ERE) in the DNA98. This resulted in transcriptional
activation of nearby genes. Many coagulation factors genes con-
tain a ERE suggesting that ethinylestradiol is able to influence
coagulation factors levels directly.
17β-Estradiol and ethinylestradiol were compared with re-
gard to their ability to translocate the estrogen receptor to the
nucleus of hepatocytes99. 100-fold higher concentrations of 17β-
estradiol was needed to lead to the same promotion of translo-
cation as ethinylestradiol in parenchyma cells in the liver of
rats. Furthermore, they also compared the metabolic pathways
and found that 17β-estradiol was much more metabolized than
ethinylestradiol. In the metabolism of 17β-estradiol, one major
route100 is the oxidation at the C-17 position which is blocked
by the ethinyl group in ethinylestradiol at the same C-17 posi-
tion (Figure 1.1). This potentially explains why 17β-estradiol
was more metabolized than ethinylestradiol.
First-pass metabolism of ethinylestradiol An overview of the first-
pass metabolism of ethinylestradiol is given in figure 1.2.
One of the enzymes involved in the ethinylestradiol first-pass
metabolism in the liver is cytochrome p-450 3A4 (CYP3A4)
which hydroxylates ethinylestradiol to hydroxy-ethinylestradiol.
Several studies looked at the effect of ethinylestradiol and differ-
ent progestagens on the content of cytochrome P-450 enzymes in
the liver and the inhibition of CYP3A4101–103. Both ethinyles-
tradiol and gestodene (third generation progestagen) were able
to reduce the total content of this enzyme family in the liver
with at least 30% and to inhibit the enzyme CYP3A4. How-
ever, a higher dose of ethinylestradiol and gestodene was used in
this study than the dose used in combined oral contraceptives
and the combination of ethinylestradiol and gestodene was not
evaluated so the question remains whether the currently used





























Figure 1.1: The oxidation at C-17 of estradiol to estrone is shown in the
top part. This oxidation is blocked by the ethinyl-group in ethinylestradiol
(indicated by circle) depicted in the bottom part
combination with gestodene is also able to inhibit the enzyme
CYP3A4 in vivo.
Taken together the data from experimental research provides




Ethinylestradiol levels vary according to the day in the cycle and
















Figure 1.2: The first-pass metabolism of ethinylestradiol in the liver. Genes
involved in this metabolism are depicted in italics
measurement, blood has to be drawn at the same moment for ev-
ery woman included in a study. However, in current case-control
studies of venous thrombosis, blood is taken at random in the
menstrual cycle and after the thrombotic event when many wo-
men have stopped using combined oral contraceptives. In most
research settings regarding venous thrombosis ethinylestradiol
levels are not commonly measured. No study has assessed the
association between the levels of ethinylestradiol and venous
thrombosis risk.
Because SHBG levels are seen as a marker for the estrogenic-
ity of combined oral contraceptives and venous thrombosis risk
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and are not affected by daily fluctuations, SHBG levels will be
measured instead of ethinylestradiol levels. To determine whether
SHBG levels are a risk factor for venous thrombosis, the asso-
ciation between increased SHBG levels and the risk of venous
thrombosis in women not using hormonal contraceptives will
be discussed in chapter 2. The association between the dose
of ethinylestradiol in combined oral contraceptives and SHBG
levels will be discussed in chapter 3.
First-pass metabolism of ethinylestradiol To determine whether
genetic variation in the first-pass metabolism of ethinylestradiol
can at least in part explain the risk of venous thrombosis in
oral contraceptive users, common genetic variation in enzymes
in this metabolism will be investigated. Many genes and their
enzymes are involved in the first-pass metabolism of ethinyles-
tradiol (Figure 1.2). Genes are selected based on their ability
to convert ethinylestradiol and on their expression in the liver.
Genetic variation in the selected genes will be assessed through
haplotypes. A haplotype is a combination of alleles on a chro-
mosome that is not affected by recombination and consequently
transmitted together. Because of this linkage, without actual
measurement, a known single nucleotide polymorphism (SNP)
can provide information about neighbouring SNPs.
Conjugation and hydroxylation are the first two steps in the
first-pass metabolism of ethinylestradiol. Sulfonation and glu-
curonidation are both conjugation steps leading to inactive and
water-soluble ethinylestradiol that can easily be excreted through
the urine or bile. The genes SULT1A1 and SULT1E1 code for
sulfotransferases that are involved in sulfonation105–110 of eth-
inylestradiol and the genes UGT1A1, UGT1A3, UGT1A9 and
UGT2B7 code for UDP-glucuronosyltransferases involved in the
glucuronidation110–113. Hydroxylation and subsequent methy-
lation, of the hydroxyl group, lead to hydroxy-ethinylestradiol
and methoxy-ethinylestradiol, respectively. To inactivate these
hormones, the aforementioned conjugation steps are repeated.
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The genes CYP1A2, CYP2C9, CYP3A4 and CYP3A5 code for
enzymes involved in the hydroxylation step102,110,114,115 and the
COMT gene codes for catechol O-methyltransferase involved in
the methylation step116. Genetic variation in these genes, their
effect on SHBG levels and the association with venous thrombo-
sis will be discussed in chapter 4.
Clinical aspects
Current guidelines advice women to refrain from using combined
hormonal contraceptives after a venous thrombosis. Progestagen-
only contraceptives can be used. Adherence to these guidelines
and potential explanations will be assessed in chapter 5.
Combined oral contraceptive use increases the risk of a first
venous thrombosis, whether contraceptive use is also associated
with a second event is unclear. To date, one study assessed the
risk of a recurrence and hormonal contraceptive use117. A total
of 14 recurrences were observed among premenopausal women
exposed to hormonal risk factors (oral contraceptive use or preg-
nancy) of which 11 occurred in women using hormonal contra-
ceptives. The incidence of a recurrence was 4.3 times higher in
hormonal contraceptive users than in non-users (incidence rate
ratio (IRR) 4.3, 95%CI: 1.7 to 11.1). We will analyse the in-
cidence rate of recurrent venous thrombosis in premenopausal
women and the effect of hormonal contraceptives used at the first
or second event in chapter 6. The effect of oral and non-oral
preparations on recurrent venous thrombosis will be discussed
as well.
Although it has been shown that there is a difference in the
risk of a first venous thrombosis per generation of progestagens,
no clear overview of the associations between different combined
oral contraceptives and the risk of venous thrombosis exists.
We set out to provide an overview of the risk of a first venous
thrombosis per combined oral contraceptive preparation. A net-
work meta-analysis will be performed because combined oral
29
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contraceptives are mostly compared to non-use or to a combined
oral contraceptive containing levonorgestrel with 30 µg ethinyl-
estradiol resulting in gaps in direct evidence. The results of the
network meta-analysis will be discussed in chapter 7.
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Background: Oral contraceptives use increases the risk of ve-
nous thrombosis as well as sex hormone binding globulin (SHBG)
levels. Furthermore, increased SHBG levels are positively associ-
ated with activated protein C (APC) resistance and thrombotic
risk in oral contraceptive users.
Objectives: To determine whether increased SHBG levels are
causally related to venous thrombosis in women not using hor-
monal contraceptives.
Methods: Premenopausal women were selected from a case-
control study on venous thrombosis, the MEGA study (23 pa-
tients; 258 controls). Women using hormonal contraceptives were
excluded. Firstly, the risk of venous thrombosis with SHBG levels
above the normal reference range (70 nmol/L) was determined.
Secondly, because multiple regulating factors affect SHBG lev-
els and residual confounding may remain, we determined six
single-nucleotide polymorphisms (SNPs) in the SHBG gene and
assessed the risk of venous thrombosis in a different case-control
study, the LETS (20 patients; 74 controls), and in MEGA study.
Finally, the association between SHBG levels and the normalized
activated partial thromboplastin time-based APC resistance (an
intermediate endpoint for venous thrombosis) was determined.
Results: Elevated SHBG levels (>70.0 nmol/L) were associated
with venous thrombosis (OR 1.92; 95%CI: 0.74-5.00). However,
this finding can be explained by residual confounding. Two SNPs
in the SHBG gene affected SHBG levels, but not venous throm-
bosis risk. Furthermore, SHBG levels in controls were not as-
sociated with APC resistance (SHBG level >70.0 versus ≤70.0
nmol/L: mean difference in normalized APC sensitivity ratio
0.03; 95%CI: -0.05 to 0.10). Exclusion of women with FV Leiden
did not materially change these results.
Conclusions: Increased SHBG levels are not causally associated
with the risk of venous thrombosis.
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Introduction
Venous thrombosis is the formation of a blood clot in the veins,
predominantly in the legs. The overall age-dependent incidence is
1-3 per 1000 persons per year1, whereas the incidence in women
of reproductive age is estimated to be 5-10 per 10,000 women-
years2. Both genetic and acquired risk factors are known to
influence the risk of venous thrombosis. An important acquired
risk factor is the use of hormonal contraceptives in women3. The
use of combined oral contraceptives (COCs) is associated with a
four-fold to six-fold increased risk of venous thrombosis4–7. The
risk of venous thrombosis is higher in so-called third generation
progestagen (e.g., desogestrel, gestodene) COC users than second
generation (e.g., levonorgestrel) COC users8–11.
Results from several previous studies have suggested that
the effect of a COC on sex hormone binding globulin (SHBG)
levels reflects the risk of venous thrombosis. SHBG is a plasma
glycoprotein that binds sex steroid hormones testosterone and
17 β -estradiol. Plasma SHBG is primarily produced in hepato-
cytes. In contraceptive users, estrogens such as ethinylestradiol
increase the production of SHBG12,13, whereas progestagens in-
duce a decrease of SHBG levels depending on the type and
dose used14,15. Therefore, the effect of COCs on SHBG levels
can be seen as the sum of the stimulatory effect of ethinyles-
tradiol and the inhibitory effect of the progestagen, resulting in
the total estrogenicity of the pill15,16. This so-called total es-
trogenicity of a COC crudely correlates with the risk of venous
thrombosis, in the sense that levenorgestrel-containing COCs
have a lower associated risk and lower SHBG levels than third-
generation pills containing desogestrel or gestodene15,17–20. Fur-
thermore, SHBG levels in COC users were positively associated
with thrombin generation-based activated protein C resistance
(APC) resistance16,21. APC resistance is the relative inability
of protein C to cleave factor Va or factor VIIIa, leading to a
prothrombotic state. APC resistance has been shown to predict
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venous thrombosis risk in both men and women22,23.
In addition to COCs, many environmental risk factors af-
fect SHBG levels, such as age24, obesity25,26, diabetes27, liver
diseases28,29, and hyperthyroidism30,31. Regarding genetic vari-
ation in the SHBG gene, the single-nucleotide polymorphisms
(SNPs) rs13894 (C/T) and rs727428 (G/A) decrease SHBG lev-
els with an increasing number of minor alleles32–34. Minor alle-
les of SNP rs6259 (Asp356Asn) were associated with increasing
SHBG levels. Furthermore, the combination of the SNPs rs6259
(Asp356Asn), rs858521 (C/G), and rs727428 (G/A) accounted
for 24% of the variation in SHBG levels in postmenopausal wo-
men33.
Although an increased SHBG level in oral contraceptive users
is a marker for the risk of venous thrombosis, the question re-
mains of whether increased SHBG levels are a risk factor for
venous thrombosis in a causal sense. The aim of this study was
threefold. First, the risk of venous thrombosis associated with
SHBG levels was evaluated in non-contraceptive users. Second,
to eliminate the influence of residual confounding, the effect on
thrombotic risk of genetic variants in the SHBG gene that af-
fect SHBG levels was assessed. A similar approach was used to
study genetic variation in the SHBG gene and SHBG levels in
association with diabetes27. Third, we investigated the associ-
ation between SHBG levels and APC resistance, which is an
established intermediate endpoint for venous thrombosis.
Methods
Participants Participants were selected from two large case-con-
trol studies, i.e., the Leiden Thrombophilia Study (LETS) and
the Multiple Environmental and Genetic Assessment of risk fac-
tors for venous thrombosis (MEGA) study. In the LETS, par-
ticipants with a first episode of venous thrombosis in the leg,
younger than 70 years and without a known malignant disorder,
were enrolled between 1 January 1988 and 31 December 1992.
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As controls, friends and partners of the patients were asked to
participate. Details of the study have been described elsewhere35.
In the MEGA study, participants with a first venous thrombosis
in the leg or arm or pulmonary embolism were recruited between
1 March 1999 and 31 August 2004. Controls were either the part-
ners of the patients or recruited through random digit dialing.
Details of the study have been described elsewhere36. Both stud-
ies included objectively verified venous thrombotic events. In
both the LETS and the MEGA study, participants were asked
to fill in a questionnaire within a few weeks after the throm-
botic event, and subsequently to provide a blood or buccal swab
sample three months after discontinuation of anticoagulant ther-
apy. The LETS and the MEGA study differed slightly in their
inclusion and exclusion criteria. To make both studies compara-
ble, patients with venous thrombosis in the arm or pulmonary
embolism were excluded from the MEGA study.
The population of interest consisted of premenopausal women
with or without a first event of venous thrombosis (NLETS=337;
NMEGA=2657). For the current study, only idiopathic venous
events were selected, so we excluded women who had any type
of cancer (NMEGA=63), were hospitalized (NLETS=22; NMEGA=
357), had undergone surgery (NLETS=29; NMEGA=277), had had
bone fractures (NLETS=2; NMEGA=81) or injuries (NMEGA=529)
in the 12 months before the event. Furthermore, women who were
pregnant (NLETS=10; NMEGA=65) or postpartum (NLETS=4;
NMEGA=17), had a miscarriage (NLETS=1; NMEGA=10), used
hormone replacement therapy (NMEGA=14) or used hormonal
contraceptives (NLETS=213; NMEGA=1013), in the 12 months
before the event were excluded. Totals of 94 and 385 women
were included from the LETS and MEGA study, respectively.
For these women, DNA was available, through either a blood
sample or buccal swab sample. Plasma was required for SHBG
measurement; therefore, women with a buccal swab sample were
excluded (NMEGA=104). The amount of plasma left in the LETS
was insufficient for measurement of SHBG levels.
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Data regarding age and body mass index (BMI) were re-
trieved from the questionnaire. The BMI (kg/m2) of these wo-
men was calculated from their reported weight and height. For
the association with SHBG levels in controls, age and BMI were
divided into three categories, i.e., for age into ≤30 years, 30-40
years and 40-50 years and for BMI into normal (≤25 kg/m2),
overweight (25-30 kg/m2) and obese (>30 kg/m2).
DNA preparation and SNP typing Blood samples were taken at
least 3 months after discontinuation of anticoagulant therapy.
Blood was drawn after an overnight abstinence from intake of
food, caffeine, and alcohol, and collected into vacuum tubes con-
taining 0.106 mol/L trisodium citrate as anticoagulant. Blood
was centrifuged to retrieve cell-free, citrated plasma. Process-
ing of blood samples and subsequent DNA isolation have been
described previously35,36.
To determine the haplotypes in the SHBG gene, the Genome
Variation Server (GVS)37 was used. The GVS incorporates in-
formation from HapMap, and is sponsored by SeattleSNPs. The
SHBG gene showed six haplotypes, hA to hF (frequencies in a
European population of Northern and Western ancestry (CEU)
according to HapMap data were 11%, 14%, 22%, 14%, 29%, and
10%, respectively). Only SNPs with a minor allele frequency of
≥5% were considered. The following haplotype-tagging SNPs
were selected: rs13894, rs6259, rs8066665, rs2955617, rs858521
and rs727428. The combination of these six SNPs led to six
haplotypes in the SHBG gene (Supplementary table). For four
of these, an effect on SHBG levels was reported previously (we
found no reports for SNPs rs8066665 and rs2955617). As the
total number of known SNPs in the SHBG gene is relatively low,
the selected SNPs were the only ones available to discriminate
between the different haplotypes.
The SNPs were determined with the MassARRAY platform
(Sequenom, San Diego, California, USA), according to manufac-
turer’s protocols (Sequenom). Genotyping determination was
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performed blinded to the case-control status. Five per cent of
the samples were repeated for allele-calling consistency; no dis-
crepancies were found.
Laboratory measurement As the amount of plasma left from
the LETS samples was not sufficient for an SHBG measure-
ment, SHBG levels were measured only from the MEGA study
(N=281). SHBG levels (nmol/L) were measured with an im-
munometric assay (Immulite; Siemens Healthcare Diagnostics,
Tarrytown, NY, USA). The sensitivity is 0.2 nmol/L and the as-
say has a log-term variation of 6% at levels of both 5 nmol/L and
80 nmol/L. The within-assay variation is 3-4% and the between-
assay variation 3.5-6%. The samples were analyzed in a single
series in random order. SHBG levels were measured without
knowledge of any of the participant’s characteristics.
APC resistance was determined in samples from the MEGA
study. APC resistance was measured with Cephotest (Nycomed
Pharma, Oslo, Norway). The normalized APC sensitivity ratio
(nAPCsr) was defined as the activated partial thromboplastin
time (APTT) in the presence of APC divided by the APTT in
the absence of APC in participants divided by the same ratio
determined in normal pool samples, i.e., (APTT+APCparticipants
/ APTT-APCparticipants) / (APTT+APCnormalpool / APTT-
APCnormalpool).
Statistical analysis First, the association between SHBG levels
and the risk of venous thrombosis was assessed in the MEGA
study. SHBG levels were dichotomized with a cut-off value of
70 nmol/L SHBG, which is above the normal reference range.
With logistic regression analysis with robust standard errors
(SEs), the risk of venous thrombosis associated with SHBG levels
of >70 nmol/L compared with ≤70 nmol/L was assessed by
calculating odds ratios (OR) with 95% confidence intervals (CIs)
with adjustment for age and BMI.
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Second, the relationship between genetic variation in the
SHBG gene and the risk of venous thrombosis was studied in
the LETS and repeated in the MEGA study. For SNPs, Hardy-
Weinberg Equilibrium was assessed with a chi-squared test in
controls. Regarding haplotypes, the posterior probabilities of the
individual haplotype combinations as estimated by PLINK (ver-
sion 1.07)38 were used as weights in the statistical analyses. No
underlying genetic model was assumed for the SNPs or haplo-
types (i.e., SNPs and haplotypes were defined categorically in
the regression model). Linear regression analysis with robust
SEs was used to determine the effect of a SNP or haplotype in
the SHBG gene on SHBG levels in controls from the MEGA
study. To determine the presence of a relevant effect of genetic
variation in the SHBG gene on SHBG levels, we used a ≥20
nmol/L difference between carriers of two copies of a minor al-
lele or haplotype and non-carriers of the given allele or haplotype.
This value was based on the minimal difference in SHBG levels
between users of a second generation oral contraceptive (which
have the lowest levels of all pill-users) and non-users. Logistic
regression with robust SEs was used to estimate the relative risk
of venous thrombosis associated with different SNPs or haplo-
types. The risks were determined in the LETS and replicated in
the MEGA study.
Finally, the association between SHBG levels and nAPCsr
was determined in the MEGA study. The association between
nAPCsr and the risk of venous thrombosis was assessed by cal-
culating the mean difference in nAPCsr between SHBG levels
>70 nmol/L and ≤70 nmol/L. The 95% confidence interval was
calculated with a robust SE. The analysis was repeated with-
out women with FV Leiden which is known to lead to APC
resistance.
Statistical analyses were performed with STATA, version 12.0
(StataCorp LP, College Station, TX, USA).
51
2. SHBG levels and venous thrombosis
Results
From the LETS, 20 patients and 74 controls were included. A to-
tal of 23 patients and 258 controls were included from the MEGA
study. Baseline characteristics of the participants from the LETS
and MEGA study are depicted in table 2.1. In the MEGA study,
the median SHBG level in the patients was 55.6 nmol/L (in-
terquartile range (IQR) 37.0, range 21.2 to 458.2 nmol/L) and
that in controls was 58.4 nmol/L (IQR 37.2, range 16.1 to 524.3
nmol/L). The influence of age and BMI on SHBG levels was
assessed in the controls from the MEGA study. SHBG levels
were higher in women aged 30-40 years than in women aged ≤30
years (mean difference: 20.6 nmol/L, 95%CI: -2.4 to 43.6). How-
ever, levels did not increase much with age after this: in women
aged 40-50 years SHBG levels were only 6.9 nmol/L higher than
in women aged ≤30 years (95%CI: -15.3 to 29.2). SHBG levels
were lower in obese women (BMI of >30 kg/m2 ) than in women
with normal weight (BMI of ≤25 kg/m2 )(mean difference: 28.6
nmol/L, 95%CI: 9.1 to 48.1). There was no difference in SHBG
level between women with a BMI of 25-30 kg/m2 and those with
a BMI of ≤25 kg/m2 (mean difference: 2.5 nmol/L, 95%CI: -11.2
to 16.3).
Nine cases (39%) and 90 controls (35%) from the MEGA
study had SHBG levels above normal reference range (>70
nmol/L) (Table 2.2). After adjustment for age and BMI, SHBG
levels above 70 nmol/L were associated with a 1.9-fold increased
risk of venous thrombosis (OR 1.92, 95%CI: 0.74 to 5.00).
To assess the association between SHBG levels and venous
thrombosis, a total of six SNPs were selected in the SHBG gene,
tagging six haplotypes (Supplementary table). In both the LETS
and MEGA study, all SNPs were found to be in Hardy-Weinberg
equilibrium (p>0.05) as measured in the controls. The effect
of genetic variation in the SHBG gene on SHBG levels was
substantial, making these SNPs informative for a ‘Mendelian
randomization’ analysis. The predefined in- or decrease of 20
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Table 2.1: Baseline characteristics from the LETS and MEGA
study
LETS study MEGA study
Cases Controls Cases Controls
Variable (N=20) (N=74) (N=29) (N=356)
Age, mean(SD) 44(5) 41 (6) 40 (8) 39 (7)
Caucasian*, (%) - - 25 (89) 313 (90)
BMI†, mean(SD) 27.1 (6.7) 25.5 (4.4) 27.7 (5.3) 24.6 (4.3)
SHBG levels‡,
median(IQR) - - 55.6 (37.0) 58.4 (37.2)
SD, standard deviation; IQR, interquartile range
* No data on ancestry was available in 9 women
† 18 women had no data on weight or height
‡ Measured in 281 women (23 cases; 258 controls)
nmol/L is substantial relative to the SHBG level of the majority
of the women in this study. In our population, 95% of women
had SHBG levels of 128.5 nmol/L or lower.
Table 2.2: SHBG levels and the risk of venous thrombosis in the MEGA
study
SHBG levels Cases Controls OR Adjusted*
(%) (%) (95%CI) (95%CI)
≤70.0 nmol/L 14(61) 168 (65) 1 1
>70.0 nmol/L 9 (39) 90 (35) 1.20 (0.50 to 2.88) 1.92 (0.74 to 5.00)
* Adjusted for age and BMI
Homozygosity for the minor allele (genotype TT) of SNP
rs13894 was associated with a decrease in SHBG levels of 50
nmol/L compared with homozygosity for the major allele (geno-
type CC). However, this was based on only one control with
the TT genotype (Figure 2.1 & Table 2.3). The G allele of SNP
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rs2955617 and the A allele of SNP rs727428 affected SHBG lev-
els (Figure 2.1 & Table 2.3). Genotype GG of SNP rs2955617
decreased SHBG levels by 20.7 nmol/L (95%CI: -8.2 to 33.1) as
compared with genotype TT. The same decrease was observed
for genotype AA of SNP rs727428 (20.9 nmol/L, 95%CI: 4.9 to
36.8). For SNP rs727428, a linear association was observed; with
each increase in the number of minor alleles, the SHBG level
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Figure 2.1: Mean difference with 95% confidence intervals (indicated with
dots and lines). The common homozygotes were selected as reference (indi-
cated with 0).
None of the cases in the LETS was homozygous for the mi-
nor allele of SNP rs2955617 (genotype GG); therefore, no risk
could be calculated. In the MEGA study, genotype GG of SNP
rs2955617 was not associated with risk of venous thrombosis (OR
1.32, 95%CI: 0.34 to 5.12). In the LETS, a decrease in the risk of
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Table 2.3: Effect of SNPs in the SHBG gene on SHBG levels
SNP N (%) Mean SHBG Mean difference
levels (95%CI) (95%CI)
rs13894
CC 227 (89) 66.7 (60.7 to 72.8) Reference
CT 27 (11) 82.0 (52.0 to 112.1) 15.3 (-15.0 to 45.6)
TT 1 (0) 16.9 -49.8 (-55.9 to -43.7)
rs6259
GG 204 (80) 70.5 (62.9 to 78.2) Reference
GA 45 (18) 59.5 (53.4 to 65.5) -11.1 (-20.8 to -1.3)
AA 5 (2) 55.0 (38.0 to 72.1) -15.5 (-32.7 to 1.6)
rs8066665
GG 91 (36) 64.8 (55.0 to 74.6) Reference
GA 127 (50) 71.4 (61.7 to 81.1) 6.6 (-7.3 to 20.4)
AA 36 (14) 66.0 (52.8 to 79.1) 1.2 (-15.2 to 17.5)
rs2955617
TT 123 (49) 70.3 (61.0 to 79.6) Reference
TG 102 (40) 71.4 (60.9 to 81.9) 1.1 (-12.9 to 15.2)
GG 28 (11) 49.6 (41.3 to 58.0) -20.7 (-33.1 to -8.2)
rs858521
CC 76 (30) 62.5 (54.7 to 70.4) Reference
CG 133 (52) 74.4 (63.7 to 85.1) 11.9 (-1.4 to 25.1)
GG 45 (18) 59.9 (51.7 to 68.1) -2.7 (-14.0 to 8.6)
rs727428
GG 85 (33) 76.0 (63.2 to 88.7) Reference
GA 125 (49) 67.5 (58.9 to 76.1) -8.4 (-23.8 to 7.0)
AA 45 (18) 55.1 (45.4 to 64.8) -20.9 (-36.8 to -4.9)
venous thrombosis was observed in women with genotype AA of
SNP rs727428 (OR 0.24, 95%CI: 0.03 to 2.19); however, this risk
was not confirmed in the MEGA study (OR 1.05, 95%CI: 0.33 to
3.33). Although we observed a linear trend in SHBG levels with
increasing number of minor alleles of this SNP, no association
was observed with risk of venous thrombosis in either the LETS
or MEGA study. Haplotype analysis gave the same results (data
not shown).
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Finally, the association between SHBG levels and APC re-
sistance was evaluated in the MEGA study. SHBG levels of
>70 nmol/L were associated with a 0.03 (95%CI: -0.05 to 0.102)
increase in nAPCsr as compared with levels of ≤70 nmol/L.
Adjustment for age and BMI did not alter the result (mean dif-
ference between SHBG levels >70 nmol/L versus ≤70 nmol/L in
nAPCsr: 0.02, 95%CI: -0.06 to 0.10). Exclusion of women with
FV Leiden did not materially change the results (mean differ-
ence: 0.03, 95%CI: -0.04 to 0.10 and adjusted for age and BMI:
0.03, 95%CI: -0.05 to 0.11).
Discussion
We set out to study whether a high SHBG level is causally re-
lated with the risk of venous thrombosis. First, we showed that
there was a mild increase in risk associated with SHBG levels
above normal (i.e., 70.0 nmol/L) after adjustment for age and
BMI in non-users of hormonal contraceptives (OR 1.92, 95%CI:
0.74 to 5.00). However, as SHBG levels are affected by many
regulating factors, residual confounding may remain. Therefore
we performed a Mendelian randomization analysis: here, genetic
variants are used that are associated with levels that, by defini-
tion, cannot have been affected by potential confounding factors.
We showed that several SNPs were associated with SHBG levels,
but not with thrombotic risk. Finally, no association could be
found in non-users of hormonal contraceptives between SHBG
levels and APC resistance, an established intermediate endpoint
for venous thrombosis.
Our results in non-users are in contrast with the results ob-
served in oral contraceptive users, where an increase in SHBG
levels is associated with an increase in nAPCsr (endogenous
thrombin potential-based)21. Apparently, both SHBG levels and
the nAPCsr are affected by oral contraceptive use (Figure 2.2a).
In non-users, there is no common factor that influences both

















































































































































































































































































































































































































































































































































































2. SHBG levels and venous thrombosis
Oral contraceptive use APC resistance Venous thrombosis
SHBG levels
Non-users




Figure 2.2: Overview of the relationship between SHBG levels, APC resis-
tance and venous thrombosis in oral contraceptive users (a) and non-users
(b)
Four of the SNPs described in our study had previously been
associated with SHBG levels, i.e., SNPs rs13894, rs6259, rs858521
and rs727428. In contrast with the current results, SNPs rs6259
was previously associated with an increase in SHBG levels32,33.
This difference may be explained by a difference in study pop-
ulation. We included premenopausal women, whereas previous
studies included only women with hirsutism or postmenopausal
women. As SNP rs13894 was present in only one woman, no
effect on SHBG levels could be demonstrated. SNPs rs858521
and rs727428 were associated with a decrease in SHBG levels in
our study, which was also reported in two other studies33,34.
A limitation of our study is the small number of patients
included. An explanation is that we restricted our study pop-
ulation to women who did not use hormonal contraceptives at
the time of thrombosis. The strength of our study is that we
used a three-pronged approach to evaluate a possible association
between SHBG levels and venous thrombosis. All analyses con-
sistently showed no association between SHBG levels and venous
thrombosis, strengthening the conclusion that SHBG levels are
not associated with the risk of venous thrombosis.
Although an association with venous thrombosis for the high-
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est levels of SHBG cannot be excluded, SHBG levels within the
range observed in this study are not causally related to an in-
creased risk of venous thrombosis. This does not imply that
SHBG level may not be a marker for venous thrombosis in oral
contraceptive users, which in all likelihood it is, but that the
level is only a marker, and not a cause. The situation is different
for APC-resistance, which is an intermediate, i.e., both a marker
and a cause. The explanation is that APC-resistance is a global
read-out of the coagulation system, whereas SHBG level is not.
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Supplementary table Haplotype structure in the SHBG gene based on
six SNPs
SNP*
Haplotype rs13894 rs6259 rs8066665 rs2955617 rs858521 rs727428
A T G G G C A
B C A G G C A
C C G A T C G
D C G A G C A
E C G G T G G
F C G G T G A
* Minor alleles are indicated in bold
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Chapter 3
Effect of ethinylestradiol and
progestagen in combined oral
contraceptives on plasma sex
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Background: Sex hormone binding globulin (SHBG) levels may
be a marker for the risk of venous thrombosis in oral contracep-
tive users. While the effects of different progestagen types on
SHBG levels are well established, the association between the
ethinylestradiol dose in combined oral contraceptives and SHBG
levels remains to be studied.
Objectives: To determine the effect of the ethinylestradiol dose
on SHBG levels.
Methods: Healthy premenopausal women using a combined oral
contraceptive were included from a case-control study (MEGA
study, N=181) and a cross-over study (DRSP study, N=101).
Women exposed to risk factors for venous thrombosis (except for
oral contraceptive use) were excluded. Mean differences with 95%
confidence intervals were estimated, adjusted for confounders and
depending on the analysis adjusted for the progestagen used.
Results: A total of 282 women were included from the MEGA
and DRSP study. The mean SHBG level in these women was
139.5 nmol/L (95%CI: 131.2 to 147.8). After restriction to 30 µg
ethinylestradiol, users of desogestrel, gestodene, or drospirenone
had about 100 nmol/L higher SHBG levels than levonorgestrel
users. SHBG levels were higher in users of ≥35 µg ethinylestra-
diol (mean difference: 136.4, 95%CI: 64.5 to 208.3) and in users
of triphasic contraceptives (mean difference 50.9 nmol/L, 95%CI:
20.7 to 81.1) than in users of 20 µg ethinylestradiol. No difference
was observed between users of 20 µg and 30 µg ethinylestradiol.
Conclusions: An increase in ethinylestradiol dose is associated
with an increase in SHBG levels in combined oral contraceptive
users.
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Introduction
The use of combined oral contraceptives, containing an estrogen
(i.e. ethinylestradiol) and a progestagen, is associated with an
increased risk of venous thrombosis1–5. Because the estrogen
compound in combined oral contraceptives was thought to cause
the increased risk of venous thrombosis, the dose of ethinylestra-
diol has over time been reduced from ≥100 µg via 50 µg to 30
µg or 20 µg, indeed resulting in a lower risk of venous thrombo-
sis6–9. The type of progestagen in combined oral contraceptives
also affects the risk of venous thrombosis, e.g., the risk of venous
thrombosis is higher in users of third generation combined oral
contraceptives (containing desogestrel or gestodene) and in users
of cyproterone acetate than in users of second generation com-
bined oral contraceptives (containing levonorgestrel)8–11. Fur-
thermore, in users of preparations containing ethinylestradiol
and drospirenone (introduced in 2001) a sixfold increased risk
of venous thrombosis compared with non-users was observed8,9,
which was later confirmed in two other studies12,13.
Results from recent studies have suggested that the effect of
a combined oral contraceptive on sex hormone binding globu-
lin (SHBG) levels could be an indicator for the risk of venous
thrombosis14–16. SHBG is a plasma glycoprotein that binds the
sex steroid hormones testosterone and 17β-estradiol but not eth-
inylestradiol. SHBG is primarily produced in hepatocytes and
variation in its plasma levels is due to multiple regulating fac-
tors such as age, body weight, sex steroids, and insulin. Users
of combined oral contraceptives containing a third generation
progestagen have higher SHBG levels than users of a second gen-
eration progestagen14,15,17–19 reflecting the difference in venous
thrombosis risk. In accordance with the hypothesis that SHBG
levels are a marker of the risk of venous thrombosis, SHBG levels
in combined oral contraceptives users are positively associated
with thrombin generation-based activated protein C (APC) resis-
tance16. APC resistance is the relative inability of protein C to
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cleave activated factor V or activated factor VIII thereby leading
to a more prothrombotic state. APC resistance has been shown
to predict venous thrombosis risk in both men and women20.
While SHBG levels have been shown to reflect the difference
in venous thrombosis risk between different types of progestagen,
the estrogen compound is thought to be the most important fac-
tor determining the venous thrombosis risk. If SHBG levels can
be considered to be a marker for venous thrombosis and ethinyl-
estradiol is the main compound in combined oral contraceptives
causing venous thrombosis, then the ethinylestradiol dose in
combined oral contraceptives should be reflected in SHBG levels.
The aim of this study was to determine whether an increase in
ethinylestradiol dose results in higher SHBG levels in healthy
premenopausal women. Additionally, we assessed the effect of
different progestagens on SHBG levels.
Methods
Participants Participants were selected from a large case-control
study, i.e., the Multiple Environmental and Genetic Assessment
of risk factors for venous thrombosis (MEGA) study and from a
crossover study, i.e., the DRSP (drospirenone/ethinylestradiol)
study. In the MEGA study, participants with a first deep venous
thrombosis in the leg or arm or pulmonary embolism were re-
cruited between 1 March 1999 and 31 August 2004 (N=4930).
Controls were either the partners of the patients or were recruited
via random digit dialling (RDD) (N=6287). All participants
were asked to fill in a questionnaire and to provide a blood or
a buccal swab sample. Details of the study have been described
elsewhere21. In the DRSP study, healthy women using the same
type of combined oral contraceptive for at least four cycles were
recruited between July and November 2002 (N=156). In this
study, women were asked to switch from their current contracep-
tive to an oral contraceptive containing either levonorgestrel or
drospirenone. All women were asked to fill in a questionnaire and
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to provide a blood sample. Blood was drawn between days 18
and 21 of the pill-cycle. Only data on contraceptive use at base-
line and blood samples collected before the switch were used for
the current analysis. Women were excluded if there were contra-
indications for combined oral contraceptive use as stated by the
World Health Organization, i.e., women with a history of deep
venous thrombosis or pulmonary embolism, women with current
deep venous thrombosis or pulmonary embolism or women un-
dergoing major surgery and prolonged immobilization. Details
of the study have been described elsewhere16.
From the MEGA study, we selected premenopausal women
without venous thrombosis (i.e., controls); both partner controls
and controls recruited through RDD were included (N=1689).
Women with known environmental thrombotic risk factors were
excluded, i.e., women who had any type of cancer (N=26), had
been hospitalized (N=154), underwent surgery (N=109), had
bone fractures (N=28), or had injuries (N=274) in the twelve
months before the index date. Because some women were ex-
posed to one or more environmental risk factors for venous
thrombosis, a total of 467 women were excluded . We also ex-
cluded women who were pregnant (N=65), were within four
weeks postpartum (N=1) or were using hormone replacement
therapy (N=13) at the index date or experienced a miscarriage
(N=8) in the twelve months before the index date. Because we
were interested in the effect of ethinylestradiol on SHBG levels,
women who were using a progestagen-only contraceptive were
also excluded (N=23). Blood samples were needed for the SHBG
measurement; therefore women who did not provide a blood sam-
ple were excluded (N=661). We excluded women who did not
use a combined oral contraceptive at the time of venipuncture
(N=279). For the current analysis, this resulted in the inclusion
of 181 healthy premenopausal women using combined oral con-
traceptives of which 73 women were partners of cases and 108
were recruited through RDD.
From the DRSP study, we excluded women exposed to known
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environmental thrombotic risk factors, i.e., women who had any
type of cancer (N=2), had been hospitalized (N=21), under-
went surgery (N=10), had bone fractures (N=2), or had injuries
(N=31) in the twelve months before the index date. All women
were using a combined oral contraceptive at the index date and
had given a blood sample. For the current analysis, this resulted
in the inclusion of 101 healthy premenopausal women.
Laboratory measurements In the MEGA study, the day of a
woman’s four week cycle of pill use (3 weeks of pill use followed
by a pill-free week) was not taken into account when inviting her
to the clinic for a blood sample. Therefore, blood was drawn ran-
domly during the four week cycle of pill use; however, whether
the women were menstruating at venipuncture was recorded. In
the DRSP study, blood was drawn between days 18 and 21 of
the four week cycle of pill-use.
Collection and processing of blood samples have been de-
scribed previously16,21. In short, for both studies, blood was
drawn after an overnight fasting for food, caffeine and alcohol
and collected in vacuum tubes containing 0.106 mol/L trisodium
citrate as anticoagulant. Blood was centrifuged to retrieve cell-
free, citrated plasma.
SHBG levels (nmol/L) were measured with an immunometric
assay (Immulite; DPC, USA). The sensitivity is 0.2 nmol/L and
has a long-term variation of 6% both at levels of 5 nmol/L and 80
nmol/L. The within-assay variation is 3 to 4% and the between-
assay variation 3.5 to 6%. The samples were analysed in one
series in random order. SHBG levels were measured without
knowledge of the type of oral contraceptive used or any other of
the participant’s characteristics.
Statistical analysis The ethinylestradiol dose was categorised
into four categories, i.e., 20 µg, 30 µg, ≥35 µg per pill and tripha-
sic preparations. Triphasic contraceptives have varying ethinyl-
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estradiol and progestagen doses per pill over 21 days. In the
MEGA study, women were using triphasic contraceptives with
the following regimen: 30 µg of ethinylestradiol in the first six
days, 40 µg for five days and 30 µg for the last ten days. In the
MEGA study, one woman used a biphasic contraceptive; during
21 days the dose of ethinylestradiol is 50 µg, the progestagen
is only included in the preparation in the last fourteen days.
Because the dose of ethinylestradiol does not change over 21
days, this woman was categorised in the ≥35 µg group. In the
DRSP study, all women were using a monophasic contraceptive.
For nine women, information on the ethinylestradiol dose in the
combined oral contraceptive was not available, however informa-
tion on progestagen used was available. For descriptive purposes,
the progestagens used in the contraceptives were divided into
second generation (i.e., levonorgestrel), third generation (i.e.,
gestodene, desogestrel, and norgestimate) and other progesta-
gens (i.e., cyproterone acetate, drospirenone and first generation
progestagens lynestrenol and norethisteron). For the calculation
of mean differences in SHBG levels, the progestagens were not
grouped by generation but separately evaluated.
The effect of the progestagen and dose of ethinylestradiol on
SHBG levels was assessed using linear regression analysis. The
analysis was adjusted for study and to ensure that the effect of
the ethinylestradiol dose on SHBG levels is independent of the
progestagen used, we adjusted this analysis for the progestagen
used in the combined oral contraceptive. The analysis of the
effect of the progestagen in combined oral contraceptives in as-
sociation with SHBG levels was restricted to subjects taking 30
µg ethinylestradiol per contraceptive pill.
To reduce random variation in SHBG levels, the analyses
were adjusted for multiple variables which can influence SHBG
levels. The data were adjusted for whether women were men-
struating at the time of venipuncture, and for age and BMI,
which are known determinants of SHBG levels in non-users22–24.
Results were expressed as the mean difference with 95% confi-
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dence interval. Statistical analyses were performed with STATA,
version 11.2 (Statacorp LP, College Station, TX, USA).
Results
Overall, 282 women using a combined oral contraceptive from
the MEGA study (N=181) and the DRSP study (N=101) were
included. The general characteristics of the combined population
and separate per study are displayed in table 3.1. On average,
women from the MEGA study were 8 years older than women
from the DRSP study (mean difference: 8, 95%CI: 6 to 10).
Women from both studies had a BMI of about 23 kg/m2. In the
MEGA study, 60% (N=109) of the women were using a second
generation progestagen, while only 35% (N=35) of the women
from the DRSP study were using this progestagen. The most
frequently used dose of ethinylestradiol was 30 µg per pill in
both studies (100 (58%) and 65 (64%) women in the MEGA and
DRSP study, respectively). 32 women (19%) from the MEGA
study were using a triphasic contraceptive. The mean SHBG
plasma level was about the same in both studies (MEGA study:
143.5 nmol/L, 95%CI: 132.9 to 154.0, IQR 94.8, range 31.2 to
390.9 & DRSP study: 132.3 nmol/L, 95%CI: 118.9 to 145.7,
IQR 106.0, range 28.0 to 284.0). The mean SHBG plasma level
in women of both studies was 139.5 nmol/L (95%CI: 131.2 to
147.8, IQR 99.8, range 28.0 to 390.9). Both studies are combined
in further analyses which were adjusted for study and potential
confounders (i.e., age and BMI).
The results in table 3.2 show that not all combinations of ethi-
nylestradiol dose and progestagen were present. A combined oral
contraceptive containing 30 µg ethinylestradiol was most often
combined with the second generation progestagen levonorgestrel,
whereas a contraceptive with 20 µg ethinylestradiol with a third
generation progestagen (i.e., desogestrel, gestodene, or norgesti-
mate).
Menstruating at venipuncture may have affected the SHBG
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Table 3.1: Baseline characteristics of study participants
MEGA study DRSP study Combined
Variables (N=181) (N=101) (N=282)
Age, mean(range) 36 (18-50) 27 (18-51) 33 (18-51)
BMI, mean(range) 23.4 (15.7-37.9) 23.3 (18.3-37.7) 23.3 (15.7-37.9)
Menstruating
at venipuncture (%)a 11 (6) - 11 (4)
Progestagen type (%)
2nd,b 109 (60) 35 (35) 144 (51)
3rd,c 46 (25) 37 (37) 83 (29)
Otherd 26 (14) 29 (29) 55 (20)
EE dose (%)e
20 µg 14 (8) 17 (17) 31 (11)
30 µg 100 (58) 65 (64) 165 (60)
≥35 µg 26 (15) 19 (19) 45 (16)
Triphasicf 32 (19) - 32 (12)
BMI, body mass index; EE, ethinylestradiol
a Data was available of 174 women from the MEGA study
b Second generation progestagen only includes levonorgestrel (N=144)
c Third generation progestagen include desogestrel (N=55), gestodene
(N=24) and norgestimate (N=4)
d Other progestagen include lynestrenol (N=6), norethisteron (N=2), cypro-
terone acetate (N=30) and drospirenone (N=17)
e No information was available on the ethinylestradiol dose in nine women
f Triphasic contraceptives contain 30 µg in the first six days, followed by 40
µg for five days and ending with ten days of 30 µg ethinylestradiol
levels. In the MEGA study, SHBG levels were compared between
menstruating women versus women taking a pill at venipuncture.
11 women were menstruating at time of venipuncture and the
mean SHBG level was 102.1 nmol/L (95%CI: 59.1 to 145.0)
whereas the mean SHBG level of the remaining women who were
taking a pill (N=163) was 145.4 nmol/L (95%CI: 134.3 to 156.6).
The mean difference was 43.4 nmol/L (95%CI: -1.0 to 87.7).
Therefore, in addition to age, BMI and study, the linear regression
analyses were adjusted for menstruating at venipuncture.
Table 3.3 shows the association of progestagen and ethinyles-
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Table 3.2: Distribution of progestagen type and ethinylestradiol
dose
Progestagen EE dose, n (%)
20 µg 30 µg ≥ 35 µg Triphasic‡
2nd,∗ 3 (10) 99 (60) 2 (5) 31 (97)
3rd,† 28 (90) 49 (30) 5 (14) 1 (3)
Other Cyproterone acetate 0 0 30 (81) 0
Drospirenone 0 17 (10) 0 0
EE, ethinylestradiol
∗ Second generation progestagen only includes levonorgestrel (N=135)
† Third generation progestagen include desogestrel (N=55), gestodene
(N=24) and norgestimate (N=4)
‡ Triphasic contraceptives contain 30 µg in the first six days, followed
by 40 µg for five days and ending with ten days of 30 µg ethinylestra-
diol
tradiol dose with SHBG levels. When we restricted our analysis
to women receiving 30 µg of ethinylestradiol, users of desogestrel,
gestodene, and drospirenone had higher SHBG levels than users
of levonorgestrel (mean difference: 112.8 nmol/L, 95%CI: 97.3
to 128.2, 80.6 nmol/L, 95%CI: 57.3 to 104.0, and 111.1 nmol/L,
95%CI: 89.8 to 132.3 for desogestrel, gestodene, and drospirenone,
respectively). Adjustment for factors influencing SHBG levels
did not change these results.
Additional to the progestagens levonorgestrel, gestodene, des-
ogestrel, and drospirenone, 30 women used cyproterone acetate.
In contrast with these other progestogens, a contraceptive with
cyproterone acetate contains 35 µg ethinylestradiol. The mean
SHBG level in users of cyproterone acetate was high at 215.9
nmol/L (95%CI: 199.7 to 232.1); much higher than in users of
oral contraceptives containing levonorgestrel with 30 µg ethinyl-
estradiol (mean difference: 135.4 nmol/L, 95%CI: 116.9 to 153.9
adjusted for study and menstruating at venipuncture).
Users of ≥35 µg of ethinylestradiol had higher SHBG lev-
els than users of 20 µg (mean difference: 145.4 nmol/L, 95%CI:
75














































































































































































































87.1 to 203.7). Also users of triphasic contraceptives had higher
SHBG levels than users of 20 µg of ethinylestradiol (mean differ-
ence: 51.0 nmol/L, 95%CI: 22.8 to 79.1). The SHBG levels were
only slightly higher in users of 30 µg compared with 20 µg of
ethinylestradiol (mean difference: 13.8 nmol/L, 95%CI: -7.1 to
34.6). Adjustment for factors influencing SHBG levels did not
change these results.
The same results were observed when the analysis was re-
stricted to most commonly used progestagens (levonorgestrel,
desogestrel and gestodene) or separately per these progestagens,
although the number of women per category was very small (data
not shown). Furthermore, similar results were observed when the
analysis was performed per study (Supplementary table).
Discussion
When restricting to combined oral contraceptive preparations
with 30 µg ethinylestradiol, users of combined oral contracep-
tives containing desogestrel, gestodene, and drospirenone had
higher SHBG levels than users of levonorgestrel. Cyproterone
acetate use was also associated with higher SHBG levels than
levonorgestrel use, although we cannot exclude an effect caused
by the difference in ethinylestradiol dose. Women using a com-
bined oral contraceptive with ≥35 µg ethinylestradiol or women
using a triphasic contraceptive had higher SHBG levels than wo-
men using a combined oral contraceptive with 20 µg. However,
SHBG levels were only slightly higher in 30 µg ethinylestradiol
users than in 20 µg users.
Estrogens such as ethinylestradiol increase the synthesis of
SHBG25, whereas progestagens induce a decrease in SHBG levels
depending on the type and dose used14,26. In women receiving
15 µg of ethinylestradiol without a progestagen, the SHBG lev-
els increased from 213.5 nmol/L on day 1 to 661.9 nmol/L on
day 21 of the pill-cycle27. In contrast, women using 150 µg lev-
onorgestrel without ethinylestradiol showed a decrease in the
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SHBG levels over 23 days from 40.4 nmol/L to 15.5 nmol/L28.
The effect of a combined oral contraceptive on SHBG levels may
be seen as the result of the stimulating effect of ethinylestradiol
and the inhibiting effect of the progestagen in the contracep-
tive14. The final net change is sometimes referred to as the total
estrogenicity of the contraceptive. It has been suggested that this
may reflect the magnitude of the risk of venous thrombosis14.
In the literature, one paper reported on the effect of different
oral contraceptives as well as the effect of the ethinylestradiol
dose in combined oral contraceptives on SHBG levels; however,
the difference in SHBG levels before and after a contraceptive
was reported. No difference in SHBG levels between different con-
traceptives was stated29. No conclusions were drawn on whether
the ethinylestradiol dose in different combined oral contracep-
tives was reflected in SHBG levels.
The positive association between ethinylestradiol dose and
SHBG levels is in line with previous findings regarding the risk
of venous thrombosis. Lidegaard et al reported that compared
with users of oral contraceptive preparations containing 30-40 µg
ethinylestradiol, the risk of venous thrombosis was higher in users
of 50 µg ethinylestradiol (OR 1.6, 95%CI: 0.9 to 2.8) and lower in
users of 20 µg (OR 0.6, 95%CI: 0.4 to 0.9)30. In the MEGA study,
we also demonstrated that within users of oral contraceptives
containing levonorgestrel, the risk of venous thrombosis adjusted
for age was higher in users of 50 µg ethinylestradiol (OR 2.2,
95%CI: 1.3 to 3.7) than in users of 30 µg9. The risk of venous
thrombosis was lower in users of 20 µg than in users of 30 µg;
both in users of progestagens gestodene (OR 0.3, 95%CI: 0.2 to
0.7) and desogestrel (OR 0.7, 95%CI: 0.4 to 1.2).
Unfortunately, ethinylestradiol levels could not be measured
directly because the blood was drawn at random during the four
week cycle of pill use in the MEGA study and without considering
the hours after a pill was taken, which both have a significant
influence on ethinylestradiol levels31. Because of a half-life of
SHBG of about 7 days32, the hours after a pill was taken do
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not influence the SHBG levels. Data were available on factors
that were previously shown to influence SHBG levels and on
whether women were menstruating at venipuncture. Regarding
the analysis between ethinylestradiol dose and SHBG levels, we
would have preferred to restrict our analysis to one progestagen;
however, the number of women per category became very small
leading to unreliable estimates. We combined two studies that
differed in their design, which may have affected our results.
However, sensitivity analyses showed that this did not influence
our results. Finally, although we excluded women exposed to
environmental risk factors, women with a positive family history
were included. Nevertheless, we do not expect that having a
positive family history influenced SHBG levels. Strengths of our
study were that we included a relative large number of combined
oral contraceptive users who were using many different types of
prescriptions. Furthermore, SHBG levels as well as the difference
in SHBG levels between different progestagens in combined oral
contraceptive users were in the same range as observed in other
studies33–35.
In conclusion, users of the progestagens desogestrel, gesto-
dene, and drospirenone had increased SHBG levels compared
with levonorgestrel users. An increase in the ethinylestradiol dose
in the combined oral contraceptive leads to an increase in the
SHBG levels in premenopausal women using these combined oral
contraceptives. This study demonstrates that SHBG levels reflect
the ethinylestradiol dose used in combined oral contraceptives
independent of the progestagen used. Because ethinylestradiol
is important in the pathogenesis of venous thrombosis among
combined oral contraceptive users, these findings strengthen the
idea that SHBG levels in combined oral contraceptive users may
be seen as a marker for the risk of venous thrombosis.
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Supplementary table Results of sensitivity analysis per study
MEGA study DRSP study
Adjusted difference Adjusted difference




Desogestrel 125.9 (103.4 to 148.4) 106.6 (84.7 to 128.4)
Gestodene 91.0 (61.4 to 120.7) 44.9 (-8.3 to 98.1)
Drospirenone 94.1 (55.9 to 132.4) 124.9 (99.8 to 150.0)
EE dose
20 µg Reference Reference
30 µg 4.8 (-30.1 to 39.7) 12.5 (-15.8 to 40.8)
≥35 µg 130.8 (49.8 to 211.7) 141.2 (73.3 to 209.0)
Triphasic 45.2 (4.4 to 86.0) -
CI, confidence interval; EE, ethinylestradiol
* Adjusted for progestagen in the case of ethinylestradiol dose,
study, menstruating at venipuncture, age and BMI

















Background: Use of ethinylestradiol, one of the active ingre-
dients in combined oral contraceptives, affects the incidence of
venous thrombosis. To explain why some women develop throm-
bosis when using oral contraceptives and others do not, we hy-
pothesized a role for the first-pass metabolism of ethinylestradiol
in the liver.
Objectives: To determine the association between genetic vari-
ation in the first-pass metabolism of ethinylestradiol, venous
thrombosis risk and the effect on SHBG levels, a marker for
venous thrombosis risk in oral contraceptive users.
Methods: Premenopausal women with venous thrombosis and
control subjects were included from two large case-control stud-
ies, i.e., the LETS and the MEGA study. Women exposed to
acquired risk factors other than combined oral contraceptives
were excluded. Haplotype-tagging SNPs were selected in 11 can-
didate genes; COMT, CYP1A2, CYP2C9, CYP3A4, CYP3A5,
SULT1A1, SULT1E1, UGT1A1, UGT1A3, UGT1A9, and UGT-
2B7. Venous thrombosis risk was expressed as odds ratios (OR)
with 95% confidence intervals (CI). For SHBG levels, mean differ-
ences with 95%CI were estimated in combined oral contraceptive-
using control subjects from the MEGA study.
Results: 262 premenopausal women (103 cases; 159 controls)
were included from the LETS and 1193 (397 cases; 796 controls)
from the MEGA study. 74 SNPs in the 11 genes were determined.
Two copies of haplotype D in the UGT2B7 gene increased venous
thrombosis risk (OR~3) as well as SHBG levels (mean difference
27.6 nmol/L, 95%CI: -61.7 to 116.9 compared with no copies)
in oral contraceptive users and not in non-users. In oral contra-
ceptive users, haplotype A and B in the CYP3A4 gene were
associated with the risk of venous thrombosis, but not in non-
users; however, the effect on SHBG levels was not directional
with the risk. None of the other haplotypes were associated with
venous thrombosis.
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Conclusion: Genetic variation in the UGT2B7 gene can at least




Combined oral contraceptive use, containing an estrogen (i.e.,
ethinylestradiol) and a progestagen, increase venous thrombosis
risk1–4. Over time the dose of ethinylestradiol was stepwise re-
duced from ≥100 µg to 50 µg and 30/20 µg, which resulted in the
intended lowering in the risk of venous thrombosis1,5,6. The risk
of venous thrombosis is the highest in the first three months of
combined oral contraceptive use, i.e., about twelve-fold increased
compared with non-users7–9. With extended use the risk remains
approximately five-fold increased9. While some high-risk groups
have been identified, i.e., women with prothrombotic genetic de-
fects and women who are obese, it is largely unknown why oral
contraceptive use leads to thrombosis in some women, and not
in others.
Because they are taken orally, combined oral contraceptives
are metabolised in the liver through the so-called first-pass me-
tabolism. In the liver many coagulation factors are produced;
therefore, we hypothesized that the first-pass metabolism of oral
contraceptives, in particular of ethinylestradiol (Figure 4.1), in-
fluences the risk of venous thrombosis, and that genetic varia-
tion in involved genes explains the different susceptibility be-
tween women. In general, the first-pass metabolism of drugs
mainly involves conjugation and hydroxylation. Sulfonation and
glucuronidation are both conjugation steps leading to inactive
and water-soluble compounds which are excreted by the kid-
neys or the intestinal tract (via bile). The genes SULT1A1 and
SULT1E1 code for sulfotransferases that are involved in sulfona-
tion of ethinylestradiol10–15 and the genes UGT1A1, UGT1A3
and UGT1A9 code for UDP-glucuronosyltransferases involved in
the glucuronidation of ethinylestradiol15–18. Hydroxylation and
subsequent methylation of the hydroxyl group lead to hydroxy-
ethinylestradiol and methoxy-ethinylestradiol, respectively. The
genes CYP1A2, CYP2C9, CYP3A4 and CYP3A5 code for en-
zymes involved in the hydroxylation step15,19–21 and the COMT
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gene codes for catechol O-methyltransferase involved in the methy-
lation step22. To inactivate hydroxyl-ethinylestradiol and meth-
oxy-ethinylestradiol, the aforementioned conjugation steps are
used.
Sex hormone binding globulin (SHBG) is a marker for the hor-
monal effects of combined oral contraceptives on venous throm-
bosis risk. SHBG is a hepatic plasma glycoprotein that binds
the sex steroid hormones testosterone and 17β -estradiol, but
not ethinylestradiol. Estrogens such as ethinylestradiol increase
the synthesis of SHBG23, while progestagens induce a decrease
in SHBG levels depending on the type and dose24,25. The effect
of a combined oral contraceptive on SHBG levels may be seen
as the result of the stimulating effect of ethinylestradiol and the
inhibiting effect of the progestagen in a contraceptive25.
The aim of this study was to explain differences in susceptibil-
ity to the prothrombotic effect of oral contraceptives by assessing
genetic variation in the first-pass metabolism of ethinylestradiol
in premenopausal women. Because the investigated enzymes are
also involved in other metabolic pathways, results from non-users
were evaluated to assess the specificity of the association with
risk. Any risk associations with venous thrombosis observed in
non-users, in whom the first-pass metabolism of ethinylestradiol
is not activated, will be a reflection of genetic variation in the
other pathways. Furthermore, genetic variation in the first-pass
metabolism of ethinylestradiol was linked to an intermediate
variable, SHBG levels, in combined oral contraceptive users. A
priori, three criteria were established to determine whether a hap-
lotype was associated with venous thrombosis through changes
in the first-pass metabolism of ethinylestradiol, i.e., a similar as-
sociation with venous thrombosis in combined oral contraceptive
users in two independent studies (LETS and MEGA study), no
association in non-users, and a direction of the effect on SHBG




Participants Participants were selected from two case-control
studies on venous thrombosis, i.e., the LETS (Leiden Throm-
bophilia Study) and the MEGA (Multiple Environmental and
Genetic Assessment of risk factors for venous thrombosis) study.
In the LETS, participants with a first, symptomatic, objectively
confirmed episode of deep venous thrombosis in the leg, younger
than 70 years and without a known malignant disorder were
enrolled between 1 January 1988 and 31 December 1992. As
controls, acquaintances and partners of the patients were invited
to participate26. In the MEGA study, participants with a first
symptomatic deep venous thrombosis in the leg or arm or pul-
monary embolism were recruited between 1 March 1999 and 31
August 2004. Controls were either the partners of the patients
or recruited through random digit dialling (RDD). Details of
the study have been described elsewhere27. Participants of both
studies were asked to fill in a questionnaire and to provide a
blood or buccal swab sample. The LETS and the MEGA study
differed slightly in their in- and exclusion criteria. To increase
homogeneity in the present analysis, only patients with a deep
venous thrombosis of the leg were studied.
The population of interest consisted of premenopausal wo-
men younger than 50 years (NLETS=347; NMEGA=2657). Wo-
men who had any type of cancer (NMEGA=63), were hospitalized
(NLETS=22; NMEGA=357), had undergone surgery (NLETS=29;
NMEGA=277), suffered bone fractures (NLETS=2; NMEGA=81)
or had soft-tissue injuries (NLETS=0; NMEGA=529) in the twelve
months before the index date were excluded. We also excluded
women who were pregnant (NLETS=11; NMEGA=65), were within
four weeks postpartum (NLETS=4; NMEGA=17) or were using
hormone replacement therapy (NMEGA=14) at the index date
or had experienced a miscarriage (NLETS=1; NMEGA=10) in the
twelve months before the index date. Oral contraceptive users
were defined as users of a combined oral contraceptive at the
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index date (i.e., a contraceptive containing ethinylestradiol and
a progestagen). Hence, in both studies women using a contracep-
tive without ethinylestradiol, e.g., progestagen-only pills, were
excluded (NLETS=2; NMEGA=26). Women without a blood or
buccal samples were also excluded (NMEGA=366). 500 patients
and 955 controls were included in the current analysis (LETS:
103 cases and 159 controls; MEGA: 397 cases and 796 controls).
In both studies, the sum of all exclusions does not add up to the
total number of excluded participants because women could be
exposed to one or more risk factors.
DNA preparation and SNP typing Collection and processing
of blood samples and buccal swabs and subsequent DNA iso-
lation have been described previously26,27. To determine the
haplotypes in the selected genes, the Genome Variation Server
(GWS)28 was used. GVS incorporates information from HapMap
and other sources and is sponsored by SeattleSNPs. Only SNPs
with a minor allele frequency of 5% or more in Caucasians were
considered.
A total of 11 genes involved in ethinylestradiol metabolism
were selected prior to genotyping, i.e.,COMT,CYP1A2,CYP2C9,
CYP3A4, CYP3A5, SULT1A1, SULT1E1, UGT1A1, UGT1A3,
UGT1A9, andUGT2B7 in which a total of 74 SNPs were selected
(Supplementary table 4.1). Care was taken to select SNPs from
each haplotype that enabled a clear distinction between highly re-
lated genes. The SNPs were either determined with the MassAR-
RAY platform (Sequenom, San Diego, California, USA) accord-
ing to manufacturer’s protocols (Sequenom) or determined with
the 5’ nuclease/Taqman assay (Assay-by-Design, Applied Biosys-
tems, Foster City, California, USA). SNP rs28946889 was deter-
mined via restriction digest of the PCR product (details available
on request). Genotyping determination was done blinded to the
case/control status and study number. Five percent of the sam-
ples were repeated for allele-calling consistency, no discrepancies
were found.
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Laboratory measurements SHBG levels (nmol/L) were measured
with an immunometric assay (Immulite 2000 XPi; Siemens Health-
care Diagnostics, Tarrytown, NY, USA) in combined oral contra-
ceptive users of the control group of the MEGA (plasma of the
LETS subjects was no longer available). The sensitivity of the as-
say is 0.2 nmol/L and the assay has a log-term variation of 6% at
levels of 5 nmol/L and 80 nmol/L. The within-assay variation is
3-4% and the between-assay variation 3.5- 6%. The samples were
analysed in a single series in random order. SHBG levels were
measured without knowledge of any other of the participant’s
characteristics.
Statistical analysis Hardy-Weinberg Equilibrium was assessed
with a Chi-squared test in controls from the LETS and MEGA
study. Due to the large number of SNPs tested we used a Bonfer-
roni correction for the Hardy-Weinberg Equilibrium tests. The
posterior probabilities of correct haplotype assignment as esti-
mated by PLINK (version 1.07)29 were used as weights in all
statistical analyses. Because women could be assigned two possi-
ble combinations of haplotypes, no number of women per copies
of a haplotype was given in the tables. Odds ratios (OR) were
calculated to determine the risk of venous thrombosis associated
with the number of copies of a specific haplotype. To account
for multiple testing, the False Discovery Rate q-value was calcu-
lated. First, the p-value of the association was derived from the
univariate unconditional logistic regression analysis between a
haplotype and venous thrombosis risk while assuming an addi-
tive model for the genetic relationship with venous thrombosis.
Second, the p-values were ranked from smallest till largest, where
rank order 1 was given to the smallest p-value. Third, the q-values
were calculated as follows; the p-values were multiplied by the
number of tests performed and then divided by the rank order
of each p-value. For each test, the q-value is then defined as the
minimum among tests with equal or higher rank. The threshold
was set at 0.20 and can be interpreted as follows: among tests
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with a q-value of 0.20 or lower, at most 20% or lower of the
tests might be a false discovery. The analyses were restricted to
combined oral contraceptives users or non-users. Linear regres-
sion analysis was used to determine the effect of a haplotype
on SHBG levels in controls using combined oral contraceptives
from the MEGA study. In this analysis, combined oral contra-
ceptive use was defined at venipuncture and not at the index
date. To determine whether a haplotype was associated with
venous thrombosis, we used several criteria. An association with
venous thrombosis in the same direction had to be present in
the LETS and MEGA study, no association in non-users and
a same directional effect on SHBG levels as expected based on
the risk association with venous thrombosis. Statistical analyses
were performed with STATA, version 12.0 (Statacorp LP, College
Station, Texas, USA).
Results
General description of the population Baseline characteristics of
the studies are given in Table 4.1. In the LETS, the mean age
in cases and controls was 35 years (range cases: 16 to 49 and
controls: 15 to 48). In the MEGA study, the mean age in the
cases was 37 years (range: 18 to 49) and in the controls 38 years
(range: 18 to 49). No information about ancestry was available in
the LETS. In the MEGA study, about 90% of cases and controls
reported to be from Western European ancestry. The majority
of the cases (80% and 87%, respectively in the LETS and the
MEGA study) were using combined oral contraceptives at the
time of the event.
Hardy-Weinberg Equilibrium Hardy-Weinberg Equilibrium was
assessed in the controls from the LETS and MEGA study. To
control for multiple testing, we performed a Bonferroni correc-
tion. All SNPs were in Hardy-Weinberg Equilibrium (p>0.0007),
except for SNP rs12445705 in the SULT1A1 gene in the MEGA
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Table 4.1: Baseline characteristics of the selected population from the
LETS and the MEGA study
LETS MEGA study
Cases Controls Cases Controls
Variables (N=103) (N=159) (N=397) (N=796)
Mean age (SD) 35 (10) 35 (9) 37 (9) 38 (8)
Caucasiana(%) - - 347 (90) 695 (89)
Pill use (%) 78 (80) 62 (42) 343 (87) 335 (42)
a No information about race was available in the LETS study
study. To exclude a measurement error, we confirmed this SNP
with a Taqman assay. The results did not materially differ be-
tween the Sequenom and Taqman assay. Consensus among con-
trols from the LETS was 95.7% and 97.1% in the MEGA study.
Results per gene family The results were grouped per gene family.
In nine genes, no associations in the same direction were observed
between the LETS and MEGA study (Supplementary tables
4.2-9). In CYP3A4, two of the five haplotypes were associated
with the risk of venous thrombosis, i.e., the similar results were
observed in both studies (Table 4.2 & 4.3), and in UGT2B7, two
of the eight haplotypes were associated with venous thrombosis
(Table 4.4 & 4.5).
Gene family CYP In combined oral contraceptive users, two
haplotypes in CYP3A4 were associated with venous thrombosis
in both studies (Table 4.2). Carrying one copy of haplotype
A was associated with a decreased risk of venous thrombosis
(ORLETS: 0.29, 95%CI: 0.11-0.76 and ORMEGA: 0.57, 95%CI:
0.37-0.89). Similar results were observed for carriers of two copies
of haplotype A (ORLETS: 0.40, 95%CI: 0.14-1.13 and ORMEGA:
0.59, 95%CI: 0.37-0.94). With an additive model, each copy of
95






































































































































































































































































the allele reduced the risk by 20-30% (ORLETS: 0.72, 95%CI:
0.45-1.17 and ORMEGA: 0.83, 95%CI: 0.66-1.03). Carrying one
copy of haplotype B increased venous thrombosis risk (ORLETS:
2.14, 95%CI: 0.76-6.05; ORMEGA: 1.86, 95%CI: 1.17-2.94). None
of the cases in the LETS study were carriers of two copies of
haplotype B, whereas only one case in the MEGA study carried
two copies of haplotype B. With an additive model, a ~1.5 fold
increase in risk was observed per extra allele (ORLETS: 1.41,
95%CI: 0.52-3.83 and ORMEGA: 1.49, 95%CI: 0.95-2.33). None
of the other haplotypes in CYP3A4 were associated with venous
thrombosis risk, i.e., associations in the same direction in both
the LETS and MEGA study were not observed.
Both haplotypes A and B in CYP3A4 were associated with
changes in SHBG levels in combined oral contraceptive users
among the controls of the MEGA study. Carrying haplotype A
increased SHBG levels in controls of the MEGA study (mean
difference one copy versus no copies: 15.8 nmol/L, 95%CI: -8.5
to 40.1 and mean difference two copies versus no copies: 26.6
nmol/L, 95%CI: -0.3 to 53.5). We observed a decrease in SHBG
levels among controls of the MEGA study carrying one copy of
haplotype B (mean difference: -29.4 nmol/L, 95%CI: -58.0 to
-0.7). For both haplotyoes, the effect on SHBG levels was in the
opposite direction as expected based on the effect on the risk
of venous thrombosis; the protective haplotype A is associated
with increased SHBG levels, whereas the reverse was true for
the pro-thrombotic haplotype B.
In table 4.3, the effect of haplotypes in CYP3A4 on risk of
venous thrombosis in non-users is given. None of the haplotypes
were associated with venous thrombosis in non-users, i.e., no
associations in the same direction were observed.
Gene family UGT Carrying one copy of haplotype D of
UGT2B7 was not associated with venous thrombosis (ORLETS:
1.02, 96%CI: 0.49-2.12 and ORMEGA: 0.93, 95%CI: 0.67-1.30).
Carriers of two copies of haplotype D in UGT2B7 had an in-
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Table 4.3: Results from carriers of haplotypes in the emphCYP3A4 gene
among non-users
LETS (N=104) FDR MEGA (N=513) FDR
Haplotype OR (95%CI) p q OR (95%CI) p q
A
0 1 1
1 0.94 (0.23-3.89) 0.71 (0.33-1.52)
2 1.13 (0.25-5.07) 0.90 (0.40-2.02)
Additive 1.10 (0.52-2.32) 0.80 0.98 1.00 (0.64-1.55) 0.99 0.99
B
0 1 1
1 0.83 (0.17-4.14) 1.33 (0.60-2.95)
2 - -
Additive 0.83 (0.17-4.14) 0.82 0.98 1.11 (0.55-2.23) 0.77 0.94
C
0 1 1
1 4.75 (0.87-25.93) 1.18 (0.26-5.31)
2 - -
Additive 4.75 (0.87-25.93) 0.07 0.98 1.18 (0.26-5.31) 0.83 0.95
D
0 1 1
1 0.59 (0.20-1.68) 1.45 (0.81-2.60)
2 1.16 (0.11-12.23) 0.93 (0.21-4.21)
Additive 0.74 (0.28-1.94) 0.54 0.98 1.22 (0.78-1.91) 0.38 0.91
E
0 1 1
1 2.14 (0.18-25.22) 0.54 (0.07-4.16)
2 - -
Additive 2.14 (0.18-25.22) 0.55 0.98 0.54 (0.07-4.16) 0.55 0.94
creased risk of venous thrombosis in both LETS and MEGA
study (ORLETS: 3.78, 95%CI: 0.40-35.84 and ORMEGA: 2.61,
95%CI: 1.07-6.34) (Table 4.4). Because the effect seemed clearly
recessive, we did not interpret the results from an additive model.
None of the other haplotypes in UGT2B7 were consistently as-
sociated with venous thrombosis in both studies. Fully in line
with the effect of this haplotype on the risk of venous throm-
bosis, no effect on SHBG levels in controls of the MEGA study
was observed in carriers of one copy of haplotype D in UGT2B7
(mean difference one copy versus no copies: -5.5 nmol/L, 95%CI:
98
-28.5 to 17.6), and an increase in SHBG levels was observed with
carriers of two copies of haplotype D (mean difference two copies
versus no copies of haplotype D: 27.6 nmol/L, 95%CI: -61.7 to
116.9).
In table 4.5, the results for the UGT2B7 gene are given in non-
users. Carriership of one copy of haplotype E was associated with
an increase in risk of venous thrombosis (ORLETS: 1.58, 95%CI:
0.15-16.42 and ORMEGA: 1.47, 95%CI: 0.32-6.77). Carriers of two
copies of haplotype E were not present in either the LETS or
MEGA study and therefore the odds ratio assuming an additive
model did not change.
Multiple testing Overall, eight tests of a total of 321 tests were
significant at a 0.05 level. Given the large number of tests, we
calculated FDR q-values which were all above 0.20.
Discussion
In a search of explanations for ethinylestradiol-associated venous
thrombosis, we studied haplotypes of 11 genes involved in eth-
inylestradiol metabolism in two case-control studies on venous
thrombosis with a total of 500 patients and 955 control women.
For nine genes we found no association of the haplotypes with
risk, while two genes (CYP3A4 and UGT2B7 ) were associated
with venous thrombosis risk. Haplotpe D in the UGT2B7 gene
showed a consistent effect on SHBG levels as well. Homozygous
carriers of haplotype D in UGT2B7 had a three-fold increased
risk of thrombosis and a substantial increase in SHBG levels. For
all genotypes the FDR was above the threshold of 0.20. How-
ever, the likelihood that the association is the result of chance
variation is unlikely given the large odds ratios in two separate
studies (3.87 and 2.61) in combined oral contraceptive users, the
absence of an effect in non-users meaning the result is specific
for the first-pass metabolism of ethinylestradiol and the substan-
tial chance in SHBG levels in combined oral contraceptive users
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Table 4.4: Results from carriers of haplotypes in the UGT2B7 gene among
non-users
LETS (N=104) FDR MEGA (N=513) FDR
Haplotype OR (95%CI) p q OR (95%CI) p q
A
0 1 1
1 1.58 (0.15-16.42) -
2 - -
Additive 1.58 (0.15-16.42) 0.70 0.98 - - -
B
0 1 1
1 1.21 (0.38-3.88) 0.49 (0.21-1.13)
2 - 0.84 (0.10-6.83)
Additive 1.07 (0.37-3.09) 0.90 0.98 0.59 (0.28-1.26) 0.17 0.89
C
0 1 1
1 0.92 (0.27-3.20) 1.46 (0.76-2.79)
2 - 1.07 (0.13-8.71)
Additive 0.72 (0.26-1.98) 0.53 0.98 1.31 (0.77-2.25) 0.32 0.91
D
0 1 1
1 2.10 (0.71-6.15) 0.90 (0.48-1.71)
2 - 2.06 (0.65-6.53)
Additive 1.25 (0.59-2.66) 0.56 0.98 1.14 (0.67-1.93) 0.63 0.94
E
0 1 1
1 1.58 (0.15-16.42) 1.47 (0.32-6.77)
2 - -
Additive 1.58 (0.15-16.42) 0.70 0.98 1.47 (0.32-6.77) 0.62 0.94
F
0 1 1
1 2.91 (0.98-8.71) 1.19 (0.64-2.20)
2 - -
Additive 1.96 (0.78-4.92) 0.15 0.98 0.87 (0.55-1.40) 0.58 0.94
G
0 1 1
1 0.43 (0.09-2.08) 0.97 (0.49-1.89)
2 - 0.96 (0.12-7.79)
Additive 0.38 (0.09-1.49) 0.17 0.98 0.97 (0.54-1.74) 0.92 0.99
H
0 1 1
1 0.98 (0.25-3.90) 1.43 (0.74-2.76)
2 - -



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































consistent with an increased risk. UGT2B7 is therefore a strong
candidate for futher investigation, and may prove clinically rel-
evant given its high odds ratio specific for oral contraceptive
use.
To bypass the first-pass metabolism of ethinylestradiol in the
liver, other types of contraception with hormones were developed
that deliver the hormones directly to the systemic circulation,
i.e., the transdermal patch and the vaginal ring. Two case reports
concerning mesenteric vein thrombosis30 and cerebral venous si-
nus thrombosis31 and two serious adverse event in two trials32,33
were reported in users of the vaginal ring. This potential asso-
ciation with venous thrombosis was confirmed in a large cohort
study showing that the use of vaginal ring increased the risk of
venous thrombosis compared to non-users34. The risk of venous
thrombosis in transdermal patch users has been assessed in two
observational studies using health insurance databases. Transder-
mal patch users have about the same risk of venous thrombosis
compared to third generation users or higher35–38, i.e., a risk
that is substantially higher than that conferred by the safest
oral contraceptives (containing second generation progestagens).
These results were confirmed by a large cohort study34.
To our knowledge, no studies regarding the genetics of the
first-pass metabolism of ethinylestradiol in association with ve-
nous thrombosis have been published before. Earlier studies of
the first-pass metabolism of estrogens showed that genetic varia-
tion in this metabolism was associated with esophageal cancer39
and prostate cancer40. However, either the CYP3A4 orUGT2B7
genes were not studied or no association was found with these
genes.
A limitation of our study is that only common genetic vari-
ation (i.e., SNPs with a frequency above 5%) was taken into
account. However, rare haplotypes were captured since these
common SNPs could code for haplotypes with a frequency below
5%. A strength of our study is that a highly selected population
was used to ensure that venous thrombosis events were only re-
103
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lated to oral contraceptive use. Furthermore, haplotypes were
used to look at the entire gene of interest in contrast to individual
SNPs.
In conclusion, genetic variation in the UGT2B7 gene explains
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Supplementary table 4.1 Overview of the selected SNPs in the 11 genes
from ethinylestradiol metabolism
Gen SNP Allel change MAF Assay
COMT rs4333017 C/T 0.175 Sequenom
COMT rs9605030 C/T 0.117 Sequenom
COMT rs9617850 G/A 0.169 Sequenom
COMT rs5746846 G/C 0.500 Sequenom
COMT rs174675 C/T 0.258 Sequenom
COMT rs5746847 C/T 0.433 Sequenom
COMT rs4680 G/A 0.483 Sequenom
COMT rs887199 G/A 0.125 Sequenom
COMT rs887204 A/G 0.292 Sequenom
COMT rs165849 A/G 0.308 Taqman
COMT rs2240713 G/A 0.068 Sequenom
CYP1A2 rs1378942 T/G 0.339 Sequenom
CYP1A2 rs762551 A/C 0.308 Sequenom
CYP1A2 rs8033381 A/G 0.263 Sequenom
CYP1A2 rs2071501 T/G 0.054 Sequenom
CYP2C9 rs9332174 A/G 0.225 Sequenom
CYP2C9 rs10509679 G/A 0.110 Sequenom
CYP2C9 rs2475377 G/A 0.059 Sequenom
CYP2C9 rs2253635 A/G 0.331 Sequenom
CYP2C9 rs4917636 A/G 0.158 Sequenom
CYP2C9 rs9332245 G/A 0.058 Taqman
CYP3A4 rs2242480 C/T 0.080 Sequenom
CYP3A4 rs6945984 T/C 0.117 Sequenom
CYP3A4 rs2246709 A/G 0.308 Sequenom
CYP3A4 rs4646437 C/T 0.133 Taqman
CYP3A5 rs4646450 C/T 0.175 Sequenom
CYP3A5 rs2740565 T/A 0.067 Sequenom
CYP3A5 rs11734 C/G 0.052 Sequenom
CYP3A5 rs7792939 T/C 0.125 Sequenom
CYP3A5 rs2687134 C/A 0.050 Taqman
SULT1A1 rs17707300 A/G 0.333 Taqman
SULT1A1 rs9924471 C/T 0.136 Sequenom
SULT1A1 rs12445705 G/A 0.121 Sequenom
SULT1A1 rs10521145 C/T 0.119 Taqman
Continued on next page
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Gen SNP Allel change MAF Assay
SULT1E1 rs1590128 A/G 0.292 Taqman
SULT1E1 rs13112570 G/A 0.360 Taqman
SULT1E1 rs12506209 C/T 0.350 Taqman
SULT1E1 rs1220833 G/A 0.017 Taqman
SULT1E1 rs3736599 G/A 0.110 Taqman
SULT1E1 rs4149526 G/T 0.292 Taqman
SULT1E1 rs3775770 G/A 0.283 Taqman
SULT1E1 rs1220724 C/T 0.142 Taqman
SULT1E1 rs1220702 C/G 0.167 Taqman
SULT1E1 rs3822173 C/T 0.108 Taqman
UGT1A rs2602376 C/T 0.220 Sequenom
UGT1A rs4553819 A/G 0.375 Sequenom
UGT1A rs10179094 T/A 0.342 Sequenom
UGT1A rs17864689 G/T 0.075 Sequenom
UGT1A rs6761246 C/A 0.373 Sequenom
UGT1A rs12466747 G/C 0.242 Sequenom
UGT1A rs7583278 C/T 0.325 Sequenom
UGT1A rs6744284 C/T 0.250 Sequenom
UGT1A rs28898590 G/T 0.058 Sequenom
UGT1A rs4663326 A/G 0.133 Taqman
UGT1A rs904855 G/C 0.092 Sequenom
UGT1A rs871514 A/G 0.424 Sequenom
UGT1A rs10179091 T/C 0.451 Taqman
UGT1A rs6742078 G/T 0.283 Sequenom
UGT1A rs11891311 G/A 0.314 Sequenom
UGT1A rs28898621 C/T 0.092 Sequenom
UGT1A rs28946889 G/T 0.306 Restriction
UGT1A rs4663972 T/C 0.225 Sequenom
UGT1A rs10203853 T/A 0.492 Sequenom
UGT1A rs12468017 T/C 0.150 Sequenom
UGT1A rs17868346 A/G 0.258 Sequenom
UGT1A rs6719561 C/T 0.383 Sequenom
UGT2B7 rs4587017 G/T 0.483 Sequenom
UGT2B7 rs3924194 C/G 0.169 Sequenom
UGT2B7 rs6600898 G/C 0.450 Sequenom
UGT2B7 rs10028494 A/C 0.133 Sequenom
UGT2B7 rs4385139 G/C 0.474 Sequenom
UGT2B7 rs6600894 G/A 0.217 Taqman
UGT2B7 rs7662029 G/A 0.500 Sequenom




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary table 4.3 Results from carriers of haplotypes in the
COMT gene among non-users
LETS (N=104) FDR MEGA (N=513) FDR




1 0.95 (0.30-2.99) 1.12 (0.58-2.16)
2 - -
Additive 0.95 (0.30-2.99) 0.93 0.98 0.92 (0.53-1.59) 0.76 0.94
B
0 1 1
1 2.25 (0.72-7.07) 1.31 (0.65-2.61)
2 - -
Additive 2.83 (1.06-7.51) 0.04 0.98 1.13 (0.61-2.09) 0.70 0.94
C
0 1 1
1 0.98 (0.33-2.93) 0.51 (0.25-1.06)
2 - 0.37 (0.05-2.85)
Additive 0.70 (0.31-1.61) 0.40 0.98 0.54 (0.29-1.02) 0.06 0.86
D
0 1 1
1 0.34 (0.04-2.89) 1.82 (0.64-5.21)
2 - -
Additive 0.34 (0.04-2.89) 0.33 0.98 1.59 (0.60-4.20) 0.35 0.91
E
0 1 1
1 1.57 (0.41-6.05) 0.78 (0.26-2.29)
2 - -
Additive 1.57 (0.41-6.05) 0.51 0.98 0.68 (0.26-1.76) 0.43 0.92
F
0 1 1
1 0.68 (0.22-2.05) 1.77 (0.85-3.66)
2 0.63 (0.14-2.75) 1.44 (0.59-3.54)
Additive 0.76 (0.36-1.61) 0.48 0.98 1.22 (0.83-1.78) 0.31 0.91
SNP rs4680
GG 1 1
GA 2.06 (0.52-8.20) 0.66 (0.33-1.31)
AA 4.04 (0.91-18.02) 1.09 (0.51-2.31)
Additive 1.24 (0.80-1.93) 0.33 0.98 1.02 (0.68-1.53) 0.93 0.99
Continued on next page
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Supplementary table 4.3 – continued from previous page
LETS (N=104) FDR MEGA (N=513)) FDR




1 0.35 (0.08-1.49) 0.47 (0.19-1.13)
2 0.44 (0.10-1.88) 0.63 (0.28-1.44)
Additive 0.77 (0.34-1.71) 0.52 0.98 0.90 (0.57-1.42) 0.65 0.94
B
0 1 1
1 - 1.51 (0.50-4.55)
2 - -
Additive - - - 1.51 (0.50-4.55) 0.46 0.94
C
0 1 1
1 1.42 (0.44-4.55) 1.05 (0.44-2.51)
2 - 1.25 (0.15-10.39)
Additive 1.42 (0.44-4.55) 0.55 0.98 1.07 (0.53-2.17) 0.84 0.95
D
0 1 1
1 1.20 (0.40-3.56) 0.90 (0.46-1.75)
2 - 1.12 (0.25-5.12)
Additive 1.64 (0.60-4.44) 0.34 0.98 0.96 (0.55-1.67) 0.88 0.97
E
0 1 1
1 0.36 (0.17-0.46) 1.26 (0.42-3.76)
2 - -











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary table 4.5 Results from carriers of haplotypes in the CYP
genes among non-users
LETS (N=104) FDR MEGA (N=513) FDR




1 0.38 (0.05-2.81) 1.05 (0.46-2.40)
2 0.77 (0.13-4.45) 0.90 (0.38-2.16)
Additive 1.14 (0.44-2.97) 0.79 0.98 0.93 (0.62-1.41) 0.74 0.94
B
0 1 1
1 2.63 (0.57-12.08) 0.62 (0.25-1.57)
2 - -
Additive 2.63 (0.57-12.08) 0.22 0.98 0.57 (0.24-1.33) 0.19 0.89
C
0 1 1
1 - 0.99 (0.26-3.80)
2 - -
Additive - - 0.99 (0.26-3.80) 0.98 0.99
D
0 1 1
1 0.95 (0.23-3.85) 1.14 (0.61-2.14)
2 - 0.51 (0.07-3.95)
Additive 0.76 (0.24-2.41) 0.64 0.98 0.98 (0.59-1.62) 0.94 0.99
E
0 1 1
1 0.63 (0.07-5.64) 1.56 (0.65-3.79)
2 - 4.50 (0.40-50.82)




1 0.68 (0.22-2.14) 1.37 (0.74-2.52)
2 1.42 (0.24-8.23) 2.79 (0.96-8.12)
Additive 0.96 (0.41-2.22) 0.92 0.98 1.53 (0.95-2.46) 0.08 0.86
B
0 1 1
1 0.64 (0.19-2.16) 0.63 (0.30-1.29)
2 - 0.60 (0.08-4.69)
Additive 0.57 (0.19-1.66) 0.30 0.98 0.66 (0.35-1.26) 0.21 0.89
C
0 1 1
1 0.53 (0.06-4.60) 0.71 (0.21-2.40)
2 - -
Additive 0.53 (0.06-4.60) 0.56 0.98 0.71 (0.21-2.40) 0.58 0.94
Continued on next page
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Supplementary table 4.5 – continued from previous page
LETS (N=104) FDR MEGA (N=513)) FDR
Haplotype OR (95%CI) p q OR (95%CI) p q
D
0 1 1
1 1.16 (0.38-3.55) 0.54 (0.29-1.02)
2 1.30 (0.27-6.28) 0.72 (0.30-1.74)
Additive 1.14 (0.54-2.43) 0.73 0.98 0.74 (0.46-1.19) 0.21 0.89
E
0 1 1
1 0.84 (0.21-3.32) 1.77 (0.90-3.50)
2 - -
Additive 1.43 (0.45-4.50) 0.55 0.98 1.33 (0.76-2.31) 0.32 0.91
F
0 1 1
1 1.18 (0.29-4.81) 1.32 (0.59-2.96)
2 - -




1 0.92 (0.22-3.88) 1.14 (0.41-3.14)
2 0.57 (0.12-2.78) 1.28 (0.46-3.54)
Additive 0.68 (0.32-1.44) 0.32 0.98 1.13 (0.72-1.77) 0.60 0.94
B
0 1 1
1 1.03 (0.11-9.88) 0.82 (0.24-2.81)
2 - -
Additive 1.03 (0.11-9.88) 0.98 0.99 0.69 (0.24-1.99) 0.50 0.94
C
0 1 1
1 0.02 (0.00-0.21) 2.01 (0.65-6.22)
2 - -
Additive 0.02 (0.00-0.21) 0.00 0.08 1.71 (0.61-4.79) 0.31 0.91
D
0 1 1
1 1.09 (0.27-4.38) 1.03 (0.46-2.30)
2 - -
Additive 0.92 (0.27-3.13) 0.90 0.98 0.95 (0.45-1.98) 0.88 0.97
E
0 1 1
1 0.95 (0.09-9.77) -
2 - -
Additive 0.95 (0.09-9.77) 0.96 0.99 - - -
Continued on next page
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Supplementary table 4.5 – continued from previous page
LETS (N=104) FDR MEGA (N=513)) FDR
Haplotype OR (95%CI) p q OR (95%CI) p q
F
0 1 1
1 - 0.78 (0.10-6.12)
2 - -
Additive - - - 0.69 (0.11-4.39) 0.69 94
G
0 1 1
1 0.94 (0.30-2.93) 1.04 (0.53-2.03)
2 2.08 (0.17-24.94) 0.88 (0.11-7.07)





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary table 4.7 Results from carriers of haplotypes in the
SULT genes among non-users
LETS (N=104) FDR MEGA (N=513) FDR




1 2.30 (0.79-6.66) 0.92 (0.48-1.76)
2 - 1.26 (0.52-3.05)
Additive 1.05 (0.57-1.92) 0.89 0.98 1.08 (0.68-1.69) 0.75 0.94
B
0 1 1
1 1.83 (0.53-6.27) 0.80 (0.43-1.48)
2 2.27 (0.48-10.71) 0.48 (0.16-1.44)
Additive 1.52 (0.74-3.14) 0.26 0.98 0.73 (0.47-1.14) 0.16 0.89
C
0 1 1
1 0.50 (0.06-4.29) 2.53 (1.14-5.63)
2 - -
Additive 0.50 (0.06-4.29) 0.53 0.98 2.08 (1.00-4.33) 0.05 0.86
D
0 1 1
1 0.57 (0.15-2.18) 0.83 (0.36-1.92)
2 - -
Additive 0.57 (0.15-2.18) 0.42 0.98 0.73 (0.35-1.54) 0.41 0.91
E
0 1 1
1 1.04 (0.20-5.37) 1.46 (0.73-2.92)
2 - 3.31 (0.34-32.78)




1 0.94 (0.35-2.53) 0.82 (0.45-1.50)
2 - 1.09 (0.40-3.02)
Additive 0.64 (0.31-1.33) 0.23 0.98 0.95 (0.59-1.52) 0.82 0.95
B
0 1 1
1 0.84 (0.29-2.41) 1.75 (0.94-3.27)
2 0.85 (0.16-4.54) 1.46 (0.55-3.86)
Additive 0.89 (0.42-1.88) 0.76 0.98 1.34 (0.90-1.97) 0.15 0.89
C
0 1 1
1 0.98 (0.32-2.98) 0.93 (0.52-1.68)
2 2.71 (0.71-10.33) 0.55 (0.16-1.91)
Additive 1.52 (0.74-3.13) 0.26 0.98 0.83 (0.54-1.29) 0.41 0.91
Continued on next page
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Supplementary table 4.7 – continued from previous page
LETS (N=104) FDR MEGA (N=513)) FDR
Haplotype OR (95%CI) p q OR (95%CI) p q
D
0 1 1
1 0.91 (0.18-4.64) -
2 - -
Additive 0.91 (0.18-4.64) 0.91 0.98 - - -
SNP rs3736599
GG 1 1
GA 0.92 (0.23-3.63) 1.47(0.75-2.89)
AA - 1.06 (0.13-8.58)




1 0.67 (0.24-1.86) 1.17 (0.64-2.15)
2 - 1.00 (0.36-2.77)
Additive 0.51 (0.23-1.15) 0.11 0.98 1.06 (0.69-1.61) 0.80 0.94
B
0 1 1
1 2.32 (0.73-7.38) 1.02 (0.55-1.90)
2 3.38 (0.75-15.28) 1.92 (0.73-5.05)
Additive 1.89 (0.94-3.81) 0.07 0.98 1.24 (0.78-1.97) 0.37 0.91
C
0 1 1
1 0.94 (0.32-2.75) 0.89 (0.46-1.73)
2 - 0.49 (0.06-377)
Additive 0.76 (0.31-1.87) 0.56 0.98 0.82 (0.48-1.42) 0.49 0.94
D
0 1 1
1 0.25 (0.03-2.03) 0.82 (0.37-1.80)
2 3.72 (0.22-63.33) -
Additive 0.73 (0.16-3.27) 0.69 0.98 0.71 (0.35-1.41) 0.33 0.91
E
0 1 1
1 1.29 (0.32-5.23) 0.73 (0.25-2.12)
2 - 4.30 (0.38-48.42)


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary table 4.9 Results from carriers of haplotypes in the UGT
genes among non-users
LETS (N=104) FDR MEGA (N=513) FDR




1 0.84 (0.26-2.68) 2.00 (1.08-3.70)
2 1.58 (0.14-17.48) 0.89 (0.25-3.16)
Additive 1.00 (0.36-2.74) 1.00 1.00 1.28 (0.87-1.89) 0.20 0.89
B
0 1 1
1 1.67 (0.16-17.44) 1.55 (0.51-4.68)
2 - -
Additive 0.79 (0.18-3.51) 0.75 0.98 1.55 (0.51-4.68) 0.44 0.92
C
0 1 1
1 - 1.60 (0.53-4.85)
2 - -
Additive - - - 1.30 (0.50-3.39) 0.59 0.94
D
0 1 1
1 2.09 (0.48-9.11) 1.62 (0.64-4.07)
2 - -
Additive 2.09 (0.48-9.11) 0.33 0.98 1.62 (0.64-4.07) 0.31 0.91
E
0 1 1
1 0.82 (0.24-2.80) 1.12 (0.59-2.13)
2 1.31 (0.21-8.41) 1.20 (0.47-3.04)
Additive 1.04 (0.39-2.75) 0.94 0.98 1.10 (0.71-1.70) 0.67 0.94
F
0 1 1
1 0.54 (0.15-1.90) 0.45 (0.22-0.93)
2 2.10 (0.17-25.88) 0.40 (0.05-3.10)




1 0.87 (0.20-3.71) 1.17 (0.53-2.61)
2 1.20 (0.24-6.01) 0.73 (0.29-1.84)
Additive 1.13 (0.48-2.68) 0.78 0.98 0.84 (0.56-1.26) 0.40 0.91
B
0 1 1
1 1.41 (0.34-5.86) 1.24 (0.42-3.70)
2 - -
Additive 1.41 (0.34-5.86) 0.63 0.98 1.24 (0.42-3.70) 0.70 0.94
Continued on next page
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Supplementary table 4.9 – continued from previous page
LETS (N=104) FDR MEGA (N=513)) FDR
Haplotype OR (95%CI) p q OR (95%CI) p q
C
0 1 1
1 0.83 (0.27-2.60) 2.06 (1.08-3.93)
2 2.22 (0.35-14.20) 1.08 (0.30-3.89)
Additive 1.17 (0.48-2.89) 0.73 0.98 1.37 (0.91-2.05) 0.13 0.89
D
0 1 1
1 0.89 (0.10-8.22) 0.82 (0.19-3.63)
2 - -
Additive 0.89 (0.10-8.22) 0.92 0.98 0.82 (0.19-3.63) 0.80 0.94
E
0 1 1
1 0.30 (0.04-2.48) 0.66 (0.25-1.75)
2 - -




1 0.89 (0.21-3.79) 1.31 (0.58-2.99)
2 0.46 (0.09-2.46) 0.78 (0.31-1.97)
Additive 0.66 (0.31-1.40) 0.28 0.98 0.84 (0.57-1.23) 0.37 0.91
B
0 1 1
1 1.64 (0.29-9.25) 0.19 (0.03-1.40)
2 - -
Additive 1.64 (0.29-9.25) 0.57 0.98 0.19 (0.03-1.33) 0.09 0.86
C
0 1 1
1 1.24 (0.41-3.74) 2.16 (1.10-4.26)
2 2.07 (0.41-10.48) 1.74 (0.66-4.56)




1 0.52 (0.17-1.55) 0.73 (0.39-1.34)
2 0.23 (0.03-1.99) 0.32 (0.07-1.38)
Additive 0.50 (0.22-1.13) 0.10 0.98 0.65 (0.40-1.04) 0.07 0.86
B
0 1 1
1 1.71 (0.59-4.91) 2.65 (1.39-5.04)
2 1.96 (0.18-21.48) 1.25 (0.35-4.53)
Additive 1.57 (0.67-3.64) 0.30 0.98 1.55 (1.06-2.27) 0.02 0.86
Continued on next page
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Supplementary table 4.9 – continued from previous page
LETS (N=104) FDR MEGA (N=513)) FDR
Haplotype OR (95%CI) p q OR (95%CI) p q
C
0 1 1
1 1.32 (0.25-7.02) 0.69 (0.16-3.02)
2 - -
Additive 1.32 (0.25-7.02) 0.74 0.98 0.69 (0.16-3.02) 0.63 0.94
D
0 1 1
1 2.01 (0.55-7.36) 1.16 (0.39-3.43)
2 - -
Additive 2.01 (0.55-7.36) 0.29 0.98 1.16 (0.39-3.43) 0.79 0.94
E
0 1 1
1 1.88 (0.33-10.63) 0.19 (0.03-1.40)
2 - -
Additive 1.25 (0.31-5.00) 0.75 0.98 0.19 (0.03-1.36) 0.10 0.86
F
0 1 1
1 1.25 (0.44-3.54) 1.83 (0.99-3.39)
2 - 0.92 (0.26-3.26)




1 0.41 (0.11-1.58) 0.93 (0.50-1.75)
2 0.89 (0.09-8.74) -
Additive 0.62 (0.20-1.87) 0.39 0.98 0.74 (0.45-1.23) 0.25 0.91
B
0 1 1
1 0.89 (0.31-2.57) 1.67 (0.89-3.14)
2 0.69 (0.07-6.50) 0.99 (0.32-3.08)
Additive 0.86 (0.37-1.99) 0.72 0.98 1.20 (0.80-1.79) 0.38 0.91
C
0 1 1
1 1.15 (0.36-3.68) 1.01 (0.49-2.12)
2 4.83 (0.28-84.00) 1.76 (0.20-15.53)
Additive 1.45 (0.54-3.92) 0.46 0.98 1.09 (0.56-2.10) 0.80 0.94
D
0 1 1
1 2.71 (0.94-7.79) 1.11 (0.59-2.11)
2 - 1.06 (0.23-4.82)
Additive 1.68 (0.73-3.86) 0.22 0.98 1.08 (0.65-1.80) 0.78 0.94
Continued on next page
136
Supplementary table 4.9 – continued from previous page
LETS (N=104) FDR MEGA (N=513)) FDR
Haplotype OR (95%CI) p q OR (95%CI) p q
E
0 1 1
1 0.74 (0.19-2.90) 0.98 (0.49-1.96)
2 1.42 (0.14-14.90) 0.66 (0.08-5.21)



















Background: Current guidelines state that women using com-
bined hormonal contraceptives at the time of a venous throm-
bosis event should stop using these combined preparations. Pro-
gestagen-only contraceptives are advised to be used in these
women. The aim of this study is to determine to what extent the
guidelines concerning hormonal contraceptive use after a venous
thrombosis are followed in daily practice.
Methods: Women younger than 50 years who experienced a
hormonal contraceptive-associated venous thrombosis were se-
lected from a case-control study, the MEGA study. Data on hor-
monal contraceptive use after a venous thrombosis was available
through an interview at venipuncture. In addition, participants
from the follow-up study provided data on advice, given by a
physician, to stop hormonal contraceptive use. Risk differences
with 95% confidence interval (CI) were calculated.
Results: 703 women were included with a mean follow-up at
interview of 10.8 months (range: 2.1 to 35.4 months). 521 (74%)
women stopped hormonal contraceptive use, 63 (9%) changed to
a different contraceptive method, and 119 (17%) continued the
same method. 143 (21%) of 682 women who used a combined oral
contraceptive at the thrombotic event were still using a combined
preparation after the event contrasting the guidelines. Women
who continued their contraceptive use had less often a positive
family history of venous thrombosis and more often surgery (RD
19%, 95%CI: 9 to 30%) or a plaster cast (RD 17%, 95%CI: 3
to 34%) at the time of venous thrombosis than women who
stopped. 39 (12%) of 332 women using a combined preparation
and who received advice to stop from a physician, continued
their combined oral contraceptive.
Conclusions: The finding that women continue their combined
oral contraceptive use after receiving advice to stop is a real
concern, in particular since there are indications that this use
could increase the risk of a recurrence.
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5. Practice after venous thrombosis
Introduction
Combined oral contraceptive use (containing ethinylestradiol
and a progestagen) is associated with an increased risk of venous
thrombosis. Regarding the use of combined oral contraceptives
after a hormonal contraceptive-associated venous thrombosis,
the WHO guideline from 2004 recommends that women with a
history of venous thromboembolic disease should refrain from
using combined hormonal contraceptives1. The same recommen-
dation is stated in national guidelines from the Netherlands2,3.
In addition, package insertions of combined oral contraceptives
advise women to refrain from the use of these contraceptives
in case of a (experienced) thromboembolic event. By law, the
manufacturer is required to list contra-indications on package in-
sertions in the Netherlands. Both national and WHO guidelines
state that progestagen-only contraceptives such as progestagen-
only pills or intra-uterine devices may be used in case of a history
of venous thrombosis1–3.
Little is known about hormonal contraceptive use after ve-
nous thrombosis in clinical practice. Only one study assessed
whether continuing hormonal contraceptives influenced the risk
of a recurrence. In the Leiden Thrombophilia Study (LETS) it
was shown that almost 30% of women continued oral contra-
ceptive use after an oral contraceptive-associated venous throm-
bosis4 and after a mean follow-up of 7.3 years approximately
45% either continued or restarted oral contraceptives5. The re-
currence rate in women who continued or restarted the use of a
hormonal contraceptive was much higher (48.8 per 1000 patient-
years) than in women who stopped hormonal contraceptive use
(10.5 per 1000 patient-years) (age-adjusted incidence rate ratio
4.3, 95%CI: 1.7 to 11.1)6.
There is limited knowledge regarding daily medical practice
after a hormonal contraceptive-associated venous thrombotic
event. To assess the adherence to the recommendations in the
guidelines, short term follow-up data on hormonal contracep-
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tive use was analyzed from the cases enrolled in the MEGA
study (a case-control study of venous thrombosis). We focused
in particular on what proportion of patients with a hormonal
contraceptive-associated venous thrombosis stopped, changed
or continued their hormonal contraceptive use. We determined
what changes were made when women changed to a different hor-
monal contraceptive method after a thrombotic event. Secondly,
we assessed whether acquired risk factors for venous thrombosis
were associated with the decision to stop, change or continue oral
contraceptive use. In a proportion of these women, long term
follow-up data was available with information about the advice
received from the physician. In these women, we assessed the
proportion of women who did receive advice to stop their oral
contraceptive use and how many followed this advice.
Methods
Study design For this study, we included patients with a first
episode of deep venous thrombosis or a pulmonary embolism,
who were enrolled in a large case-control study on risk factors
for venous thrombosis, i.e., the Multiple Environmental and Ge-
netic Assessment of risk factors for venous thrombosis (MEGA)
study7. Consecutive patients younger than 70 years with a first
symptomatic deep vein thrombosis in the leg or arm or pul-
monary embolism were recruited from six anticoagulation clinics
in the Netherlands between 1 March 1999 and 31 August 2004
(N=5183). Control subjects were partners or recruited via ran-
dom digit dialling. Only the case group is included in the current
analysis.
All patients completed a detailed questionnaire on risk factors
for venous thrombosis, including the use of oral contraceptives.
The questions covered a period of one year before the thrombotic
event. Three months after discontinuation of the anticoagulation
therapy, patients were invited to the anticoagulation clinic for
a blood sample. During this visit participants were interviewed
145
5. Practice after venous thrombosis
regarding the period from the venous thrombotic event until the
venipuncture. This interview included items on the change of
hormonal contraceptive methods since the diagnosis of venous
thrombosis. Patients included in the MEGA case-control study
subsequently took part in a follow-up study. In the follow-up
questionnaire, a question was asked whether or not advice from
the treating physician was received regarding contraceptive use
after the first event. Because not all patients participated in
this follow-up study, data was available in a proportion of the
included women for the current analysis.
Of 5183 cases included in the MEGA study, 2799 were women
of whom 1703 were younger than 50 years. Women not taking
hormonal contraceptives at the time of a venous thrombosis
were excluded (N=569). Of 431 women no data was available
on hormonal contraceptive use after the thrombotic event, i.e.,
at the time of venipuncture. In total, 703 women were included
in the current analysis of which 414 women also filled in the
follow-up questionnaire and thus had data on advice received
from a physician.
Analysis We first determined what proportion of women with
venous thrombosis during hormonal contraceptive use stopped,
continued, or changed their hormonal contraceptive use after the
event. Baseline characteristics (i.e., age, body mass index (BMI),
current smoking, positive family history, and type of contracep-
tion) were studied separately for women who stopped, changed,
or continued their contraception. BMI was analyzed as a cat-
egorical variable with three categories: BMI ≤25 kg/m2, BMI
25-30 kg/m2, and BMI >30 kg/m2. Smoking behaviour was rep-
resented as current, past, or never smokers. A positive family
history was defined as having one or more first-degree relatives
with a history of venous thrombosis. Contraception was divided
into combined hormonal contraceptives (i.e., containing ethinyles-
tradiol and a progestagen) and progestagen-only contraceptives.
The most commonly used administration route for combined
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formulations is orally but occasionally it is administered trans-
dermally or transvaginally. Progestagen-only formulations are
administered orally (mini pill) as well as subcutaneously (via
implant or injection) or intrauterinely (intrauterine device). In
our study, none of the women used a combined transdermal
patch or combined vaginal ring. All other applications of hor-
mones were used. Combined oral contraceptives were further
subdivided according to the type of progestagen used; first gen-
eration (i.e., lynestrenol and norethisteron), second generation
(i.e., levonorgestrel), and third generation combined oral con-
traceptives (i.e., gestodene, desogestrel and norgestimate). The
progestagens introduced after the third generation progestagens,
i.e., cyproterone acetate and drospirenone, were analysed sep-
arately. Progestagen-only contraceptives were subdivided into
oral progestagen-only contraceptives (the so-called progestagen-
only pills (POP)), hormonal intra-uterine device, implants, and
injectables.
Secondly, we assessed which type of hormonal contraceptive
women started to use when they changed their hormonal contra-
ceptive use after the thrombotic event.
Thirdly, we determined whether exposure to an acquired risk
factor for venous thrombosis was associated with stopping, chang-
ing, or continuing to use hormonal contraceptives. The following
acquired risk factors were taken into account: surgery, plaster
cast, immobilization, injury, and travel. A thrombotic event was
classified as secondary to surgery, plaster cast, immobilization,
or injury when one or more of these risk situations had occurred
within 3 months prior to the thrombotic event. A thrombotic
event was classified as secondary to travel when a patient had
travelled for more than 4 hours in the period of eight weeks prior
to the thrombotic event.
Finally, in women with data about advice received from a
physician, we determined what proportion of women stopped,
changed, or continued their contraceptive use when they were
advised to stop.
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Risk differences (RD) with 95% confidence intervals (CI) were
calculated between different proportions. The Newcombe method
10 was used to calculate these risk differences as this method
performed better with low sample sizes8. All statistical analyses
were performed with STATA, version 12.0 (Statacorp LP, College
Station, TX, USA).
Results
A total of 703 women with a hormonal contraceptive-associated
venous thrombosis provided information on contraceptive use
after the event. At an average of 10.8 months (range: 2.1 to 35.4
months) after venous thrombosis, 521 (74%) women had stopped
the use of hormonal contraceptives, 63 (9%) changed to another
hormonal contraceptive and 119 (17%) had continued with the
same contraceptive.
General characteristics of the study population are presented
in table 5.1 for women who stopped, changed or continued hor-
monal contraceptives. On average, women were about the same
age (stop: 36 years (range 18 - 49), change: 34 years (range 20
- 48) and continue: 36 years (range 18 - 49)). The proportion
of women stopping, changing or continuing their hormonal con-
traceptive did not markedly differ between BMI categories or
smoking behaviour. Women with a positive family history of
venous thrombosis were more likely to stop and less likely to
change or continued their hormonal contraceptive than women
without a positive family history. The vast majority was using a
combined preparation at the time of venous thrombosis and the
most commonly used progestagen was a second or third genera-
tion progestagen. Women using a combined oral contraceptive
were more likely to stop and less likely to change or continue
their contraceptive than women using a progestagen-only con-
traceptive. While no difference in age was observed, users of a
first generation progestagen in their combined oral contracep-
tives were more likely to stop their contraceptive use and users
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of cyproterone acetate and drospirenone were more likely to
continue their contraceptive than users of other progestagens.
Table 5.1: Baseline chacteristics
Women who Stop Change Continue
N=521 N=63 N=119
Age, mean (range), years 36 (18-49) 34 (20-48) 36 (18-49)
BMIa, kg/m2
>30 (%) 126 (76) 11 (7) 29 (17)
25-30 (%) 156 (75) 20 (10) 33 (16)
<25 (%) 210 (73) 29 (10) 50 (17)
Smokinga
Current (%) 213 (76) 22 (8) 45 (16)
Past (%) 89 (77) 10 (9) 17 (15)
Never (%) 203 (71) 30 (11) 52 (18)
Positive family historya
Yes (%) 115 (82) 7 (5) 18 (13)
No (%) 300 (72) 40 (10) 75 (18)
Contraception
Combined oral contraceptives (%) 508 (75) 60 (9) 114 (17)
First generation (%) 32 (86) 1 (3) 4 (11)
Second generation (%) 212 (76) 13 (5) 53 (19)
Third generation (%) 213 (74) 37 (13) 38 (13)
Cyproterone acetate (%) 45 (64) 8 (11) 17 (24)
Drospirenone (%) 6 (67) 1 (11) 2 (22)
Progestagen-only contraceptives (%) 12 (60) 3 (15) 5 (25)
Oral progestagen-onlyb(%) 0 (0) 1 (100) 0 (0)
Intra-uterine device (%) 0 (0) 0 (0) 1 (100)
Implanon (%) 1 (100) 0 (0) 0 (0)
Injectables (%) 11 (65) 2 (12) 4 (24)
Unknown (%) 1 (100) 0 (0) 0 (0)
a Data on BMI, smoking, and family history was available in 665, 682, and
556 women, respectively.
b User of lynestrenol, a progestagen belonging to the first generation
An overview of the contraceptive used at and after the event
among women who changed their contraceptive is given in table
5.2. The majority of these women changed to either a second gen-
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eration combined oral contraceptive (41%) or to an intra-uterine
device (40%). 54% of third generation combined oral contra-
ceptive users switched to a second generation contraceptives,
whereas 54% of second generation combined oral contraceptive
users changed to an intra-uterine device (Table 5.2).
Regarding adherence to the guidelines, of 682 women who
were using a combined oral contraceptive at the venous throm-
bosis event, 508 (74%) women discontinued use of combined oral
contraceptives. However, 143 (21%) either changed to another
combined oral contraceptive or continued to use their combined
preparation, while 31 (5%) women changed to progestagen-only
preparations.
At the time of interview not all women had stopped anticoag-
ulant therapy. Hormonal contraceptive use might be continued
to prevent pregnancy during anticoagulant therapy. 64 (10%)
women were using anticoagulant therapy at time of the inter-
view. After excluding these women, the distribution of women
who stopped, changed or continued their contraceptive did not
change; 421 (76%) women stopped, 46 (8%) changed and 85
(15%) continued their contraceptive use.
Risk differences (RD) in acquired risk factors - surgery, plas-
ter cast, immobilization, injury and travel - for the women who
stopped, continued or changed their contraceptive method are
presented in table 5.3. Of the 349 women not exposed to any
risk factor, 267 (77%) stopped, 31 (9%) changed and 51 (15%)
continued their contraceptive use. 337 women were exposed to
one or more acquired risk factors, of which 240 (71%) stopped,
31 (9%) changed and 66 (20%) continued their contraceptive use.
Women, who had undergone surgery within 3 months prior to
the diagnosis of thrombosis, were less likely to stop their contra-
ceptive use than unexposed women (58% versus 77%, RD -19%,
95%CI: -30 to -8%) and more likely to continue their contracep-
tive use (34% versus 15%, RD 19%, 95%CI: 9 to 30%). Women,
who had a plaster cast within 3 months prior to the diagnosis of





















































































































































































































































































































































































































5. Practice after venous thrombosis
unexposed women (59% versus 77%, RD -17%, 95%CI: -35 to
-1%) and more likely to continue their contraceptive use (31%
versus 15%, RD 17%, 95%CI: 3 to 34%). Regarding women ex-
posed to immobilization, injure or travel, no differences were
observed between exposed and unexposed women.
Finally, a total of 414 women had information on whether
they received advice to stop using hormonal contraceptives. 341
(82%) were advised to stop using hormonal contraceptives, while
67 (16%) women did not receive this advice. Six women stated
that they did not know whether they received any advice. Women
who received advice regarding hormonal contraceptive use were
more likely to stop their contraceptive use than women who
did not receive any advice (83% versus 34%, RD 49%, 95%CI:
36 to 60%) (Table 5.4). Of 332 women using a combined oral
contraceptive who were advised to stop, 277 (83%) did stop their
preparation, 16 (5%) changed to progestagen-only contraceptives
and 39 (12%) either continued or changed to another combined
preparation.
Discussion
In this study we found that the majority of women with a first
episode of venous thrombosis while using a hormonal contracep-
tive method had discontinued the use of hormonal contraceptives
after the thrombotic event. However, about 25% of these women
either changed or continued their contraceptive. Anticoagulant
therapy at the time of interview did not explain why women
continued their contraceptive use. Women who had had a throm-
bosis following surgery or plaster cast continued their hormonal
contraceptive method more often than unexposed women. The
majority of the women who received advice to stop using their
hormonal contraceptive, did follow this advice.
The majority of women changing oral contraceptives, change
to a combined preparation with a second generation progestagen


















































































































































































































































































































































































































5. Practice after venous thrombosis
second generation combined oral contraceptive may be the lower
risk for venous thrombosis in these users compared with either
third generation or cyproterone acetate users9–12. However, these
risk estimates are for a first event and whether these estimates
can also be applied to a second event is unclear.
The association between the presence of certain acquired risk
factors (surgery or a plaster cast) and the continuation of oral
contraceptive use suggests that physicians think it is safe to
continue oral contraceptives when a strong acquired risk factor
for thrombosis has been established as an (additional) cause of
the thrombotic event. Venous thrombosis is a multicausal disease,
i.e., for the occurrence of deep vein thrombosis a combination
of risk factors needs to be present13. The recurrence rate in
surgically provoked events is low in patients without other clinical
risk factors14,15, whether this is also the case in women with a
surgically provoked thrombotic event who use and continue to use
oral contraceptives is unknown. It is therefore unclear whether
the continuation of combined oral contraceptives is justified in
this subgroup of patients.
Little is known about hormonal contraceptive use after ve-
nous thrombosis in clinical practice and about the risk of a
recurrence in hormonal contraceptive users. The recommenda-
tions in the WHO guideline are based on studies which only
included first events. No data on second events were available be-
fore publication of the WHO guideline in 2004. Only one study,
which was published in 2010, analyzed the recurrence rate of
thromboembolic disease in women who had actually continued
or stopped oral contraceptive use after their first episode of oral
contraceptive-associated venous thrombosis. They found that an
increased rate for venous thrombosis in hormonal contraceptive
users compared to non-users6. However, only 11 recurrences were
found among hormonal contraceptive users. The number became
too low per type of contraceptive to infer any other conclusions.
The statements regarding progestagen-only contraceptive use
in the WHO guideline were based on one observational study
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from the WHO16. Because of different types of progestagen and
different doses for different applications, it is difficult to come
to a conclusion about progestagen-only preparations and the
risk of a first event. Even less is known about progestagen-only
preparations and the risk of a second event. The previous study
also reported on recurrences in progestagen-only preparations6;
however, only 2 recurrences were observed in injectable users
among a few progestagen-only preparation users.
This is one of the few studies to provide information on con-
traceptive use after a hormonal contraceptive-associated venous
thrombosis. We had detailed information on contraceptive use
before and after venous thrombosis, as well as on acquired risk
factors. Therefore we were able to examine whether the presence
of these risk factors was associated with the decision to stop or
continue oral contraceptives, although we do not know whether
this was actually taken into account with the decision making.
Although we know whether these women were advised to stop
their contraceptive use, we do not know why women stopped,
changed or continued their contraceptive use. In particular, in
women who received advice to stop using their contraceptive, it
would be beneficial to know their reason to continue their contra-
ceptive. In the Netherlands, the WHO guideline is implemented
in national guidelines and we observed that about 20% do not
follow the advice from the physician to stop their contraceptive
use. The percentage of women receiving no advice may be dif-
ferent per country depending on implementation of guidelines.
However, the problem that women continue their combined oral
contraceptive use after receiving advice to stop is a real concern.
In conclusion, the fact that women seemed to disregard the
advice from a physician is a real concern, emphasized by the po-
tential increased risk of a recurrence when continuing hormonal
contraceptives.
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Background: There is a large body of literature available on
hormonal contraceptive use and the risk of a first venous throm-
botic event. Despite guideline recommendations to discontinue
hormonal contraceptive use after a thrombotic event, still a size-
able proportion of women continue or start using hormonal con-
traceptives after a venous thrombosis. The aim of this study
was to evaluate the effect of this use on the recurrence risk in
premenopausal women.
Methods: Patients with a first venous thrombosis included in
the MEGA case-control study between 1999 and 2004, were fol-
lowed for a recurrent venous thrombotic event up to 2009. In-
cluded in the current analyses were premenopausal female pa-
tients with a first venous thrombosis and for whom detailed
information was available on hormonal contraceptive use dur-
ing follow-up. Time-dependent Cox-proportional hazards models
were used to estimate hazard ratios (HR) with 95% confidence
intervals (CI), adjusted for age and BMI at baseline
Results: 702 premenopausal women with a first venous throm-
bosis were followed for a total of 4673 woman-years (median 7.0
years; range, 12 days to 9.9 years) during which 74 recurrent
events occurred resulting in a recurrence rate of 15.8 (95%CI:
12.6 to 19.8) per 1000 woman-years. 210 women used hormonal
contraceptives, mainly orally administered, during follow-up with
a total follow-up of 545 woman-years. They experienced 21 re-
current thrombotic events indicating a rate of 38.5 per 1000
woman-years, which was triple the rate of non-use during follow-
up (HR 2.8, 95%CI: 1.7 to 4.7). None of the women (N=20,
70 woman-years of follow-up) using a levonorgestrel-releasing
intra-uterine device developed a recurrent venous thrombosis.
Discussion: Hormonal contraceptive use after a first venous
thrombosis increases the risk of a recurrent venous thrombotic
event. A levonorgestrel-releasing intra-uterine device may be a
safe contraceptive to use after a venous thrombosis.
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Introduction
Combined oral contraceptives (containing ethinylestradiol and
a progestagen) increase the risk of a first venous thrombosis
two- to fourfold1–4. Several studies have assessed the risk of
venous thrombosis associated with oral progestagen-only pills
(POP)5–9; however, because these may be prescribed to a subset
of women who are already at increased risk of venous thrombosis,
no definite conclusions can be drawn.
Oral contraceptive use is the most common route of adminis-
tration. However, steroid hormones for contraceptive use can also
be administered via other administration routes or applications,
i.e., intrauterinely (intrauterine device (IUD)), transdermally
(patch), subcutaneously (injectable or implant), or transvaginally
(ring). Regarding non-oral contraceptives, the use of combined
preparations (i.e., a vaginal ring or a transdermal patch) is asso-
ciated with an increased risk of a first venous thrombosis10–12.
Progestagen-only non-oral preparations, i.e., the levonorgestrel-
releasing IUD or the injectable preparation containing methoxy-
progesterone acetate, appear to affect the risk of venous throm-
bosis differently. Whereas the risk of a first venous thrombosis
is not increased in intra-uterine device (IUD) users12,13, there is
an association with a mildly elevated risk of venous thrombosis
for the use of an injectable containing methoxyprogesterone ac-
etate8,13,14. Overall, there is a large body of literature available
about hormonal contraceptive use and the risk of a first venous
thrombosis.
National15,16 and international17 guidelines advise to dis-
continue hormonal contraceptive use after a venous thrombotic
event, in particular combined preparations (oral contraceptive,
transdermal patch and vaginal ring). The guidelines are based
on the assumption that risk factors for a first event also increase
the risk of a recurrence. However, this is not necessarily so18.
The absolute risk of recurrent venous thrombosis is higher than
of a first venous thrombosis. The populations at risk differ and
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therefore, possibly also the risk profiles.
Despite these guidelines, still a large proportion of women
either continues or starts hormonal contraceptive use after a first
venous thrombosis. One study found that 39% of women using
hormonal contraceptives at the first event either continued or
restarted after the event19. Furthermore, we previously reported
that in the participants of our study, 143 (21%) of 682 combined
oral contraceptive users at the first event continued combined
oral contraceptive use after the event20.
Currently, there is only one report on recurrent venous throm-
bosis risk associated with hormonal contraceptive use21. The
aim of the present study was therefore to evaluate the effect of
hormonal contraceptive use, administration route and type of
combined oral contraceptive (dose of ethinylestradiol and type
of progestagen) on the recurrence risk of venous thrombosis in
premenopausal women.
Methods
Participants Participants were cases from a population-based
case-control study; the Multiple Environmental and Genetic As-
sessment of venous thrombosis (MEGA) study. Details of the
study have been described elsewhere22. Between 1 March 1999
and 31 August 2004, 4956 consecutive patients with an objec-
tively diagnosed first deep vein thrombosis of the leg or pul-
monary embolism were included. Patients were aged 18-70 years
and were enrolled from six anticoagulation clinics in the Nether-
lands. Anticoagulation clinics monitor all patients taking vitamin
K antagonists in a well-defined geographical area. All patients
filled in a questionnaire on risk factors for venous thrombosis.
About three months after discontinuation of the anticoagulation
therapy, patients were invited to the anticoagulation clinic for
a blood sample. During this visit participants were interviewed
regarding the period from the venous thrombotic event until the
venipuncture. This interview included items on the change of
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hormonal contraceptive methods since the diagnosis of venous
thrombosis.
Of 4956 eligible patients, 4731 gave informed consent for
follow-up. During follow-up, patients received a short question-
naire containing questions on recurrence of venous thrombosis
and the use of oral anticoagulation therapy. Patients willing to fill
in a detailed questionnaire on risk factors for venous thrombosis
during follow-up received this questionnaire by mail or internet.
This detailed questionnaire contained questions about hormonal
contraceptive use after the first venous thrombosis, type of con-
traceptive used and when applicable starting date and date of
discontinuation of hormonal contraceptives. Patients participat-
ing in a pilot study received only a detailed questionnaire which
also included the question on recurrence.
Questionnaires were sent by mail to patients between January
2008 and December 2009. Questions were asked by telephone in-
terview when questionnaires were not returned. During the same
period information about recurrences was retrieved from the an-
ticoagulation clinics where patients were initially included for
their first event and, in case they moved house, at the clinic
nearest to their new address. Deaths due to recurrent venous
thrombosis were obtained at the Central Bureau of Statistics
(CBS) and were included. Discharge letters, to obtain informa-
tion on diagnostic procedures, were requested from the clinician
who diagnosed the recurrence according to the patient or the
anticoagulation clinic. Patients were followed from the date of
their first episode of venous thrombosis until a second throm-
botic event or until the end-of-study, defined as the date of filling
in the short questionnaire. In case patients did not fill in the
short questionnaire, they were followed until the last known visit
to the anticoagulation clinic, death, or emigration. Details of
the follow-up study have been described elsewhere23. This study
was approved by the Medial Ethics Committee of the Leiden
University Medical Center.
For the current analyses, we focussed on premenopausal wo-
164
men with venous thrombosis younger than 50 years (N=1526).
Women who were pregnant (N=42), were postpartum (defined
as four weeks after delivery) (N=18), or were users of hormone
replacement therapy (N=16) at the time of the first event were
excluded. Women with a diagnosis of cancer in the five years prior
to the first event were also excluded (N=51). Of the remaining
1399 premenopausal women, 845 (60%) women provided infor-
mation on hormonal contraceptive use by filling in the detailed
questionnaire. Data on hormonal contraceptive use provided in
the detailed questionnaire was crosschecked with data retrieved
at the time of the first venous thrombosis and at the time of
venipuncture in the case-control study. 143 (17%) women were
inconclusive about their contraceptive use and were excluded
from further analyses. A total of 702 women were included in
the present analysis. 13 women only provided data regarding
duration of use but not the type of contraceptive. These women
were only included in the overall analysis of hormonal contracep-
tive use during follow-up.
Recurrent venous thrombosis A recurrent event was defined by
information provided by patients through the short question-
naire, anticoagulation clinics, or discharge letters. A decision
rule regarding certainty of the diagnosis was made according to
the information collected per patient. In short, reported recur-
rences were classified into certain recurrences when there was a
discharge letter stating a diagnosis of a recurrent event based
on clinical and radiological data, or when both the anticoagula-
tion clinic and the patient reported a recurrent event at either a
clearly different location than the first event or more than one
year has passed since the first event, or when a registered death
from a recurrent event at least six months after the first event
was found. Details of this decision rule have been described previ-
ously23. In this study, certain recurrences were used as endpoint
and patients with an uncertain recurrence were censored at time
of their uncertain recurrence.
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Hormonal contraceptives Hormonal contraceptive use was de-
fined as use of a contraceptive that contains steroid hormones.
Users of a copper-IUD were considered non-users. Hormonal
contraceptive use was categorised according to the route of ad-
ministration route, i.e., into oral and non-oral preparations. Oral
preparations were stratified into combined and progestagen-only
preparations. Because many different preparations of combined
oral contraceptives are available, these contraceptives were cat-
egorised according to the dose of ethinylestradiol and type of
progestagen. Non-oral preparations were further stratified ac-
cording to the specific application (vaginal ring, transdermal
patch, implant, injectable, and levonorgestrel-releasing intrauter-
ine device (IUD)).
Statistical analysis In this analysis premenopausal women with
information on hormonal contraceptive use after a first venous
thrombosis from a detailed questionnaire were included. The
start of follow-up was defined as the date of the first venous
thrombosis. The end of follow-up was defined as the date of a
recurrent event or the date of filling in the short questionnaire
or the detailed questionnaire, in case of participation in the
pilot, when no recurrent event developed. Observation time was
calculated as the time at risk from the first thrombotic event to
the end of follow-up.
Hormonal contraceptive use was taken as a time-dependent
exposure to allow for women switching from use to non-use and
vice versa during follow-up. Consequently, one woman could con-
tribute follow-up time for hormonal contraceptive use as well
as for non-use. The risk of recurrent venous thrombosis was es-
timated for hormonal contraceptive use at the first event and
for hormonal contraceptive use during follow-up. The effect of
oral and non-oral preparations on the risk of recurrent venous
thrombosis was assessed and compared with non-use. All analy-
ses were adjusted for the confounders’ age and BMI (at baseline).
Time-dependent Cox-proportional hazards models were used to
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calculate hazard ratios (HR). All statistical analyses were per-
formed with STATA, version 12.0 (Statacorp LP, College Station,
TX, USA).
Results
702 women with a first venous thrombotic event were followed for
a total of 4673 woman-years (median 7.0 woman-years; range,
12 days to 9.9 woman-years). Baseline characteristics of the
study population are given in table 6.1. On average, women
were 36 years of age (range 18 to 49 years) at baseline. 290 (43%)
women had a BMI at baseline <25 kg/m2. 533 (76%) women
used hormonal contraceptives at the first venous thrombotic
event, whereas 169 (24%) were non-users at the first event.
Table 6.1: Baseline characteristics of premenopausal
women with venous thrombosis
All
Variables N=702
Age at 1st event, mean(range), yrs 36 (18-49)
BMI at 1st event
<25 kg/m2 290 (43)
25-30 kg/m2 214 (32)
>30 kg/m2 163 (24)
Hormonal contraceptive use at 1st event 533 (76)
BMI, body mass index
Among 702 women, 74 recurrences occurred, of which 21 re-
currences were during hormonal contraceptive use. Overall, the
rate of recurrent venous thrombosis was 15.8 (95%CI: 12.6 to
19.8) per 1000 woman-years. The recurrence rate in hormonal
contraceptive users at the first event was similar (15.1, 95%CI:
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11.6-19.8 per 1000 woman-years) as in non-users at the first event
(18.0, 95%CI: 11.6-27.9) (Table 6.2). This was evident from the
hazard ratio for users at the first event compared to non-users
(HR 0.9, 95%CI: 0.5 to 1.5, adjusted for age and BMI) (Table
6.2).
Among women using hormonal contraceptives during follow-
up, we observed a recurrence rate of 38.5 (95%CI: 25.1 to 59.1)
per 1000 woman-years and among non-users during follow-up, a
rate of 12.8 (95%CI: 9.8 to 16.8). This implied that hormonal
contraceptive use after a first venous thrombosis tripled the risk
of recurrent thrombosis (HR 3.0, 95%CI: 1.8 to 5.0). After ad-
justment for age and BMI at the first event, the hazard ratio did
not change (HR 2.8, 95%CI: 1.7 to 4.7) (Table 6.2). Restricted
to women who were using hormonal contraceptives at the first
event, a similar risk increase was found associated with hormonal
use during follow-up, with those who discontinued use as refer-
ence group (HR 3.4, 95%CI: 1.9-5.9, and after adjustment for
age and BMI: HR 3.1, 95%CI: 1.7-5.4) (Table 6.2).
Hormonal contraceptive preparations were classified into oral
and non-oral (Table 6.2). 16 recurrences occurred during oral
contraceptive use (all combined oral contraceptives). The recur-
rence rate for combined oral contraceptive use during follow-up
was 41.1 (95%CI: 25.1-67.1) per 1000 woman-years, again three-
fold higher than for non-use during follow-up (HR 3.2, 95%CI:
1.8 to 5.7; HR 2.9 after adjustment for age and BMI, 95%CI:
1.6 to 5.2). Only two women used a vaginal ring during follow-
up of whom 1 had a recurrence, suggestive of a high recurrence
risk. Because only one recurrence occurred among 31 non-oral
preparation users, vaginal ring, levonorgestrel-releasing IUD, in-
jectable and implanon users, no reliable risk estimates could
be inferred. However, notable was that out of 20 women using
a levonorgestrel-releasing IUD (70 woman-years of follow-up),
none had a recurrence.
The recurrence rate per type (dose and content) combined





















































































































































































































































































































































































































































































































































































































































































































































































































































































tradiol and progestagen were associated with the risk of recurrent
venous thrombosis. Within users of combined oral contraceptives
containing levonorgestrel, users of 50 µg ethinylestradiol had a
two-fold higher recurrence rate than users of 30 µg ethinyles-
tradiol with levonorgestrel (HR 2.3, 95%CI: 0.3-16.7, adjusted
for age). Within contraceptives with 30 µg ethinylestradiol, con-
traceptives with desogestrel were associated with a higher risk
of recurrence than contraceptives with levonorgestrel (HR 3.4,
95%CI: 0.8-14.9, adjusted for age). The risk of a recurrence was
about equal in users of cyproterone acetate compared with users
of 30 µg ethinylestradiol with levonorgestrel (HR 1.1, 95%CI: 0.1-
11.6, adjusted for age). Out of 17 users of a triphasic preparation,
5 women had a recurrence leading to an eight-fold higher rate
than in users of 30 µg ethinylestradiol with levonorgestrel (HR
7.5, 95%CI: 1.7-33.6, adjusted for age). One woman was using a
triphasic contraceptive with norethisterone and 16 women with
levonorgestrel. After excluding the user of norethisterone, the
results were unchanged (age-adjusted HR 7.5, 95%CI: 1.7-33.6).
Discussion
In a study comprising 702 premenopausal women with venous
thrombosis, we assessed the association between hormonal con-
traceptive use and recurrent venous thrombosis. Women using
hormonal contraceptives, in particular combined oral contracep-
tives, after a first venous thrombosis have a threefold higher risk
of recurrence than non-users. The use or non-use of hormonal
contraceptives at the first event did not affect the risk of recurrent
venous thrombosis. Among combined oral contraceptives users
during follow-up, both the dose of ethinylestradiol as well as the
progestagens influenced the recurrence rates. Users of triphasic
contraceptives were found to have the highest recurrence rates
among combined oral contraceptives. Interestingly, among 20
levonorgestrel-releasing IUD users, none had a recurrent venous
thrombosis.
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To date, only one other study (LETS) evaluated the risk
of recurrent venous thrombosis among women using hormonal
contraceptives in a prospective follow-up study21. That analysis
was restricted to women who used hormonal contraceptives at
the first event. The authors observed a recurrence rate of 48.8
(95%CI: 24.3-87.2) among hormonal contraceptive users during
follow-up and a recurrence rate of 10.5 (95%CI: 4.5-20.7) among
non-users. The recurrence rate among non-users was similar as
reported in the current study (10.5 versus 11.2); however, their
recurrence rate in hormonal contraceptive users was slightly
higher (48.8 versus 38.6). This is most likely due to differences
in the distribution of types of contraceptives in the LETS and
the MEGA study, between which a decade elapsed. In both the
LETS and the present study, the recurrence rate among tripha-
sic contraceptive users was increased compared with non-users
(138.9 (95%CI: 16.8-501.7) versus 200.0 per 1000 women-years
(95%CI: 83.2-480.4)). Why the risk of a recurrence is higher for
these types of contraceptives is currently unexplained, in partic-
ular because there is no difference reported between monophasic
and triphasic contraceptives regarding the risk of a first venous
thrombosis.
A limitation of our study is that data on hormonal contracep-
tive use were obtained through a detailed questionnaire which
not every patient of the MEGA follow-up study was willing to
fill in, reducing the number of women included in our analyses.
The reason for not returning the questionnaire may have intro-
duced selection bias. We therefore assessed the recurrence rate
in patients who filled in the detailed questionnaire (responders)
and patients who did not (non-responders) and this proved to be
similar (IRresponders 17.6, 95%CI: 14.5-21.5 and IRnon−responders
17.3, 95%CI: 12.3-24.1). Most likely, selection bias did not influ-
ence our results. A further limitation of the present study is the
assessment of menopausal status. Menopausal status was based
on statements from the women at baseline and not on medical
data. Potentially, peri- or postmenopausal women could have
172
been included. However, menopausal status is to our knowledge
not related to thrombotic risk and therefore, this potential mis-
classification cannot have affected our risk estimates. Strengths
of our study are its size, and that we used a decision rule to
ascertain recurrence by which we ensured that only certain re-
currences were included in our analyses. Furthermore, detailed in-
formation on participants’ hormonal contraceptive use obtained
during follow-up made it possible to perform a time-dependent
survival analysis, allowing switches from exposed to non-exposed
during follow-up and vice versa.
In conclusion, hormonal contraceptive use after a first ve-
nous thrombotic event increased the risk of a recurrence. Al-
though numbers are small, results suggest that the use of an
levonorgestrel-releasing IUD may be a safe option after a venous
thrombotic event. Among combined oral contraceptive users, the
increase in risk depended on the ethinylestradiol dose, progesta-
gen and whether the contraceptive was triphasic or not.
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Background: Oral contraceptive use is associated with venous
thrombosis risk. Although the risk of venous thrombosis has
been evaluated for various estrogen doses and types of progesta-
gen, no comprehensive comparison involving commonly used oral
contraceptives is available.
Methods: A network meta-analysis was performed to assess the
risk of thrombosis associated with oral contraceptive use at the
level of individual types of contraceptives. Electronic databases
(Pubmed, Embase, Web of Science, Cochrane, CINAHL, Aca-
demic Search Premier and ScienceDirect) were searched in Novem-
ber 2011 to identify potential relevant articles. We selected pub-
lications that assessed the effect of combined oral contracep-
tives on venous thrombosis (i.e., deep venus thrombosis and
pulmonary embolism) in healthy women. Two independent re-
viewers extracted data from included publications. The network
meta-analysis was performed using an extension of frequenist
random-effects models for mixed multiple treatment compar-
isons and relative risks (RR) with 95% confidence intervals (CI)
were reported.
Results: A total of 2011 publications were retrieved through
a search strategy; 24 publications reporting on 25 studies were
included. Combined oral contraceptive use increased the risk of
venous thrombosis compared with non-use (RR 3.6, 95 %CI: 2.9-
4.6). Oral contraceptives containing a third generation progesta-
gen (desogestrel, gestodene or norgestimate) were associated with
a higher risk of venous thrombosis than oral contraceptives with
levonorgestrel (second generation) (RR 1.6, 95%CI: 1.3-1.9). Sen-
sitivity analyses stratified by funding source, study design, or
confirmed venous thrombosis did not change the findings. From
the network meta-analysis at the level of individual type, the
highest thrombosis risk was observed among 50 µg ethinylestra-
diol with levonorgestrel (RR 6.7, 95%CI: 4.0-11.2, compared with
non-use), 35 µg ethinylestradiol with cyproterone acetate (RR
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5.5, 95%CI: 3.9-7.7) and 30 µg ethinylestradiol with drospirenone
(RR 6.0, 95%CI: 4.1-8.9), while the lowest risk was observed
among 20 µg with levonorgestrel (RR 2.6, 95%CI: 1.5-4.5).
Conclusion: All combined oral contraceptives are associated
with an increased risk of venous thrombosis. The effect size de-
pends on the progestagen and the dose of ethinylestradiol.
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Introduction
In 1960, shortly after the introduction of the first combined
oral contraceptive, a case of venous thrombosis associated with
contraceptive use was reported1. Since then many observational
studies showed that combined oral contraceptives, containing
both an estrogen and a progestagen, are associated with a two-
fold to six-fold increased risk of venous thrombosis2–5. Despite
the low incidence of venous thrombosis of about 3 per 10,000
woman-years among women of reproductive age6, the impact
of combined oral contraceptives on venous thrombosis is large
because worldwide many women use oral contraceptives.
Because the estrogen compound (ethinylestradiol) in com-
bined hormonal contraceptives was thought to cause the in-
creased thrombosis risk, the dose of ethinylestradiol has been
lowered from 150-100 µg in the earliest brands to 50 µg in the
1960s to 30-35 µg and 20 µg in the 1970s7–9. The reduced dose
of ethinylestradiol in contraceptives was indeed associated with
a reduction in the risk of venous thrombosis10–14. Furthermore,
the currently prescribed combined oral contraceptives contain-
ing 30 µg of ethinylestradiol are associated with a higher risk
of venous thrombosis than contraceptives containing 20 µg15,16.
Besides adjustments in the dose of ethinylestradiol, the progesta-
gen compound was also changed in an effort to reduce side-
effects. After the first generation progestagens (e.g., norethis-
terone, lynestrol), new progestagens were developed, called sec-
ond (i.e., levonorgestrel (LNG)) and third generation progesta-
gens (i.e., gestodene (GSD), desogestrel (DSG), norgestimate
(NGM))17. However, third generation combined oral contracep-
tive users have a higher risk of venous thrombosis than second
generation users15,16,18,19. Other progestagens have been devel-
oped after the introduction of the third generation progestagens,
e.g. drospirenone (introduced in 2001). The use of drospirenone
in a combined oral contraceptive also increased the risk of venous




The aim of the present network meta-analysis was to provide
an overview of the risk of venous thrombosis per combined oral
contraceptive in healthy women. Furthermore, the effect of the
generation of a progestagen in combined oral contraceptive was
assessed. A network meta-analysis was performed because com-
bined oral contraceptives are mostly compared with non-use or
with a contraceptive containing levonorgestrel with 30 µg ethinyl-
estradiol resulting in gaps in direct evidence. In other words, not
every combined oral contraceptive has been directly compared
with all other possible combined oral contraceptives. A network
meta-analysis allows evidence from direct and indirect compar-
isons to be summarized in a weighted average for all possible
comparisons.
Methods
Search strategy and selection criteria A detailed overview of the
search strategy and selection criteria can be found in the sup-
plementary data22. Publications of interest were observational
studies (i.e., cohort or (nested) case-control studies) that included
healthy women using combined oral contraceptives. The primary
outcome of interest was a fatal or non-fatal first event of venous
thrombosis (deep venous thrombosis or pulmonary embolism).
Publications with a minimum of 10 events in total were eligible.
The following databases were searched; Pubmed (918 articles
retrieved), Embase (1198), Web of Science (298), Cochrane (57),
CINAHL (111), Academic Search Premier (183) and ScienceDi-
rect (103). Our search terms consisted of MeSH (sub)headings,
text words, and word variations for “combined oral contracep-
tive”, “estrogens”, “progestagens” and “venous thromboembo-
lism”. This search strategy was amended for each database. Each
database was searched from inception until 22 November 2011
(date of final search). No language restriction was applied. Beside
database searches, references of potential interesting publications
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were searched.
A standard form was used to select publications. Two in-
vestigators (BHS, MdB) independently assessed publications for
eligibility. Titles and abstracts were screened and if deemed po-
tentially relevant, full-texts were retrieved. Any disagreements
between the investigators were discussed and if necessary, a third
reviewer (OMD) was asked to resolve any disagreements. In case
of multiple publications from the same study, the publication
with the most updated or the most inclusive data was chosen
for inclusion.
Data collection Two investigators (BHS, MdB) independently
extracted data using a standard form. Data were extracted on
type of combined oral contraceptive (dose and type of estrogen
and progestagen), crude numbers for exposure and outcome via
a 2-by-2 table, crude and adjusted risk estimates, and variables
adjusted for in the analysis.
Risk of bias assessment was based on design features that
could potentially bias the association between exposure and out-
come. We assessed adequacy of exposure (oral contraceptive) and
outcome (venous thrombosis) measurement. Specific for cohort
studies, loss-to-follow-up assessment was taken into account and
for case-control studies, the sampling of controls. Women are
more likely to remember that they used oral contraceptives than
what specific preparation they used23,24. Therefore, assessment
of type of combined oral contraceptive through an interview or
questionnaire was deemed as high risk of bias, while informa-
tion from a prescription database was judged as low risk. Only
25-33% of patients presenting with clinical symptoms sugges-
tive of venous thrombosis are diagnosed with venous thrombo-
sis25.Therefore, objectively confirmed venous thrombosis in all
patients was judged as low risk of bias. Venous thrombosis was
objectively confirmed when a deep venous thrombosis was di-
agnosed by plethysmography, ultrasound examination, CT, or
venography; or when a pulmonary embolism was diagnosed by
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ventilation-perfusion (V/Q) scanning, spiral computed tomog-
raphy, or pulmonary angiography26,27. Less than 10% loss-to-
follow-up was considered to represent a low risk of bias. For
case-control studies, controls selected from a hospital population
was considered to confer a high risk of bias.
For sensitivity analyses, data on funding source and first-time
use were abstracted.
In case of incomplete data on dose/type of estrogen or pro-
gestagen, authors were sent an email for extra information. Emails
were sent on 25 July 2012 with a reminder on 20 August 2012.
In total, 80% replied to our emails.
Classification of type or combined oral contraceptives For the
network meta-analysis per generation of progestagen, the follow-
ing progestagens were considered first generation; lynestrenol
and norethisterone. Norgestrel and levonorgestrel were catego-
rized as second generation progestagens, whereas desogestrel,
gestodene and norgestimate were classified as third generation
progestagens17. This classification was irrespective of the ethi-
nylestradiol dose. Publications, for which our classification could
not be applied but which did provided their own classification,
were included irrespective of whether this classification differed
from our own. To assess the influence of combining different clas-
sifications, we repeated the analysis in studies where our own
classification of generations could be applied.
Many different combined oral contraceptives are available.
The most commonly used combined oral contraceptives were
selected for analysis, namely 20 µg ethinylestradiol with lev-
onorgestrel (20LNG), 30 µg ethinylestradiol with levonorgestrel
(30LNG), 50 µg ethinylestradiol with levonorgestrel (50LNG),
20 µgg ethinylestradiol with gestodene (20GSD), 30 µg ethinyl-
estradiol with gestodene (30GSD), 20 µg ethinylestradiol with
desogestrel (20DSG), 30 µg ethinylestradiol with desogestrel
(30DSG), 35 µg ethinylestradiol with norgestimate (35NRG), 35
µg ethinylestradiol with cyproterone acetate (35CPA), and 30
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µg ethinylestradiol with drospirenone (30DRSP).
Statistical analysis A network meta-analysis was conducted per
generation of progestagen in a combined oral contraceptive and
per selected oral contraceptive preparation.
An extension of frequentist random-effects models for mixed
multiple treatment comparisons was used. Network meta-analysis
was performed with the mvmeta command for STATA as de-
scribed by White et al28. Crude data (i.e., data from a 2-by-2
table) were used in the analysis. Odds ratio, risk ratio or rate
ratio and appropriate variances were computed and combined in
the analysis leading to an overall relative risk (RR). For publica-
tions with zero events in one group, all groups in that publication
were inflated by adding 0.5.
When enough studies provided data on the same stratum (i.e.,
data on generations of progestagen or on specific contraceptive
preparations), consistency of the results was checked through
interaction analysis. An interaction term was added to the model
to estimate the difference in results from direct and indirect
evidence. All potential interactions were tested in an overall
test to determine whether there were any inconsistencies in our
network meta-analysis. Inconsistencies were only checked when
there was more than one study comparing the same groups.
The following sensitivity analyses were planned: per study
design, per funding source (whether industry sponsored or not),
within first-time users, and according to risk of bias.
All statistical analyses were performed with STATA, version
12.0 (Statacorp LP, College Station, TX, USA).
Results
Characteristics of included studies A total of 2011 publications
were retrieved through electronic and references searches. 1912
were excluded after screening of title and abstract and 75 publi-
cations were excluded after detailed assessment of the full-text.
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Reasons for exclusion are shown in the flow chart (Figure 7.1,
Supplementary table 7.1). Overall, 25 studies published in 24
articles were included. Two publications provided important ad-
ditional information to studies included in the meta-analysis (in-
formation on first-time use); data from these publications were
added to respective studies already included. Details of included
studies are shown in table 7.1. Seven cohort studies, three nested
case-control studies and 15 case-control studies were included.
Based on data from 14 studies that included a non-user group,
combined oral contraceptive use was found to be associated with
a four-fold increased risk of venous thrombosis (RR 3.6, 95%CI:
2.9-4.6).
2868 publications retrieved through electronic searches
910 duplicates





 1872 based on selection criteria
 38 reporting on the same study
 2 unattainable
99 publications selected for data abstraction
75 publications excluded
 69 based on selection criteria
 6 reporting on the same study
24 publications included in network meta-analysis









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Risk of bias A total of eight studies assessed combined oral con-
traceptive use through an interview or questionnaire (Supplemen-
tary table 7.2). Only five studies objectively confirmed venous
thrombosis in all patients, whereas eleven studies objectively
confirmed venous thrombosis in a proportion of the population
or subjectively confirmed venous thrombosis. Six case-control
studies selected controls from a hospitalized population. Of the
seven cohort studies, none reported any information about loss-
to-follow-up.
Network meta-analysis comparing generations of progestagens
A total of 23 studies were included for the analysis stratified
per generation of progestagen in a combined oral contraceptive.
Two studies reported solely on the risk of venous thrombosis in
drospirenone, which is not classified as a certain generation of
progestagen. Details of the number of events and total number
of women or total follow-up time per group (i.e., non-use, first
generation, second generation and third generation) are provided
in supplementary table 7.3.
Results of the network meta-analysis according to genera-
tions of progestagen are shown in table 7.2. Users of oral con-
traceptives with a first generation progestagen had a 3.4-fold
increased risk compared with non-users (95%CI: 2.5-4.5), for
second generations the risk was 2.8-fold increased (95%CI: 2.3-
3.5) and third generation users the risk was 4.5-fold increased
(95%CI: 3.6-5.5). Third generation users had a higher risk of ve-
nous thrombosis than second generation users (RR 1.6, 95%CI:
1.3-1.9). Restriction to studies where our classification of genera-
tions could be applied, the results remained the same (RR1st 3.6,
95%CI: 2.5-5.2; RR2nd 2.9, 95%CI: 2.3-3.8; RR3rd 5.2, 95%CI:
4.0-6.6 compared with non-use). A formal interaction test did
not show inconsistencies in the network (χ2= 3.17, p = 0.67).
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Table 7.2: Overview of the results of the network meta-analysis per gener-
ation of progestagen
Reference group
Non-use 1st 2nd 3rd
RR (95%CI) RR (95%CI) RR (95%CI) RR (95%CI)
Non-use 1
1st 3.4 (2.5-4.5) 1
2nd 2.8 (2.3-3.5) 0.8 (0.6-1.1) 1
3rd 4.5 (3.6-5.5) 1.3 (1.0-1.7) 1.6 (1.3-1.9) 1
Network meta-analysis comparing different combined oral con-
traceptives Twelve studies had data available per type of oral
contraceptive preparation (Supplementary table 7.4). In all these
12 studies at least one preparation was compared with non-use or
two types were compared directly. Results of the network meta-
analysis per combined oral contraceptive preparation are shown
in table 7.3. All selected preparations were associated with a
two-fold or more increased risk of venous thrombosis compared
with non-use (Figure 7.2). The relative risk estimate was the
highest in 50LNG users and the lowest in 20LNG and 20GSD
users. There was a dose-related effect of ethinylestradiol within
gestodene and levonorgestrel users, but not in desogestrel users
(Table 7.3). In other words, taking either 20DSG or 30DSG as
reference did not materially alter the risk estimates for other
contraceptives. The risk of venous thrombosis with the use of
35CPA and 35DRSP was approximately the same as 50LNG
(RR30CPA 0.8, 95%CI: 0.5-1.5 and RR30DRSP 0.9, 95%CI: 0.5-
1.7 compared with 50LNG). A formal interaction test could not
be performed because none of the studies provided data on the
same groups (Supplementary table 7.3).
Sensitivity analysis Because of the low number of included stud-
ies, sensitivity analyses were limited to analyses stratified on




























































Figure 7.2: Results of the network meta-analysis per contraceptive pill on
a logarithmic scale. The dots indicate the overall RR with lines representing
the 95% confidence interval. Non-use was taken as the reference group
tively confirmed venous thrombosis (Table 7.4). Results from
the sensitivity analysis stratified on funding source showed that
the risk estimate for third generation users (compared with non-
users) was lower in the industry-sponsored studies than in non-
industry-sponsored studies (RR 3.3 versus RR 5.2). In cohort
studies, the risk estimate for third generation users (compared
with non-users) was higher than in case-control studies (RR 6.1
versus RR 4.3). All risk estimates were higher in studies with







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































We performed a network meta-analysis based on 25 studies. Over-
all, combined oral contraceptive use increased the risk of venous
thrombosis four-fold. We observed that all generations of pro-
gestagens were associated with an increased risk of venous throm-
bosis and that third generation users had an increased venous
thrombosis risk compared with second generation users. All indi-
vidual types of combined oral contraceptives increased thrombo-
sis risk compared with non-use. The contraceptives 30DRSP and
35CPA increased the risk of venous thrombosis compared with
any other contraceptive except for 50LNG. Users of 20LNG had
the lowest risk of venous thrombosis. Whether 20GSD can be
considered as safe as 20LNG remains to be determined, because
only one study16 contributed data on 32 women using 20GSD.
In this meta-analysis, bias was potentially introduced by the
lack of objectively confirming venous thrombosis in all studies.
Only 25-33% of patients with clinical symptoms of thrombosis are
diagnosed with venous thrombosis25. Including cases in a study
without objectively confirmed venous thrombosis would lead to
overestimating the association when oral contraceptive users
were more likely to be diagnosed than non-users. However, two
studies showed that this bias is unlikely to depend on combined
oral contraceptive use18,19. In studies with clinically diagnosed
venous thrombosis without objective confirmation, women are
misclassified irrespective of their contraceptive use leading to non-
differential misclassification. Therefore, results of such studies
may be an underestimation of the true association. This was
confirmed by the results from our sensitivity analysis where the
risk estimates were higher in studies with objectively confirmed
venous thrombosis.
Strengths and limitations The internal validity of the network
meta-analysis was assessed through interaction analysis mod-



































































































































































































































































dicated that potential inconsistencies are likely the results of
chance. A limitation of our network meta-analysis is that the
publications had to provide the number of users with number
of events per type of combined oral contraceptive. A total of 16
studies provided information on combined oral contraceptive use
and risk of venous thrombosis without specifying which contra-
ceptive types were used. Therefore, the number of publications
included for the meta-analysis per contraceptive is relatively low.
A further limitation may be that the classification of generations
of progestagen was not the same in every publication. However,
no clear consensus exists on the classification into generations
of progestagen. For instance, norgestimate can be categorised
as a second or a third generation progestagen. However, restric-
tion on studies where our classification could be applied did
not change the results. Network meta-analysis summarizes data
from direct and indirect comparisons in a weighted average. A
strength of our analysis is that through a network meta-analysis
the data on cimbined oral contraceptives were most effectively
used. This resulted in a comprehensive overview of the risk of
venous thrombosis in commonly used oral contraceptives.
Two other meta-analyses18,50 have evaluated the risk of ve-
nous thrombosis in third generation contraceptive users versus
second generation users. Both found an increased risk in third
generation users (RR 1.5 95%CI: 1.2-1.818 and RR 1.57 95%CI:
1.24-1.9850) in line with our result. Although they differed in
their included studies, the majority of included studies from both
meta-analyses were included in our analysis. To date, no other
meta-analysis summarized the data on venous thrombosis risk
per combined oral contraceptive preparation.
Meaning of the study Although we observed that the risk of ve-
nous thrombosis increased with the dose of ethinylestradiol, this
was dependent on the progestagen provided. There was no differ-
ence in the venous thrombosis risk between 20DSG and 30DSG,
whereas oral contraceptives with other progestagens with differ-
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ent doses of ethinylestradiol did show a difference in risk. It is
unclear why the dose effect of ethinylestradiol might depend on
the progestagen. A possibility is that there is a difference in
inhibitory effects of the progestagen on the procoagulant effect
of ethinylestradiol. Oral contraceptive use increases the levels of
factors II, VII, VIII, protein C and decreases the levels of an-
tithrombin and protein S. Clinical studies have showed that this
effect on coagulation factors was more pronounced in desogestrel
users than in levonorgestrel users, and limited to combined oral
contraceptives51,52.
The results per combined oral contraceptive preparation show-
ed that combining different preparations into generations may
not be an appropriate way to present the risk of thrombosis.
The risk of venous thrombosis depended both on the dose of
ethinylestradiol as well as on the progestagen provided. We sug-
gest abstaining from any classification of contraceptives, but to
compare the risk of venous thrombosis per oral contraceptive
preparation.
What do these results mean for clinical practice? Prescribing
combined oral contraceptives may not be a good choice with
regard to the risk of venous thrombosis. However, if a woman
persists in using combined oral contraceptives, only the con-
traceptive with the lowest risk of venous thrombosis and good
compliance should be prescribed, namely levonorgestrel with 30
µg ethinylestradiol. Current practice is to increase the dose of
ethinylestradiol in case of disruptions in bleeding patterns53. In
all likelihood, our results indicate that prescribing 50LNG in
case of spotting during the use of 30LNG might carry a serious
adverse effect.
Conclusions Combined oral contraceptives were associated with
an increased risk of venous thrombosis. The effect size may de-
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Supplementary data
Search strategy of the review
PubMed (“Contraceptives, Oral"[mesh] OR "Contraceptives, Oral"[Phar-
macological Action] OR "oral contraceptives" OR "oral contraceptive" OR
"Contraceptives, Oral, Combined"[Mesh] OR "combined oral contraceptives"
OR "combined oral contraceptive" OR ((norethisterone OR norethisteron*
OR norethindrone OR norethindron* OR "ethynodiol diacetate" OR lynes-
trenol OR lynestrenol* OR norethynodrel OR norethynodrel* OR dienogest
OR dienogest* OR levonorgestrel OR levonorgestrel* OR norgestrel OR
norgestrel* OR dl-norgestrel OR dl-norgestrel* OR desogestrel OR deso-
gestrel* OR norgestimate OR norgestimat* OR gestodene OR gestoden* OR
"medroxyprogesterone acetate" OR "chlormadinone acetate" OR nomege-
strol OR nomegestrol* OR nestorone OR nestoron* OR "Cyproterone ac-
etate" OR Drospirenone OR Drospirenon* OR oestrogen*[ti] OR estro-
gen[ti]) AND ("Ethinyl Estradiol"[mesh] OR "Ethinyl Estradiol" OR ethinyl-
estradiol OR ethinylestradiol* OR Mestranol OR Mestranol* OR "estradiol
valerate"[Supplementary Concept] OR "estradiol valerate" OR progesto-
gen*[ti]))) AND ("deep vein thrombosis"[ti] OR "deep venous thrombo-
sis"[ti] OR "Venous Thrombosis"[ti] OR "Vein Thrombosis"[ti] OR "Venous
Thrombosis"[mesh:noexp] OR "Thrombophlebitis"[mesh] OR "Upper Ex-
tremity Deep Vein Thrombosis"[mesh] OR Thrombophlebitis[ti] OR "pul-
monary embolism"[ti] OR "pulmonary embolism"[mesh] OR "venous throm-
boembolism"[ti] OR "Venous Thromboembolism"[mesh] OR "venous throm-
boembolic disorders"[ti] OR (venous[ti] AND thromboembolic[ti] AND dis-
order[ti]) OR "venous thromboembolic diseases"[ti] OR "venous thromboem-
bolic disease"[ti] OR "venous thrombotic"[ti] OR ("Thromboembolism"[mesh:
noexp] AND (venous[tiab] OR vein[tiab] OR veins[tiab))) AND (risk OR
risks OR risk factor OR risk factors) AND (women OR woman OR woman*
OR women* OR girl OR girls OR female) NOT (animals NOT (human
AND animals))
EMBASE (exp oral contraceptive agent/ OR "oral contraceptives".mp
OR "oral contraceptive".mp OR "combined oral contraceptives".mp OR
"combined oral contraceptive".mp OR (((norethisterone OR norethisteron*
OR norethindrone OR norethindron* OR "ethynodiol diacetate" OR lynes-
trenol OR lynestrenol* OR norethynodrel OR norethynodrel* OR dienogest
OR dienogest* OR levonorgestrel OR levonorgestrel* OR norgestrel OR
norgestrel* OR dl-norgestrel OR dl-norgestrel* OR desogestrel OR deso-
gestrel* OR norgestimate OR norgestimat* OR gestodene OR gestoden* OR
"medroxyprogesterone acetate" OR "chlormadinone acetate" OR nomege-
strol OR nomegestrol* OR nestorone OR nestoron* OR "Cyproterone ac-
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etate" OR Drospirenone OR Drospirenon*).mp OR oestrogen*.ti OR estro-
gen.ti) AND (("Ethinyl Estradiol" OR ethinylestradiol OR ethinylestradiol*
OR Mestranol OR Mestranol* OR "estradiol valerate" OR "estradiol valer-
ate").mp OR progestogen*.ti))) AND (("deep vein thrombosis" OR "deep
venous thrombosis" OR "Venous Thrombosis" OR "Vein Thrombosis").ti OR
exp deep vein thrombosis/ OR Vein Thrombosis/ OR Thrombophlebitis/
OR Thrombophlebitis.ti OR "pulmonary embolism".ti OR exp lung em-
bolism/ OR "venous thromboembolism".ti OR exp Venous Thromboem-
bolism/ OR "venous thromboembolic disorder*".ti OR "venous thromboem-
bolic disease*".ti OR "venous thrombotic".ti) AND (exp risk/ OR risk*.mp
OR exp risk factor/) AND ((women OR woman OR woman* OR women*
OR girl OR girls OR female).mp OR exp female/) AND (exp human/ OR
human.ti OR patient.ti OR patients.ti)
Web of Science TS=("oral contraceptives" OR "oral contraceptive" OR
combined oral contraceptive* OR ((norethisterone OR norethisteron* OR
norethindrone OR norethindron* OR "ethynodiol diacetate" OR lynestre-
nol OR lynestrenol* OR norethynodrel OR norethynodrel* OR dienogest
OR dienogest* OR levonorgestrel OR levonorgestrel* OR norgestrel OR
norgestrel* OR dl-norgestrel OR dl-norgestrel* OR desogestrel OR deso-
gestrel* OR norgestimate OR norgestimat* OR gestodene OR gestoden* OR
"medroxyprogesterone acetate" OR "chlormadinone acetate" OR nomege-
strol OR nomegestrol* OR nestorone OR nestoron* OR "Cyproterone ac-
etate" OR Drospirenone OR Drospirenon*) AND ("Ethinyl Estradiol" OR
ethinylestradiol OR ethinylestradiol* OR Mestranol OR Mestranol* OR
"estradiol valerate" OR "estradiol valerate"))) AND TI=("deep vein throm-
bosis" OR "deep venous thrombosis" OR "Venous Thrombosis" OR "Vein
Thrombosis" OR "Vein Thrombosis" OR Thrombophlebitis OR "pulmonary
embolism" OR "venous thromboembolism" OR "venous thromboembolic
disorder*" OR "venous thromboembolic disease*" OR "venous thrombotic")
AND TS=risk* AND TS=(women OR woman OR woman* OR women* OR
girl OR girls OR female) Cochrane (http://www3.interscience.wiley.com/cgi-
bin/mrwhome/106568753/HOME) ("oral contraceptives" OR "oral contra-
ceptive" OR combined oral contraceptive* OR ((norethisterone OR norethis-
teron* OR norethindrone OR norethindron* OR "ethynodiol diacetate"
OR lynestrenol OR lynestrenol* OR norethynodrel OR norethynodrel*
OR dienogest OR dienogest* OR levonorgestrel OR levonorgestrel* OR
norgestrel OR norgestrel* OR dl-norgestrel OR dl-norgestrel* OR deso-
gestrel OR desogestrel* OR norgestimate OR norgestimat* OR gestodene
OR gestoden* OR "medroxyprogesterone acetate" OR "chlormadinone ac-
etate" OR nomegestrol OR nomegestrol* OR nestorone OR nestoron* OR
"Cyproterone acetate" OR Drospirenone OR Drospirenon*) AND ("Ethinyl
Estradiol" OR ethinylestradiol OR ethinylestradiol* OR Mestranol OR Mes-
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tranol* OR "estradiol valerate" OR "estradiol valerate"))) AND ("deep vein
thrombosis" OR "deep venous thrombosis" OR "Venous Thrombosis" OR
"Vein Thrombosis" OR "Vein Thrombosis" OR Thrombophlebitis OR "pul-
monary embolism" OR "venous thromboembolism" OR "venous thromboem-
bolic disorder*" OR "venous thromboembolic disease*" OR "venous throm-
botic") AND risk* AND (women OR woman OR woman* OR women* OR
girl OR girls OR female)
CINAHL TITLE/ABSTRACT/KEYWORD (oral contraceptives OR
oral contraceptive OR combined oral contraceptive* OR ((norethisterone
OR norethisteron* OR norethindrone OR norethindron* OR ethynodiol
diacetate OR lynestrenol OR lynestrenol* OR norethynodrel OR norethyn-
odrel* OR dienogest OR dienogest* OR levonorgestrel OR levonorgestrel*
OR norgestrel OR norgestrel* OR dl-norgestrel OR dl-norgestrel* OR des-
ogestrel OR desogestrel* OR norgestimate OR norgestimat* OR gestodene
OR gestoden* OR medroxyprogesterone acetate OR chlormadinone acetate
OR nomegestrol OR nomegestrol* OR nestorone OR nestoron* OR Cypro-
terone acetate OR Drospirenone OR Drospirenon*) AND (Ethinyl Estradiol
OR ethinylestradiol OR ethinylestradiol* OR Mestranol OR Mestranol* OR
estradiol valerate OR estradiol valerate))) AND (deep vein thrombosis OR
deep venous thrombosis OR Venous Thrombosis OR Vein Thrombosis OR
Vein Thrombosis OR Thrombophlebitis OR pulmonary embolism OR ve-
nous thromboembolism OR venous thromboembolic disorder* OR venous
thromboembolic disease* OR venous thrombotic) AND risk* AND (women
OR woman OR woman* OR women* OR girl OR girls OR female)
Academic Search Premier (oral contraceptives OR oral contracep-
tive OR combined oral contraceptive* OR ((norethisterone OR norethis-
teron* OR norethindrone OR norethindron* OR ethynodiol diacetate OR
lynestrenol OR lynestrenol* OR norethynodrel OR norethynodrel* OR
dienogest OR dienogest* OR levonorgestrel OR levonorgestrel* OR nor-
gestrel OR norgestrel* OR dl-norgestrel OR dl-norgestrel* OR desogestrel
OR desogestrel* OR norgestimate OR norgestimat* OR gestodene OR
gestoden* OR medroxyprogesterone acetate OR chlormadinone acetate OR
nomegestrol OR nomegestrol* OR nestorone OR nestoron* OR Cyproterone
acetate OR Drospirenone OR Drospirenon*) AND (Ethinyl Estradiol OR
ethinylestradiol OR ethinylestradiol* OR Mestranol OR Mestranol* OR
estradiol valerate OR estradiol valerate))) AND (deep vein thrombosis OR
deep venous thrombosis OR Venous Thrombosis OR Vein Thrombosis OR
Vein Thrombosis OR Thrombophlebitis OR pulmonary embolism OR ve-
nous thromboembolism OR venous thromboembolic disorder* OR venous
thromboembolic disease* OR venous thrombotic) AND risk* AND (women
OR woman OR woman* OR women* OR girl OR girls OR female)
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ScienceDirect TITLE((oral contraceptives OR oral contraceptive OR
combined oral contraceptive* OR ((norethisterone OR norethisteron* OR
norethindrone OR norethindron* OR ethynodiol diacetate OR lynestrenol
OR lynestrenol* OR norethynodrel OR norethynodrel* OR dienogest OR
dienogest* OR levonorgestrel OR levonorgestrel* OR norgestrel OR nor-
gestrel* OR dl-norgestrel OR dl-norgestrel* OR desogestrel OR desogestrel*
OR norgestimate OR norgestimat* OR gestodene OR gestoden* ORmedrox-
yprogesterone acetate OR chlormadinone acetate OR nomegestrol OR nome-
gestrol* OR nestorone OR nestoron* OR Cyproterone acetate OR Drospi-
renone OR Drospirenon*) AND (Ethinyl Estradiol OR ethinylestradiol OR
ethinylestradiol* OR Mestranol OR Mestranol* OR estradiol valerate OR
estradiol valerate))) AND (deep vein thrombosis OR deep venous thrombo-
sis OR Venous Thrombosis OR Vein Thrombosis OR Vein Thrombosis OR
Thrombophlebitis OR pulmonary embolism OR venous thromboembolism
OR venous thromboembolic disorder* OR venous thromboembolic disease*
OR venous thrombotic) AND risk* AND (women OR woman OR woman*
OR women* OR girl OR girls OR female))
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Criteria for considering studies for this review
Types of studies Observational studies in this review will include case-
control, cohort and nested case-control designs. If available, RCT will also
be evaluated and included.
Types of participants Participants will be healthy women taking com-
bined oral contraceptives. We will exclude studies of women on hormone
replacement therapy, studies of women taking non-oral or progestagen-only
contraceptives and studies of women with recurrent venous thrombosis.
Types of interventions Combined oral contraceptive use will be com-
pared to non-use or to a reference combined oral contraceptive (for example,
levonorgestrel with 30 µg of ethinylestradiol). We define a woman as a
non-user when either she has never been exposed to a combined oral con-
traceptive or she was a former/previous combined oral contraceptive user.
We will categorize the combined oral contraceptive type according to the
estrogen type and dose and to the progestagen type.
Types of outcome measures The outcome will be fatal or non-fatal first






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary table 7.2 Overview of risk of bias per study
Study Source Exposure Outcome Follow-up
population* assessment assessment
N. Gronich 2011 NA Low risk Unclear Unclear
S.S. Jick 2011 Low risk Low risk Unclear NA
L. Parkin 2011 Low risk Low risk High risk NA
L.A.J. Heinemann 2010 Low risk High risk High risk NA
A. van Hylckama Vlieg 2009 Low risk High risk Low risk NA
S.S. Jick 2006 Low risk Low risk Unclear NA
E. Samuelsson 2004 NA Low risk Low risk Unclear
K. Hedenmalm 2004 NA Low risk High risk Unclear
L.A.J. Heinemann 2002 High risk High risk High risk NA
L. Parkin 2000 Low risk High risk High risk NA
R.D.T. Farmer 2000 NA Low risk High risk Unclear
M.A. Lewis 1999 High risk Low risk Unclear NA
R.M.C. Herings 1999 NA Low risk Unclear Unclear
J.C. Todd 1999 NA Low risk High risk Unclear
I. Martinelli 1999 Low risk Unclear Unclear NA
K.W.M. Bloemenkamp 1999 Low risk High risk Low risk NA
Ø. Lidegaard 1998 Low risk High risk High risk NA
R.D.T. Farmer 1998 Low risk Low risk Unclear NA
B.S. Andersen 1998 Low risk Low risk Low risk NA
M.A. Lewis 1996 High risk High risk Unclear NA
R. Farmer 1996 NA Low risk Unclear Unclear
K.W.M. Bloemenkamp 1995 Low risk Low risk Low risk NA
WHO 1995 High risk Low risk High risk NA
WHO1 1995 High risk Low risk High risk NA
WHO2 1995 High risk Low risk High risk NA
NA, not applicable due to cohort design in case of source population or due to case-
control design in case of follow-up
* Case-control studies: population of controls, hospitalized or community-based.
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Supplementary table 7.3 Included publications with data on generation
of progestagens
Design Study Non-use* 1st* 2nd* 3rd*
1 Hylckama 2009 421/1523 55/81 382/672 412/582
Heinemann 2002 246/2115 45/190 131/865 28/195
Lewis 1999 171/1268 38/97 142/562 137/401
Bloemenkamp 1999 83/511 18/46 8/22 33/67
Bloemenkamp 1995 46/150 8/13 20/38 37/52
WHO1 1995 168/855 29/74 156/392 53/104
WHO2 1995 505/2220 26/65 153/337 18/25
2 Heinemann 2010 70/1215 - 61/245 62/238
Parkin 2000 9/95 - 3/11 12/27
Lidegaard 1998 203/1037 - 31/85 120/244
WHO 1995 397/1916 - 137/340 71/127
3 Samuelsson 2004 32/171206 - - 17/14819
Martinelli 1999 41/179 - - 43/79
Andersen 1998 27/133 - - 16/23
4 Hedenmalm 2004 - 36/1898899 74/6343562 83/1739393
Farmer 2000 - 12/39421 98/307070 161/374129
5 Gronich 2011 - - 23/33187 384/651455
Jick 2006 - - 70/386 211/950
Herrings 1999 - - 29/121411 49/88295
Todd 1999 - - 32/76993 53/92052
Farmer 1998 - - 27/116 15/79
Lewis 1996 - - 96/419 156/451
Farmer 1996 - - 14/76600 15/65100
1st, first generation; 2nd, second generation; 3rd, third generation



















































































































































































































































































































































































































































































































































































































This thesis focussed on the role of hormonal contraceptives
in the pathogenesis of venous thrombosis and its association
with a first and recurrent venous thrombosis. We set out to
research the mechanisms behind combined oral contraceptive-
associated venous thrombosis, to assess the association between
hormonal contraceptive use and recurrent venous thrombosis and
to provide an overview of the risk of a first venous thrombosis per
type of combined oral contraceptive. In this section, the research
questions of the thesis and its implications will be discussed.
Mechanism behind combined oral contraceptive-associated
venous thrombosis
Sex hormone binding globulin (SHBG) levels are said to be a
marker of venous thrombosis in combined oral contraceptive
users reflecting the difference in risk between different contra-
ceptives1,2. For instance, SHBG levels are higher in users of con-
traceptives with a third generation progestagenn (desogestrel,
gestodene and norgestimate) than in users of a second generation
(levonorgestrel), reflecting the difference in venous thrombosis
risk. Although the association between SHBG levels and contra-
ceptive use has been established, the question remained whether
SHBG level is an intermediate, i.e., meaning both a marker and
a cause, or only a marker for venous thrombosis risk. In chapter
2, we used a Mendelian randomization approach to show that
SHBG level was only a marker and not a cause of venous throm-
bosis. A disadvantage of this analysis is the requirement that the
changes in protein levels caused by genetic variation, which may
be minor, are also causative of the disease of interest. However,
we observed changes in SHBG levels caused by genetic variation
in the SHBG gene in the same magnitude as changes caused
by oral contraceptive use, rendering this approach feasible. We
were able to include only 23 women with venous thrombosis,
and over 200 women without venous thrombosis. Despite this
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low number of patients, our three-pronged approach consistently
showed that increased SHBG levels were not causally related
with venous thrombosis.
The association between SHBG levels and different progesta-
gens in combined oral contraceptives has been well established1,2,
but the association with the ethinylestradiol dose remains to be
determined. The ethinylestradiol dose in combined oral contra-
ceptives is positively associated with the risk of venous throm-
bosis3,4. For SHBG levels to be considered as a useful marker
of venous thrombosis in combined oral contraceptive users, the
ethinylestradiol dose should also be reflected in SHBG levels. In
chapter 3, we were able to show that with increasing ethinyles-
tradiol dose, SHBG levels increased as well. Although we were
not able to restrict our analysis to one specific progestagen, we
did adjust for the progestagen. Furthermore, the observed SHBG
levels were similar as previously reported.
The relevance of the first-pass metabolism of ethinylestradiol
for the risk of venous thrombosis was assessed through haplo-
types in genes coding for enzymes involved in this metabolism
and their effect on SHBG levels. We found that carrying two
copies of haplotype D in the gene UGT2B7 was associated with
an increased risk of venous thrombosis, described in chapter 4.
We only assessed genetic variation in this metabolism through
common variation (SNPs with a minor allele frequency of more
than 5%). However, these common SNPs could code for rare hap-
lotypes (frequency below 5%). The first-pass metabolism may
not be as pivotal in the pathogenesis of venous thrombosis as
previously thought. Other contraceptives were developed to by-
pass the first-pass metabolism of ethinylestradiol, namely the
transdermal patch and the vaginal ring. Users of these contracep-
tives, however, still have an increased risk of venous thrombosis5.
Therefore, although we show that genetic variation in the first
pass metabolism may explain part of the pathogenesis of com-
bined oral contraceptive-associated venous thrombosis, currently
we cannot fully explain how combined oral contraceptives cause
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venous thrombosis.
Hormonal contraceptive use after a first event
Guidelines6–8 recommend that women should refrain from using
combined preparations after a first event of venous thrombosis.
Progestagen-only preparations could be used instead. Are these
guidelines followed in daily practice? We found that about 25%
of women continued using hormonal contraception after a venous
thrombotic event, either by continuing their oral contraceptive
or by switching. This includes women changing to a progestagen-
only contraceptive which is according to the guidelines. However,
we found that 21% continued or changed to another combined
oral contraceptive. Women without a positive family history of
venous thrombosis, or women with thrombosis following surgery
or a plaster cast were more likely to continue or switch contra-
ceptives. Because venous thrombosis is a multicausal disease,
it is difficult to indicate one factor that solely causes venous
thrombosis. From our data it is not possible to know exactly
why decisions to continue or stop were made. However, 12% of
women who received advice from a physician to stop their con-
traceptive, still continued or changed to another combined oral
contraceptive.
Current guidelines are from 2009 and do not include a study
from 2010 showing that continuing or restarting hormonal con-
traceptives after a first event increases the risk of recurrence9.
In our study, we found 21 recurrences while women were using
hormonal contraceptives. In line with this previous publication,
we observed a three-fold increased risk of a recurrent venous
thrombosis while using hormonal contraceptives. Whether or
not the first event occurred during use of hormonal contracep-
tives did not affect the risk of recurrence. Regarding different
preparations, we found that combined oral contraceptive use in-
creased the risk of a recurrence about three-fold. The risk of a
recurrence was highest (about eight times increased) in users
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of triphasic contraceptives. Furthermore, results indicated that
a levonorgestrel-releasing IUD could be safely used after a first
event.
Overview per type of contraceptive
The literature was searched for studies that assessed the risk of
a first venous thrombosis per type of combined oral contracep-
tive. Through a network meta-analysis, we were able to combine
direct and indirect evidence in a weighted average. All hormonal
contraceptives increased the risk of venous thrombosis. The dose
effect of ethinylestradiol depended on the progestagen. We ob-
served no difference in risk between 20 µg ethinylestradiol with
desogestrel or 30 µg ethinylestradiol with desogestrel users. Fur-
thermore, users of 20 µg ethinylestradiol with gestodene seemed
to have the same risk of venous thrombosis as 20 µg ethinyles-
tradiol with levonorgestrel. Although only one study had data
on 20 µg ethinylestradiol with gestodene users, it is worth inves-
tigating this observation further. Previous reports have already
suggested the risk of venous thrombosis for gestodene users is
not equal to desogestrel but somewhere between levonorgestrel
and desogestrel use, for an equal dose of ethinylestradiol3. The
effects of these compounds on SHBG levels point in the same
direction1,2.
Conclusion
The research outlined in this thesis has contributed to our under-
standing of the pathogenesis of venous thrombosis in combined
oral contraceptive users. SHBG levels are only marker for ve-
nous thrombosis and not a cause and are affected not only by
the type of progestagen but also by the ethinylestradiol dose
in combined oral contraceptive. Genetic variation in the first-
pass metabolism of ethinylestradiol was associated with venous
thrombosis in combined oral contraceptive users. A substantial
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proportion of women disregard the advice of a physician to stop
their contraceptive use after a venous thrombosis, while contin-
uing hormonal contraceptive use, in particular combined oral
contraceptives, after a first venous thrombotic event increased
the risk of a recurrence. A levonorgestrel-releasing intra-uterine
device may be a safe option after a venous thrombotic event.
221
8. Discussion and recommendations
Recommendations
Clinical recommendations
• Regardless of exposure to risk factors for venous thrombo-
sis, women should stop using combined hormonal contra-
ceptives after a venous thrombosis.
• After a venous thrombosis, the use of a levonorgestrel-
releasing IUD is likely to be a safe option.
• In women without a history of venous thrombosis, switch-
ing to a contraceptive with a higher ethinylestradiol dose,
for control of breaktrhough bleeding, is not rational and
likely to be detrimental.
Scientific recommendations
• When evaluating the risk of venous thrombosis, refrain
from any classification of contraceptives.
• Regarding the mechanism behind combined oral contra-
ceptive-associated venous thrombosis, variation in protein
levels, caused by factors other than genetic, or variation in
ethinylestradiol levels may be pivotal in the pathogenesis of
combined oral contraceptive-associated venous thrombosis.
• A proportion of women disregards the advice of a physician
to stop their contraceptive use after a venous thrombosis.
It would useful to know why they disregard this advice.
• Triphasic contraceptives increase the risk of recurrence in
hormonal contraceptives more than monophasic prepara-
tions containing the same progestagen. The mechanism
behind this is unknown.
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• Literature on progestagen-only contraceptives is sparse,
because only a small group of women are using these con-
traceptives. Therefore, large studies are needed to evaluate
the effect of these contraceptives, both for a first event and
a second event of venous thrombosis
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Combined oral contraceptive use is associated with an in-
creased risk of venous thrombosis which has consistently been
shown in several observational studies. Over time, many different
combined oral contraceptives, i.e., different doses of estrogen (eth-
inylestradiol) and different types of progestagen, were developed
to reduce the risk of venous thrombosis and other side effects.
Use of combined oral contraceptives affects the levels of several
coagulation factors and thereby shifts the balance in coagulation
towards a prothrombotic state. However, the mechanism behind
these changes remains unclear. In chapter 1, the available liter-
ature about steroid hormones use for different applications was
evaluated. The use of orally administered synthetic sex steroid
hormones (combined therapy either for contraceptive use or for
hormone replacement therapy) was associated with an increased
risk of venous thrombosis. It remains unclear whether estrogens,
progestagens, or both were involved in the pathogenesis of venous
thrombosis. Because combined oral contraceptives are orally ad-
ministered, it has been reasoned that the first-pass metabolism
in the liver may play a role. The association between ethinyles-
tradiol dose and the risk of venous thrombosis in contraceptives
with the same progestagen indicated that ethinylestradiol may
be pivotal in the pathogenesis.
The aim of the research presented in this thesis was to
evaluate the mechanism behind combined oral contraceptive-
associated venous thrombosis, to identify the clinical implica-
tions of hormonal contraceptive use after a venous thrombotic
event and to provide an overview of the risk of venous thrombosis
per combined oral contraceptive.
Biochemical aspects
The European Medicines Agency recommends to measure sex
hormone binding globulin (SHBG) levels to evaluate the risk
of venous thrombosis in newly developed contraceptives. SHBG
levels are positively associated with venous thrombosis risk and
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are said to reflect the estrogenicity of a contraceptive. The effect
on SHBG levels of combined oral contraceptives is seen as a
marker for venous thrombosis risk, but whether these levels are
also a cause of venous thrombosis remained to be determined.
We determined whether SHBG levels above normal were a risk
factor for venous thrombosis or that it was merely a marker of
venous thrombosis risk in women using hormonal contraceptives.
In chapter 2, we used a mendelian randomization analysis to
show that SHBG levels above normal in women not using hor-
monal contraceptives are not a cause of venous thrombosis. We
showed that SHBG levels above normal were associated with
an increased risk of venous thrombosis of about 2-fold, adjusted
for age and BMI. However, residual confounding could have in-
fluenced these results. Therefore, we determined six SNPs in
the SHBG gene of which two were found to affect SHBG levels.
These SNPs were not associated with the risk of venous throm-
bosis. We concluded that SHBG levels were not causally related
with the risk of venous thrombosis in women not using hormonal
contraceptives. Although an effect of progestagens on SHBG lev-
els has been shown in many studies, the effect of the dose of
ethinylestradiol remained to be determined. In chapter 3, we
showed that the dose of ethinylestradiol in combined oral contra-
ceptives was positively associated with the SHBG levels. This
was not affected by the type of progestagen in the contraceptives.
We studied the association between genetic variation in the first-
pass metabolism of ethinylestradiol, SHBG levels and the risk
of venous thrombosis in premenopausal women in chapter 4.
Genetic variation was evaluated through haplotypes in selected
genes. Several criteria were devised to ensure that the observed
effect was through a change in the first-pass metabolism of ethi-
nylestradiol. First, the same association between haplotype and
venous thrombosis had to be observed in two case-control studies,
namely the LETS and MEGA study. Second, no association be-
tween this haplotype and venous thrombosis in non-users should
be observed in either study. Third, the direction of the associa-
228
tion with venous thrombosis should be reflected in SHBG levels
in combined oral contraceptive users. Carriers of two copies of
haplotype D in the UGT2B7 gene had a threefold increased
risk of venous thrombosis, increased SHBG levels in combined
oral contraceptive users and no association was observed in non-
users, i.e. all three criteria were fulfilled. Genetic variation in the
UGT2B7 gene may at least in part explain the risk of venous
thrombosis in combined oral contraceptive users.
Clinical aspects
National and international guidelines state that women should
refrain from using combined hormonal contraceptives (i.e., oral
contraceptives, transdermal patches or vaginal rings) after a ve-
nous thrombosis. Progestagen-only contraceptives (i.e., implants,
intra-uterine devices, injectables or progestagen-only pills) may
be used instead. In chapter 5, the proportion of women who
stop, change or continue their hormonal contraceptive after they
experienced a hormonal contraceptive-associated venous throm-
bosis was evaluated. Although the majority of women stop using
a hormonal contraceptive after a thrombotic event, about 20%
continued to use combined oral contraceptives or switched to a
different combined oral contraceptive. Women were more likely
to continue their contraceptive use when they were without a
positive family history of venous thrombosis, or if they were ex-
posed to a surgery or a plaster cast within three months prior to
the initial venous thrombotic event. However, exposure to risk
factors for venous thrombosis has not been taken into account
in the guidelines. The majority of women (82%) were advised to
stop their hormonal contraceptive. 12% of women who received
advice either continued or switched to another combined hor-
monal contraceptive. It posed a real concern that some women
seemed to disregard the advice from a physician, emphasized by
the potential increased risk of a recurrence when they continue
using hormonal contraceptives. The next step was to evaluate
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the risk of a recurrent event when hormonal contraceptives are
used after a venous thrombosis, described in chapter 6. The
recurrence rate was similar in women who used hormonal con-
traceptive at the first event versus those who did not. The use of
hormonal contraceptives, mainly combined oral contraceptives,
during follow-up, however, increased the recurrence rate about
three-fold. Combined oral contraceptive use increased the risk
for a recurrence about three-fold compared with non-use. We
also found that among 20 intra-uterine device users with a total
follow-up of 70 woman-years, none experienced a recurrent event.
These results suggest that the use of a levonorgestrel-releasing
intra-uterine device may be a safe method for contraception after
a venous thrombosis. Among combined oral contraceptive users,
the increase in risk depended on the ethinylestradiol dose, type
of progestagen and whether the contraceptive was triphasic or
not.
To distinguish the risk of venous thrombosis between dif-
ferent contraceptives, combined oral contraceptives are mostly
divided into different categories according to either the dose of
ethinylestradiol (i.e., 20, 30 or ≥35 µg) or into different gener-
ations of progestagens (i.e., first (norethisterone, lynestrenol),
second (levonorgestrel, norgestrel) and third generation (gesto-
dene, desogestrel, norgestimate)), as well as ‘other’ (cyproterone
acetate and drospirenone, of which the latter sometimes is er-
roneously referred to as ‘fourth generation’). To evaluate the
risk of venous thrombosis in a newly developed combined oral
contraceptive, it is mostly compared with non-use or with the
most commonly prescribed contraceptive, namely levonorgestrel
with 30 µg ethinylestradiol. To assess the risk of venous throm-
bosis per combined oral contraceptive, a network meta-analysis
was performed, described in chapter 7. All ten combined oral
contraceptives commonly used and included in the analysis in-
creased the risk of venous thrombosis. The highest risk of ve-
nous thrombosis was found among users of drospirenone with
30 µg ethinylestradiol, cyproterone acetate with 35 µg ethinyles-
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tradiol and levonorgestrel with 50 µg ethinylestradiol. Users of
levonorgestrel with 20 µg ethinylestradiol had the lowest risk of






In de laatste vijf decennia is de associatie tussen combina-
tiepreparaten (progestagenen en oestrogenen) van orale anticon-
ceptiva en veneuze trombose langzaam maar zeker vastgesteld.
In de loop van deze tijd zijn er aanpassingen aan die combi-
natie geweest om zowel het risico op veneuze trombose als op
andere bijwerkingen te verlagen. Hiertoe werd de oestrogeen-
dosis (ethinyloestradiol) verlaagd en werden er nieuwe typen
progestagenen ontwikkeld. Hormonaal anticonceptivumgebruik
beënvloedt de spiegels van verschillende stollingsfactoren waar-
door de stollingsbalans naar een protrombotische staat verschuift.
Hoe deze veranderingen tot stand komen, is grotendeels onbe-
kend. In hoofdstuk 1 is de literatuur over het gebruik van
exogene geslachtshormonen door vrouwen voor verschillende toe-
passingen en het risico op veneuze trombose geëvalueerd. Daaruit
bleek dat zowel het gebruik van orale anticonceptiva als oraal
hormoongebruik ter verlichting van menopausale symptomen
het risico op veneuze trombose verhoogde. Tot op heden is het
onduidelijk of de oestrogene component, de progestagene compo-
nent of de combinatie van beide essentieel is bij het ontstaan van
een trombose. Echter, de eerder beschreven associatie tussen de
dosis van ethinyloestradiol in combinatiepreparaten en het risico
op veneuze trombose bevestigt dat ethinyloestradiol een belang-
rijke rol speelt bij het ontstaan van een trombose. In het geval
van oraal gebruik is het mogelijk dat, naast andere biologische
processen, het afbraakmechanisme in de lever een rol speelt. Het
doel van het onderzoek gepresenteerd in dit proefschrift was
1. het mechanisme van veneuze trombose in vrouwen die
gecombineerde orale anticonceptiva gebruiken te evalueren,
2. de klinische implicatie van anticonceptivumgebruik na een
eerste trombose te beoordelen en
3. een overzicht van het risico op veneuze trombose per gecom-




Ter evaluatie van nieuw ontwikkelde hormonale anticonceptiva
adviseert het Europees Geneesmiddelen Agentschap (EMA) sinds
2005 om ‘sex hormoon binding globuline’ (SHBG) te meten.
SHBG is positief geassocieerd met veneuze trombose. Daarnaast
zijn SHBG spiegels mogelijk een weergave van de totale oe-
strogeniciteit van een hormonaal anticonceptivum. Het effect
van gecombineerde orale anticonceptiva op SHBG wordt gezien
als een marker van het risico op veneuze trombose. Of dit ef-
fect op SHBG ook zelf veneuze trombose kan veroorzaken, is
nog onbekend. De vraag is of SHBG een risicofactor is voor
veneuze trombose of alleen een marker van een verhoogde kans
op veneuze trombose in vrouwen die orale anticonceptiva ge-
bruiken. In hoofdstuk 2 is de associatie tussen SHBG en het
risico op veneuze trombose nader bestudeerd in vrouwen die
geen hormonaal anticonceptivum gebruikten. Verhoogd SHBG
(>70 nmol/L) bleek met een tweemaal verhoogd risico op veneuze
trombose geassocieerd te zijn. Echter, andere risicofactoren, naast
leeftijd en BMI, hebben mogelijk dit resultaat beïnvloed. Daar-
toe hebben wij een Mendeliaanse randomisatie-analyse gebruikt.
Hierbij is de associatie tussen genetische varianten (‘single nu-
cleotide polymorphism’, SNPs), die geassocieerd zijn met SHBG,
en het risico op veneuze trombose bestudeerd. Er zijn zes SNPs
in het SHBG gen bepaald, waarvan twee SHBG spiegels beïn-
vloedden. Deze twee SNPs bleken niet geassocieerd te zijn met
het risico op veneuze trombose. Verhoogd SHBG is derhalve
niet causaal gerelateerd aan het risico op veneuze trombose in
vrouwen die geen orale anticonceptiva gebruiken. Het effect van
progestagenen op SHBG spiegels is in verscheidene studies aange-
toond. Daarentegen is het effect van de dosis van ethinyloestra-
diol op SHBG spiegels nog onbekend. In hoofdstuk 3 wordt
duidelijk dat de dosis van ethinyloestradiol in gecombineerde
orale anticonceptiva positief geassocieerd is met SHBG spiegels.
Dit resultaat was onafhankelijk van het type progestageen in
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gecombineerde orale anticonceptiva. In hoofdstuk 4 is de asso-
ciatie tussen genetische variatie in het afbraakmechanisme van
ethinyloestradiol, SHBG en veneuze trombose in premenopausale
vrouwen bestudeerd. Ter beoordeling van genetische variatie in
geselecteerde genen zijn haplotypes gebruikt. Voorafgaande aan
de analyses, werden drie criteria vastgesteld om te bepalen of een
haplotype geassocieerd was met het risico op veneuze trombose
door middel van veranderingen in het afbraakmechanisme van
ethinyloestradiol. Als eerste moest in twee patiënt-controle stud-
ies, de LETS en MEGA studie, dezelfde associatie tussen hap-
lotype en veneuze trombose worden waargenomen. Als tweede
mocht er geen associatie tussen haplotype en veneuze trombose
in niet-gebruiksters van anticonceptiva worden waargenomen.
Als derde moest in gebruiksters van gecombineerde orale anti-
conceptiva de associatie tussen haplotype en veneuze trombose
worden gereflecteerd in de associatie tussen haplotype en SHBG.
In totaal zijn er 74 haplotype bepalende SNPs gemeten in de vol-
gende 11 kandidaatgenen COMT, CYP1A2, CYP2C9, CYP3A4,
CYP3A5, SULT1A1, SULT1E1, UGT1A1, UGT1A3, UGT1A9
en UGT2B7. Enkel haplotype D in het UGT2B7 gen voldeed aan
alle drie vooraf gestelde criteria. Draagsters van twee kopieën van
haplotype D in het UGT2B7 gen hadden een driemaal verhoogd
risico op veneuze trombose én een verhoogd SHBG spiegel. Er
werd geen associatie tussen haplotype D en veneuze trombose in
niet-gebruiksters van anticonceptiva gevonden. Genetische vari-
atie in het UGT2B7 gen kan in ieder geval een deel van het
risico op veneuze trombose in gecombineerde orale anticoncep-
tiva gebruiksters verklaren.
Klinische aspecten
In nationale en internationale richtlijnen wordt geadviseerd dat
vrouwen na een veneuze trombose geen gecombineerde hormonale
anticonceptiva (anticonceptiepil, pleister of vaginale ring) gebrui-
ken. Daarentegen kunnen progestageen-alleen anticonceptiva
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Samenvatting
(implantaat, spiraal, injectie of pil) gebruikt worden. Tot dusver
is het onduidelijk in hoeverre deze richtlijnen ook daadwerkelijk
gevolgd worden. In hoofdstuk 5 is geëvalueerd hoeveel vrouwen
na een veneuze trombose tijdens hormonaal anticonceptivumge-
bruik stoppen, veranderen of doorgaan met hun hormonale an-
ticonceptiva. Alhoewel de meerderheid van vrouwen stopt met
het gebruik van hormonale anticonceptie na een veneuze trom-
bose, gaat ongeveer 20% door met het gebruik of verandert naar
een ander type oraal combinatiepreparaat. Vrouwen waren meer
geneigd om door te gaan met hun hormonale anticonceptiva als
zij geen familieleden hadden met veneuze trombose of als zij
waren blootgesteld aan een operatie of gipsbeen in de drie maan-
den voorafgaande aan de trombose. In de huidige richtlijnen
wordt echter geen advies over anticonceptivumgebruik gegeven
bij een blootstelling aan een ander risicofactor naast hormoonge-
bruik. Naast het hormoongebruik van vrouwen na een trombose,
is er ook gekeken of advies over hormoongebruik was gegeven
door de behandelend arts. De meerderheid van vrouwen (82%)
had het advies van de arts gekregen om te stoppen met hor-
monale anticonceptivum gebruik. Van hen ging 12% ondanks
dit advies toch door met het gebruik of veranderde naar een
ander oraal combinatiepreparaat. Met in ogenschouw nemend
het mogelijk verhoogde risico op een tweede trombose bij anti-
conceptivumgebruik is het verontrustend dat een substantieel
aantal vrouwen het advies van de arts niet volgen. Echter, tot op
heden is er weinig bekend over het risico op een tweede trombose
bij hormoongebruik na een eerste trombose. In hoofdstuk 6 is
het risico op een tweede trombose bij gebruik van hormonale an-
ticonceptiva na een eerste trombose bekeken. De incidentie van
een tweede trombose in vrouwen die hormonale anticonceptiva
gebruikten ten tijde van de eerste trombose was gelijk aan de
incidentie in vrouwen die geen hormonale anticonceptiva gebruik-
ten. Het risico op een tweede trombose was driemaal verhoogd in
gebruiksters van hormonale anticonceptiva na een eerste trom-
bose, in het bijzonder in gebruiksters van gecombineerde orale
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anticonceptiva. Opvallend was dat onder 20 gebruiksters van een
levonorgestrel-houdend spiraaltje met een totale follow-up tijd
van 70 jaar geen tweede trombose is waargenomen. Dit resul-
taat suggereert, ondanks de kleine aantallen vrouwen op wie de
waarneming is gebaseerd, dat het gebruik van een levonorgestrel-
houdend spiraaltje een veilige methode is na een eerste trombose.
Het risico op een tweede trombose onder gecombineerde orale
anticonceptiva gebruiksters bleek af te hangen van de ethiny-
loestradiol dosis, progestageen type en of de pil monofasisch of
trifasisch was.
Gecombineerde oral anticonceptiva worden meestal onder-
verdeeld naar de dosis van ethinyloestradiol (oftewel 20, 30 of
≥35 µg) of in generaties van progestageen (eerste generatie
gestagenen: norethisteron, lynestrenol; tweede: levonorgestrel,
norgestrel; en derde generatie: gestodeen, desogestrel, norgesti-
maat), als ook ‘andere’ typen (cyproteron acetaat en drospirenon,
de laatste worden soms geclassificeerd als een vierde generatie).
Ter evaluatie van het risico op veneuze trombose voor een nieuw
anticonceptivum wordt het risico vergeleken met niet-gebruiksters
of met gebruiksters van levonogestrel met 30 µg ethinyloestradiol.
In hoofdstuk 7 is een netwerk meta-analyse uitgevoerd om het
risico van veneuze trombose per anticonceptiepil te beoordelen.
Alle tien geselecteerde anticonceptiepillen verhoogden het risico
op veneuze trombose. De hoogste risico’s werden in gebruiksters
van drospirenon met 30 µg ethinyloestradiol, cyproterone acetaat
met 35 µg ethinyloestradiol of levonorgestrel met 50 µg ethiny-
loestradiol gevonden. Het laagste risico op veneuze trombose
werd in gebruiksters van levonorgestrel met 20 µg ethinyloestra-
diol geobserveerd. Het gebruik van een combinatiepreparaat met
levonorgestrel en de laagst mogelijke dosis van ethinyloestradiol,
met in ogenschouw nemend de compliantie, is de veiligste optie
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